chr1	1179760	1179766	Q5T7M4	0	-	1179760	1179766	102,0,51	1	6	0	.	Cleavage;	by	FURIN.
chr1	1289860	1289866	Q9BRK3	0	-	1289860	1289866	102,0,51	1	6	0	.	Cleavage.
chr1	1568236	1568242	O75900	0	+	1568236	1568242	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr1	2543575	2543581	Q495T6	0	-	2543575	2543581	102,0,51	1	6	0	.	Cleavage.
chr1	9791819	9791825	O94985	0	-	9791819	9791825	102,0,51	1	6	0	.	Cleavage.
chr1	9791906	9791912	O94985	0	-	9791906	9791912	102,0,51	1	6	0	.	Cleavage.
chr1	10155631	10155637	O95155	0	+	10155631	10155637	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	and	caspase-7.
chr1	10161184	10161190	O95155	0	+	10161184	10161190	102,0,51	1	6	0	.	Cleavage;	by	caspase-6	and	granzyme	B.
chr1	10523222	10523228	O00273	0	-	10523222	10523228	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	10527333	10527339	O00273	0	-	10527333	10527339	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	11087667	11087673	O00187	0	-	11087667	11087673	102,0,51	1	6	0	.	Cleavage.
chr1	11710003	11710006	Q9UK22	0	-	11710003	11710006	102,0,51	1	3	0	.	Important	for	carbohydrate	binding.
chr1	11884559	11884562	P51797	0	+	11884559	11884562	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	outer	aqueous	phase	to	the	interior	of	the	protein;	involved	in	linking	H(+)	and	Cl(-)	transport.
chr1	11887236	11887239	P51797	0	+	11887236	11887239	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	protein	to	the	inner	aqueous	phase.
chr1	11918343	11918349	P16860	0	-	11918343	11918349	102,0,51	1	6	0	.	Cleavage;	by	FAP.	Pubmed:21314817
chr1	19209662	19209665	P30038	0	-	19209662	19209665	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	19612849	19612852	O95154	0	-	19612849	19612852	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr1	19635119	19635122	O43488	0	-	19635119	19635122	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr1	20302268	20302271	P14555	0	-	20302268	20302271	102,0,51	1	3	0	.	Important	for	integrin	binding.	Pubmed:18635536
chr1	20304517	20304520	P14555	0	-	20304517	20304520	102,0,51	1	3	0	.	Important	for	integrin	binding.	Pubmed:18635536
chr1	21212846	21212852	O43432	0	-	21212846	21212852	102,0,51	1	6	0	.	Cleavage;	by	foot-and-mouth	disease	virus	leader	protease.
chr1	21212849	21212855	O43432	0	-	21212849	21212855	102,0,51	1	6	0	.	Cleavage;	by	enterovirus/rhinovirus	protease	2A.
chr1	22151270	22154359	P98160	0	-	22151270	22154359	102,0,51	1	3089	0	.	Cleavage;	by	BMP1.
chr1	24180930	24180933	P04066	0	-	24180930	24180933	102,0,51	1	3	0	.	May	be	important	for	catalysis.
chr1	27189868	27189871	P31947	0	+	27189868	27189871	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr1	27190087	27190090	P31947	0	+	27190087	27190090	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr1	27216353	27216356	Q9H9Y4	0	-	27216353	27216356	102,0,51	1	3	0	.	Stabilizes	the	phosphate	intermediate;	shared	with	dimeric	partner.
chr1	27434310	27434313	P19634	0	-	27434310	27434313	102,0,51	1	3	0	.	Not	glycosylated.
chr1	27440646	27440649	P19634	0	-	27440646	27440649	102,0,51	1	3	0	.	Channel	pore-lining.
chr1	28293585	28293591	Q9H6D3	0	+	28293585	28293591	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	31347153	31347159	O75056	0	-	31347153	31347159	102,0,51	1	6	0	.	Cleavage	of	ectodomain.
chr1	32084898	32084901	O43613	0	+	32084898	32084901	102,0,51	1	3	0	.	Important	for	responses	to	orexin.	Pubmed:26950369
chr1	32210279	32210285	O60241	0	-	32210279	32210285	102,0,51	1	6	0	.	Cleavage;	by	furin.	Pubmed:20367554
chr1	33549656	33549659	Q96A70	0	+	33549656	33549659	102,0,51	1	3	0	.	Not	modified.
chr1	35650191	35652604	P23246	0	-	35650191	35652604	102,0,51	1	2413	0	.	Breakpoint	for	translocation	to	form	SFPQ-TFE3.
chr1	40315875	40315878	Q9H3H1	0	-	40315875	40315878	102,0,51	1	3	0	.	Interaction	with	substrate	tRNA.
chr1	40319689	40319692	Q9H3H1	0	-	40319689	40319692	102,0,51	1	3	0	.	Interaction	with	substrate	tRNA.
chr1	41949728	41949734	P20800	0	-	41949728	41949734	102,0,51	1	6	0	.	Cleavage;	by	KEL.
chr1	43162612	43162853	P67809	0	+	43162612	43162853	102,0,51	1	241	0	.	Cleavage;	by	20S	proteasomal	protease.
chr1	43393320	43393323	P11166	0	-	43393320	43393323	102,0,51	1	3	0	.	Not	glycosylated.
chr1	44442274	44442277	Q99437	0	+	44442274	44442277	102,0,51	1	3	0	.	Essential	for	proton	translocation.
chr1	45479005	45479008	P06132	0	+	45479005	45479008	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	45798142	45798145	Q9UIF7	0	-	45798142	45798145	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	46032573	46032576	P14550	0	+	46032573	46032576	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.	Pubmed:7669785
chr1	46032573	46032576	V9HWI0	0	+	46032573	46032576	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr1	53370733	53370736	Q86YB7	0	-	53370733	53370736	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr1	53372221	53372224	Q86YB7	0	-	53372221	53372224	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr1	55319775	55319781	Q15392	0	-	55319775	55319781	102,0,51	1	6	0	.	Cleavage;	by	caspase.
chr1	55349308	55349314	Q15392	0	-	55349308	55349314	102,0,51	1	6	0	.	Cleavage;	by	caspase.
chr1	55512249	55512255	Q8NBP7	0	+	55512249	55512255	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr1	55518078	55518084	Q8NBP7	0	+	55518078	55518084	102,0,51	1	6	0	.	Cleavage;	by	furin	and	PCSK5.
chr1	57333330	57333333	P07357	0	+	57333330	57333333	102,0,51	1	3	0	.	Not	glycosylated.
chr1	59247926	59247929	P05412	0	-	59247926	59247929	102,0,51	1	3	0	.	Necessary	for	synergistic	transcriptional	activity	with	SMAD3.
chr1	62916304	62916310	O94782	0	+	62916304	62916310	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:16531995
chr1	66834505	66834508	Q07343	0	+	66834505	66834508	102,0,51	1	3	0	.	Binds	AMP,	but	not	cAMP.
chr1	79387333	79387339	Q9HBW9	0	-	79387333	79387339	102,0,51	1	6	0	.	Cleavage.
chr1	82433841	82433847	O95490	0	+	82433841	82433847	102,0,51	1	6	0	.	Cleavage.
chr1	84394904	84394907	Q6ZT98	0	-	84394904	84394907	102,0,51	1	3	0	.	Binds	negatively	charged	residues	of	beta-tubulin	C-terminal	tails.	Pubmed:25959773
chr1	84414339	84414342	Q6ZT98	0	-	84414339	84414342	102,0,51	1	3	0	.	Binds	negatively	charged	residues	of	beta-tubulin	C-terminal	tails.	Pubmed:25959773
chr1	86916382	86916388	Q9UQC9	0	+	86916382	86916388	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr1	86961324	86961330	A8K7I4	0	+	86961324	86961330	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:23112050
chr1	87043721	87043727	Q14CN2	0	+	87043721	87043727	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr1	89225903	89225909	Q16513	0	+	89225903	89225909	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	89273453	89273459	Q16513	0	+	89273453	89273459	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	93073281	93073284	O60447	0	-	93073281	93073284	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	EVI5-TRNG10	fusion	protein.
chr1	93995295	93995298	Q5T0N5	0	+	93995295	93995298	102,0,51	1	3	0	.	Mediates	end-to-end	attachment	of	dimers.
chr1	101343302	101343308	Q9UBQ6	0	-	101343302	101343308	102,0,51	1	6	0	.	Cleavage.
chr1	104117908	104117911	P19961	0	+	104117908	104117911	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	104164262	104164265	P04746	0	+	104164262	104164265	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:10091666,	Pubmed:10769135,	Pubmed:11914097
chr1	104203045	104203048	P04745	0	+	104203045	104203048	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	104234165	104234168	P04745	0	-	104234165	104234168	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	104297184	104297187	P04745	0	+	104297184	104297187	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	110217428	110217431	P28161	0	+	110217428	110217431	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr1	110884886	110888162	Q96T37	0	+	110884886	110888162	102,0,51	1	3276	0	.	Breakpoint	for	translocation	to	form	RBM15-MKL1.
chr1	111146261	111146264	P16389	0	-	111146261	111146264	102,0,51	1	3	0	.	Important	for	binding	with	the	scorpion	mesomartoxin;	when	the	scorpion	mesomartoxin-rKv1.2/KCNA2	interaction	is	modeled,	this	residue	is	close	to	the	'Y-57'	residue	of	the	toxin.
chr1	111146648	111146651	P16389	0	-	111146648	111146651	102,0,51	1	3	0	.	Important	for	normal,	slow	channel	gating.
chr1	114944082	114945384	Q9UPN9	0	-	114944082	114945384	102,0,51	1	1302	0	.	Breakpoint	for	translocation	to	form	TRIM33-RET	oncogene.
chr1	120506269	120506272	Q04721	0	-	120506269	120506272	102,0,51	1	3	0	.	Essential	for	O-xylosylation.
chr1	145415694	145415700	Q6ZVN8	0	+	145415694	145415700	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr1	149937714	149937717	Q6GQQ9	0	-	149937714	149937717	102,0,51	1	3	0	.	Stabilizes	the	conformation	of	the	regulatory	loop.	Pubmed:27732584
chr1	150131415	150131421	Q53GL0	0	+	150131415	150131421	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	150131520	150131526	Q53GL0	0	+	150131520	150131526	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	150551532	150551538	Q07820	0	-	150551532	150551538	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	150551622	150551628	Q07820	0	-	150551622	150551628	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	153920779	153920782	Q53ET0	0	-	153920779	153920782	102,0,51	1	3	0	.	Required	for	ubiquitination	and	degradation.
chr1	153946364	153946370	Q8TEY5	0	+	153946364	153946370	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr1	154246311	154246317	O00165	0	+	154246311	154246317	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr1	154407557	154407560	P08887	0	+	154407557	154407560	102,0,51	1	3	0	.	Not	glycosylated.
chr1	154542306	154542309	P17787	0	+	154542306	154542309	102,0,51	1	3	0	.	Key	residue	that	may	interfere	with	effective	access	of	the	conotoxin	BuIA	to	the	channel	binding	site.
chr1	154543704	154543707	P17787	0	+	154543704	154543707	102,0,51	1	3	0	.	Key	residue	for	a	rapid	dissociation	(K(off))	from	the	conotoxin	BuIA.
chr1	154543728	154543731	P17787	0	+	154543728	154543731	102,0,51	1	3	0	.	Key	residue	for	a	rapid	dissociation	(K(off))	from	the	conotoxin	BuIA.
chr1	155264298	155264301	P30613	0	-	155264298	155264301	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	155279702	155279705	P30613	0	-	155279702	155279705	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	155287740	155287743	P14324	0	+	155287740	155287743	102,0,51	1	3	0	.	Important	for	determining	product	chain	length.
chr1	155287743	155287746	P14324	0	+	155287743	155287746	102,0,51	1	3	0	.	Important	for	determining	product	chain	length.
chr1	156104751	156104754	P02545	0	+	156104751	156104754	102,0,51	1	3	0	.	Heptad	change	of	phase.
chr1	156105727	156105730	P02545	0	+	156105727	156105730	102,0,51	1	3	0	.	Stutter.
chr1	156105742	156105745	P02545	0	+	156105742	156105745	102,0,51	1	3	0	.	Heptad	change	of	phase.
chr1	156108515	156108521	P02545	0	+	156108515	156108521	102,0,51	1	6	0	.	Cleavage;	by	endoprotease.
chr1	156212827	156212830	P02818	0	+	156212827	156212830	102,0,51	1	3	0	.	Not	hydroxylated.
chr1	156446294	156446300	Q14814	0	-	156446294	156446300	102,0,51	1	6	0	.	Cleavage.
chr1	156844188	156844364	P04629	0	+	156844188	156844364	102,0,51	1	176	0	.	Breakpoint	for	translocation	to	form	TRK	and	TRK-T3.
chr1	156845412	156845415	P04629	0	+	156845412	156845415	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	TRK-T1.
chr1	156845442	156845445	P04629	0	+	156845442	156845445	102,0,51	1	3	0	.	Interaction	with	SHC1.
chr1	156851413	156851416	P04629	0	+	156851413	156851416	102,0,51	1	3	0	.	Interaction	with	PLCG1.
chr1	157559246	157566121	Q96PJ5	0	-	157559246	157566121	102,0,51	1	6875	0	.	Breakpoint	for	insertion	to	form	FCRL4-IGHA1	fusion	protein.
chr1	159141627	159141630	Q8N126	0	+	159141627	159141630	102,0,51	1	3	0	.	Not	glycosylated.
chr1	160011848	160011851	P78508	0	-	160011848	160011851	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr1	160054267	160054270	Q92806	0	+	160054267	160054270	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr1	161816305	161816311	P18850	0	+	161816305	161816311	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr1	164532544	164761732	P40424	0	+	164532544	164761732	102,0,51	1	229188	0	.	Breakpoint	for	translocation	to	form	TCF3-PBX1	oncogene.
chr1	169509605	169509611	P12259	0	-	169509605	169509611	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr1	169511186	169511192	P12259	0	-	169511186	169511192	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr1	169511258	169511264	P12259	0	-	169511258	169511264	102,0,51	1	6	0	.	Cleavage;	by	activated	protein	C.
chr1	169512113	169512119	P12259	0	-	169512113	169512119	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr1	169512203	169512209	P12259	0	-	169512203	169512209	102,0,51	1	6	0	.	Cleavage;	by	activated	protein	C.
chr1	169519044	169519050	P12259	0	-	169519044	169519050	102,0,51	1	6	0	.	Cleavage;	by	activated	protein	C.
chr1	169524532	169524538	P12259	0	-	169524532	169524538	102,0,51	1	6	0	.	Cleavage;	by	activated	protein	C.
chr1	171607785	171607791	Q99972	0	-	171607785	171607791	102,0,51	1	6	0	.	Cleavage;	by	CAPN2.
chr1	172628581	172628587	P48023	0	+	172628581	172628587	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A.
chr1	172629270	172629276	P48023	0	+	172629270	172629276	102,0,51	1	6	0	.	Cleavage;	by	ADAM10.
chr1	173873143	173873149	P01008	0	-	173873143	173873149	102,0,51	1	6	0	.	Reactive	bond.
chr1	174606539	174606542	Q5R372	0	+	174606539	174606542	102,0,51	1	3	0	.	Arginine	finger.
chr1	174652695	174652698	Q5R372	0	+	174652695	174652698	102,0,51	1	3	0	.	Glutamine	finger.
chr1	176012902	176012905	Q8NHY2	0	-	176012902	176012905	102,0,51	1	3	0	.	Interaction	with	TRIB1.	Pubmed:27041596
chr1	176015321	176015324	Q8NHY2	0	-	176015321	176015324	102,0,51	1	3	0	.	Interaction	with	TRIB1.	Pubmed:27041596
chr1	180601400	180601403	Q9UBH6	0	+	180601400	180601403	102,0,51	1	3	0	.	Important	for	inositol	polyphosphate	binding.	Pubmed:27080106
chr1	180651501	180651504	Q9UBH6	0	+	180651501	180651504	102,0,51	1	3	0	.	Important	for	inositol	polyphosphate	binding.	Pubmed:27080106
chr1	181549885	181549888	Q15878	0	+	181549885	181549888	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	181690905	181690908	Q15878	0	+	181690905	181690908	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	181725215	181725218	Q15878	0	+	181725215	181725218	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	181741214	181741217	Q15878	0	+	181741214	181741217	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	182785910	182785913	Q9BXD5	0	+	182785910	182785913	102,0,51	1	3	0	.	Involved	in	proton	transfer	during	cleavage.
chr1	186332091	186332094	P12270	0	-	186332091	186332094	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	TRK-T1.
chr1	186643751	186643754	P35354	0	-	186643751	186643754	102,0,51	1	3	0	.	Aspirin-acetylated	serine.
chr1	192998336	192998339	Q5LJA5	0	-	192998336	192998339	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr1	192998336	192998339	Q5LJA9	0	-	192998336	192998339	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr1	192998336	192998339	Q9Y5K5	0	-	192998336	192998339	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr1	198233281	198233284	Q8TDX7	0	+	198233281	198233284	102,0,51	1	3	0	.	Autoinhibitory.
chr1	201020255	201020258	Q13698	0	-	201020255	201020258	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	201031082	201031085	Q13698	0	-	201031082	201031085	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	201044728	201044731	Q13698	0	-	201044728	201044731	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	201058409	201058412	Q13698	0	-	201058409	201058412	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr1	201970538	201970541	Q9H4A4	0	+	201970538	201970541	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	203317203	203317206	Q06828	0	-	203317203	203317206	102,0,51	1	3	0	.	Not	sulfated.
chr1	203317209	203317212	Q06828	0	-	203317209	203317212	102,0,51	1	3	0	.	Not	sulfated.
chr1	204159671	204159677	Q15726	0	-	204159671	204159677	102,0,51	1	6	0	.	Cleavage;	by	MMP2	and	MMP9.
chr1	205741693	205743964	O14966	0	-	205741693	205743964	102,0,51	1	2271	0	.	Cleavage;	by	S.Typhimurium	viral	protease	GtgE.
chr1	207240976	207240979	O60825	0	+	207240976	207240979	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	207240997	207241000	O60825	0	+	207240997	207241000	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	207243702	207243705	O60825	0	+	207243702	207243705	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr1	226252145	226252148	P84243	0	+	226252145	226252148	102,0,51	1	3	0	.	Interaction	with	ZMYND11.	Pubmed:24590075
chr1	228210371	228210377	P56704	0	+	228210371	228210377	102,0,51	1	6	0	.	Cleavage;	by	TIKI1	and	TIKI2.
chr1	230410295	230410298	Q10471	0	+	230410295	230410298	102,0,51	1	3	0	.	Not	glycosylated.
chr1	233750268	233750271	O00180	0	+	233750268	233750271	102,0,51	1	3	0	.	Important	for	increased	permeability	to	Na(+)	when	K(+)	levels	are	subphysiological.	Pubmed:21653227
chr1	233802420	233802423	O00180	0	+	233802420	233802423	102,0,51	1	3	0	.	Part	of	a	hydrophobic	barrier	that	is	stochastically	dewetted	and	limits	ion	permeability.	Pubmed:22431633,	Pubmed:25001086
chr1	233807045	233807048	O00180	0	+	233807045	233807048	102,0,51	1	3	0	.	Part	of	a	hydrophobic	barrier	that	is	stochastically	dewetted	and	limits	ion	permeability.	Pubmed:25001086
chr1	236702218	236702221	O00214	0	+	236702218	236702221	102,0,51	1	3	0	.	Critical	for	binding	to	sialylated	and	sulfated	oligosaccharides.	Pubmed:21288902
chr1	242159527	242159533	Q9BXW4	0	-	242159527	242159533	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr10	4873031	4873034	Q96JD6	0	+	4873031	4873034	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5008180	5008183	Q04828	0	+	5008180	5008183	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr10	5008270	5008273	Q04828	0	+	5008270	5008273	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5008271	5008274	H0Y804	0	+	5008271	5008274	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5014485	5014488	Q04828	0	+	5014485	5014488	102,0,51	1	3	0	.	May	be	involved	in	the	mediating	step	between	the	transformation	of	progesterone	and	the	release	of	the	cofactor.
chr10	5043705	5043708	P52895	0	-	5043705	5043708	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5138676	5138679	P42330	0	+	5138676	5138679	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr10	5138766	5138769	A0A0A0MSS8	0	+	5138766	5138769	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5138766	5138769	P42330	0	+	5138766	5138769	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5138766	5138769	S4R3Z2	0	+	5138766	5138769	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	5144400	5144403	P42330	0	+	5144400	5144403	102,0,51	1	3	0	.	Involved	in	ligand	recognition	and	product	release.
chr10	5147855	5147858	P42330	0	+	5147855	5147858	102,0,51	1	3	0	.	Involved	in	ligand	recognition	and	product	release.
chr10	5242218	5242221	P17516	0	+	5242218	5242221	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr10	5242308	5242311	P17516	0	+	5242308	5242311	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr10	6262753	6262756	Q16875	0	+	6262753	6262756	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:22275052
chr10	6262774	6262777	Q16875	0	+	6262774	6262777	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:22275052
chr10	6264895	6264898	Q16875	0	+	6264895	6264898	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:22275052
chr10	13386854	13386857	P49903	0	-	13386854	13386857	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr10	17171656	17171662	O60494	0	-	17171656	17171662	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr10	17277209	17277212	P08670	0	+	17277209	17277212	102,0,51	1	3	0	.	Stutter.
chr10	18828314	18828317	Q08289	0	+	18828314	18828317	102,0,51	1	3	0	.	Required	for	CaMK2D-binding.
chr10	21959377	21959380	P55197	0	+	21959377	21959380	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient	B).
chr10	22015172	22015175	P55197	0	+	22015172	22015175	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient	C).
chr10	22016783	22016786	P55197	0	+	22016783	22016786	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient	A).
chr10	27066167	27112069	Q8IZP0	0	-	27066167	27112069	102,0,51	1	45902	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-ABI1.
chr10	43609002	43609008	P07949	0	+	43609002	43609008	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr10	43610166	43610172	P07949	0	+	43610166	43610172	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr10	43610181	43612034	P07949	0	+	43610181	43612034	102,0,51	1	1853	0	.	Breakpoint	for	translocation	to	form	PCM1-RET;	RET-CCDC6;	RET-GOLGA5;	RET-TRIM24	and	RET-TRIM33	oncogenes.
chr10	43622031	43622037	P07949	0	+	43622031	43622037	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr10	43882285	43882288	P52597	0	-	43882285	43882288	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882354	43882357	P52597	0	-	43882354	43882357	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882438	43882441	P52597	0	-	43882438	43882441	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882450	43882453	P52597	0	-	43882450	43882453	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882813	43882816	P52597	0	-	43882813	43882816	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882882	43882885	P52597	0	-	43882882	43882885	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882972	43882975	P52597	0	-	43882972	43882975	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43882984	43882987	P52597	0	-	43882984	43882987	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43883107	43883110	P52597	0	-	43883107	43883110	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43883176	43883179	P52597	0	-	43883176	43883179	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43883272	43883275	P52597	0	-	43883272	43883275	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	43883284	43883287	P52597	0	-	43883284	43883287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr10	44876251	44876254	P48061	0	-	44876251	44876254	102,0,51	1	3	0	.	Important	for	dimer	formation.
chr10	45878086	45878089	P09917	0	+	45878086	45878089	102,0,51	1	3	0	.	Essential	for	stabilizing	binding	to	COTL1.
chr10	45894149	45894152	P09917	0	+	45894149	45894152	102,0,51	1	3	0	.	Essential	for	stabilizing	binding	to	COTL1.
chr10	51582936	51584618	Q13772	0	+	51582936	51584618	102,0,51	1	1682	0	.	Breakpoint	for	rearrangement	to	form	RET/PTC3	oncogene.
chr10	60146049	60146052	Q00059	0	+	60146049	60146052	102,0,51	1	3	0	.	Intercalates	between	bases	and	promotes	DNA	bending.
chr10	60154123	60154126	Q00059	0	+	60154123	60154126	102,0,51	1	3	0	.	Intercalates	between	bases	and	promotes	DNA	bending.
chr10	61612457	61665882	Q16204	0	-	61612457	61665882	102,0,51	1	53425	0	.	Breakpoint	for	translocation	to	form	RET-CCDC6	oncogene.
chr10	70432799	70441158	Q8NFU7	0	+	70432799	70441158	102,0,51	1	8359	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-TET1	oncogene.
chr10	71906009	71906015	Q2T9J0	0	-	71906009	71906015	102,0,51	1	6	0	.	Cleavage.
chr10	72358444	72358447	P14222	0	-	72358444	72358447	102,0,51	1	3	0	.	Important	for	oligomerization.
chr10	72358834	72358837	P14222	0	-	72358834	72358837	102,0,51	1	3	0	.	Important	for	oligomerization.
chr10	73050805	73050811	Q8IZJ1	0	+	73050805	73050811	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.	Pubmed:12598906
chr10	73587845	73587848	P07602	0	-	73587845	73587848	102,0,51	1	3	0	.	Not	glycosylated;	in	variant	MLD-SAPB	Ile-217.
chr10	76788245	76788251	Q8WYB5	0	+	76788245	76788251	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6B-CREBBP.
chr10	76978919	76978922	P45880	0	+	76978919	76978922	102,0,51	1	3	0	.	Involved	in	hexokinase	binding.
chr10	90674385	90674388	Q96FJ0	0	+	90674385	90674388	102,0,51	1	3	0	.	Indirect	zinc-binding.
chr10	91162131	91162134	P09914	0	+	91162131	91162134	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91162155	91162158	P09914	0	+	91162155	91162158	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91162482	91162485	P09914	0	+	91162482	91162485	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91162590	91162593	P09914	0	+	91162590	91162593	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91162785	91162788	P09914	0	+	91162785	91162788	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91162899	91162902	P09914	0	+	91162899	91162902	102,0,51	1	3	0	.	Interaction	with	the	5'-triphosphate	group	of	PPP-RNA.
chr10	91177052	91177055	Q13325	0	+	91177052	91177055	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177064	91177067	Q13325	0	+	91177064	91177067	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177076	91177079	Q13325	0	+	91177076	91177079	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177403	91177406	Q13325	0	+	91177403	91177406	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177511	91177514	Q13325	0	+	91177511	91177514	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177703	91177706	Q13325	0	+	91177703	91177706	102,0,51	1	3	0	.	Interaction	with	PPP-RNA.
chr10	91177817	91177820	Q13325	0	+	91177817	91177820	102,0,51	1	3	0	.	Interaction	with	the	5'-triphosphate	group	of	PPP-RNA.
chr10	93870940	93870943	Q8NE35	0	-	93870940	93870943	102,0,51	1	3	0	.	Required	for	RNA-binding	activity.	Pubmed:24343026
chr10	93904732	93904735	Q8NE35	0	-	93904732	93904735	102,0,51	1	3	0	.	Required	for	RNA-binding	activity.	Pubmed:24343026
chr10	93904738	93904744	Q8NE35	0	-	93904738	93904744	102,0,51	1	6	0	.	Cleavage;	by	CAPN2.
chr10	99190852	99190855	P18669	0	+	99190852	99190855	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr10	99359469	99359472	Q86XE5	0	+	99359469	99359472	102,0,51	1	3	0	.	Involved	in	proton	transfer	during	cleavage.
chr10	102307861	102307864	Q9NWT6	0	+	102307861	102307864	102,0,51	1	3	0	.	Important	for	dimer	formation.
chr10	103559165	103559171	O60502	0	-	103559165	103559171	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.	Pubmed:18586680
chr10	104159365	104159371	Q00653	0	+	104159365	104159371	102,0,51	1	6	0	.	Cleavage	(when	cotranslationally	processed).
chr10	104159473	104159840	Q00653	0	+	104159473	104159840	102,0,51	1	367	0	.	Breakpoint	for	translocation	to	form	NFKB2-IGHA1	oncogene.
chr10	105218286	105218289	Q8IU99	0	-	105218286	105218289	102,0,51	1	3	0	.	Not	glycosylated.
chr10	105762247	105762253	Q9H2G2	0	+	105762247	105762253	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr10	115337840	115337846	Q14520	0	+	115337840	115337846	102,0,51	1	6	0	.	Cleavage.
chr10	115337843	115337849	Q14520	0	+	115337843	115337849	102,0,51	1	6	0	.	Cleavage.
chr10	115345616	115345622	Q14520	0	+	115345616	115345622	102,0,51	1	6	0	.	Cleavage.
chr10	116038575	116038581	Q5GFL6	0	+	116038575	116038581	102,0,51	1	6	0	.	Cleavage.
chr10	118960731	118960734	Q7Z418	0	+	118960731	118960734	102,0,51	1	3	0	.	Not	glycosylated.
chr10	124248449	124248452	Q92743	0	+	124248449	124248452	102,0,51	1	3	0	.	Involved	in	trimer	stabilization.	Pubmed:21297635
chr10	124248455	124248458	Q92743	0	+	124248455	124248458	102,0,51	1	3	0	.	Involved	in	trimer	stabilization.	Pubmed:21297635
chr10	124266260	124266263	Q92743	0	+	124266260	124266263	102,0,51	1	3	0	.	Involved	in	trimer	stabilization.	Pubmed:21297635
chr10	131755559	131755562	Q9H4W6	0	-	131755559	131755562	102,0,51	1	3	0	.	Interaction	with	DNA.
chr10	131755586	131755589	Q9H4W6	0	-	131755586	131755589	102,0,51	1	3	0	.	Interaction	with	DNA.
chr10	135182448	135182451	P30084	0	-	135182448	135182451	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr11	1215355	1215361	P98088	0	+	1215355	1215361	102,0,51	1	6	0	.	Cleavage.
chr11	3752805	3756423	P52948	0	-	3752805	3756423	102,0,51	1	3618	0	.	Breakpoint	for	translocation	to	form	NUP98-CCDC28A.
chr11	3752805	3756423	P52948	0	-	3752805	3756423	102,0,51	1	3618	0	.	Breakpoint	for	translocation	to	form	NUP98-PHF23	oncogene.
chr11	4139550	4139553	P23921	0	+	4139550	4139553	102,0,51	1	3	0	.	Important	for	hydrogen	atom	transfer.
chr11	4139574	4139577	P23921	0	+	4139574	4139577	102,0,51	1	3	0	.	Allosteric	effector	binding,	determines	substrate	specificity.
chr11	4139664	4139667	P23921	0	+	4139664	4139667	102,0,51	1	3	0	.	Allosteric	effector	binding,	determines	substrate	specificity.
chr11	4147922	4147925	P23921	0	+	4147922	4147925	102,0,51	1	3	0	.	Important	for	hydrogen	atom	transfer.
chr11	4159442	4159445	P23921	0	+	4159442	4159445	102,0,51	1	3	0	.	Important	for	electron	transfer.
chr11	4159445	4159448	P23921	0	+	4159445	4159448	102,0,51	1	3	0	.	Important	for	electron	transfer.
chr11	4159592	4159595	P23921	0	+	4159592	4159595	102,0,51	1	3	0	.	Interacts	with	thioredoxin/glutaredoxin.
chr11	4159601	4159604	P23921	0	+	4159601	4159604	102,0,51	1	3	0	.	Interacts	with	thioredoxin/glutaredoxin.
chr11	5247833	5247836	P68871	0	-	5247833	5247836	102,0,51	1	3	0	.	Not	glycated.
chr11	5247872	5247875	P68871	0	-	5247872	5247875	102,0,51	1	3	0	.	Not	glycated.
chr11	5247941	5247944	P68871	0	-	5247941	5247944	102,0,51	1	3	0	.	Not	glycated.
chr11	13379987	13379990	O00327	0	+	13379987	13379990	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr11	13379996	13379999	O00327	0	+	13379996	13379999	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr11	13379999	13380002	O00327	0	+	13379999	13380002	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr11	13380011	13380014	O00327	0	+	13380011	13380014	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr11	13380131	13380134	O00327	0	+	13380131	13380134	102,0,51	1	3	0	.	Important	for	interaction	with	CLOCK.	Pubmed:23229515
chr11	17190490	17190493	O00443	0	-	17190490	17190493	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17190502	17190505	O00443	0	-	17190502	17190505	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17190526	17190529	O00443	0	-	17190526	17190529	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17190535	17190538	O00443	0	-	17190535	17190538	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17190541	17190544	O00443	0	-	17190541	17190544	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17190556	17190559	O00443	0	-	17190556	17190559	102,0,51	1	3	0	.	Not	phosphorylated.
chr11	17409158	17409161	B2RC52	0	-	17409158	17409161	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr11	22833451	22833457	O43903	0	+	22833451	22833457	102,0,51	1	6	0	.	Cleavage;	by	a	caspase	during	apoptosis.
chr11	27679937	27679943	P23560	0	-	27679937	27679943	102,0,51	1	6	0	.	Cleavage;	by	S1P.
chr11	36597539	36597542	P15918	0	+	36597539	36597542	102,0,51	1	3	0	.	Essential	for	DNA	hairpin	formation,	participates	in	base-stacking	interactions	near	the	cleavage	site.
chr11	46341831	46341837	Q96BA8	0	+	46341831	46341837	102,0,51	1	6	0	.	Cleavage;	by	S1P.
chr11	46701806	46701809	Q07960	0	-	46701806	46701809	102,0,51	1	3	0	.	Involved	in	G-protein	binding	to	GAPs.
chr11	46747440	46747446	P00734	0	+	46747440	46747446	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr11	46748151	46748157	P00734	0	+	46748151	46748157	102,0,51	1	6	0	.	Cleavage;	by	factor	Xa.
chr11	46748343	46748349	P00734	0	+	46748343	46748349	102,0,51	1	6	0	.	Cleavage;	by	factor	Xa.
chr11	57097846	57097852	Q08945	0	-	57097846	57097852	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	and/or	caspase-7.
chr11	57381943	57381949	P05155	0	+	57381943	57381949	102,0,51	1	6	0	.	Reactive	bond	for	chymotrypsin.
chr11	57381946	57381952	P05155	0	+	57381946	57381952	102,0,51	1	6	0	.	Reactive	bond.
chr11	57569448	57569451	O60716	0	+	57569448	57569451	102,0,51	1	3	0	.	Essential	for	interaction	with	cadherins.
chr11	57571103	57571106	O60716	0	+	57571103	57571106	102,0,51	1	3	0	.	Essential	for	interaction	with	cadherins.
chr11	61544900	61544906	Q9Y2G1	0	+	61544900	61544906	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:23966832
chr11	62383226	62383229	O94766	0	-	62383226	62383229	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr11	62384205	62384208	O94766	0	-	62384205	62384208	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr11	62747006	62747009	Q4U2R8	0	-	62747006	62747009	102,0,51	1	3	0	.	Important	for	interaction	with	cidofovir	and	PAH.
chr11	62749420	62749423	Q4U2R8	0	-	62749420	62749423	102,0,51	1	3	0	.	Important	for	interaction	with	cidofovir.
chr11	63533501	63533504	C9JLR9	0	-	63533501	63533504	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	C11orf95-MLK2	fusion	protein.
chr11	63720231	63720234	Q86UY6	0	+	63720231	63720234	102,0,51	1	3	0	.	Essential	for	catalytic	activity.	Pubmed:25619998
chr11	63755816	63755819	Q96FW1	0	+	63755816	63755819	102,0,51	1	3	0	.	Required	for	proximal	ubiquitin-binding.	Pubmed:19211026
chr11	63919863	63919866	Q9BQ69	0	-	63919863	63919866	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	RUNX1-MACROD1.	Pubmed:17532767
chr11	64081466	64081469	P11474	0	+	64081466	64081469	102,0,51	1	3	0	.	Required	for	DNA-dependent	dimerization.
chr11	64525777	64525780	P11217	0	-	64525777	64525780	102,0,51	1	3	0	.	May	be	involved	in	allosteric	control.
chr11	64525816	64525819	P11217	0	-	64525816	64525819	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr11	64526092	64526095	P11217	0	-	64526092	64526095	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr11	64950214	64950220	P07384	0	+	64950214	64950220	102,0,51	1	6	0	.	Cleavage;	for	78	kDa	form.
chr11	64950250	64950256	P07384	0	+	64950250	64950256	102,0,51	1	6	0	.	Cleavage;	for	75	kDa	form.
chr11	65779620	65779623	Q15828	0	+	65779620	65779623	102,0,51	1	3	0	.	Reactive	site.
chr11	66613356	66613359	Q9Y256	0	+	66613356	66613359	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr11	66613368	66613371	Q9Y256	0	+	66613368	66613371	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr11	67173113	67173116	Q8IV04	0	+	67173113	67173116	102,0,51	1	3	0	.	Arginine	finger.
chr11	67173437	67173440	Q8IV04	0	+	67173437	67173440	102,0,51	1	3	0	.	Glutamine	finger.
chr11	74204295	74204298	A6NK58	0	-	74204295	74204298	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Cys.
chr11	75282999	75283005	P50454	0	+	75282999	75283005	102,0,51	1	6	0	.	Reactive	bond	homolog.
chr11	85670100	85685753	Q13492	0	-	85670100	85685753	102,0,51	1	15653	0	.	Breakpoint	for	translocation	to	form	CALM/MLLT10	fusion	protein.
chr11	86176139	86176142	Q16798	0	-	86176139	86176142	102,0,51	1	3	0	.	Important	for	activity.
chr11	87847167	87847170	P57729	0	-	87847167	87847170	102,0,51	1	3	0	.	Not	methylated.
chr11	95826678	96074549	Q8IZL2	0	-	95826678	96074549	102,0,51	1	247871	0	.	Breakpoint	for	translocation	to	form	the	CRTC1-MAML2	and	MAML2-CRTC1	fusion	proteins.	Pubmed:15729701
chr11	102206695	102206701	Q13489	0	+	102206695	102206701	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BIRC3-MALT1.
chr11	102665993	102665999	P03956	0	-	102665993	102665999	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:2557822
chr11	102667814	102667817	P03956	0	-	102667814	102667817	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:10092871
chr11	103814201	103814207	Q9GZP0	0	-	103814201	103814207	102,0,51	1	6	0	.	Cleavage.
chr11	103814207	103814213	Q9GZP0	0	-	103814207	103814213	102,0,51	1	6	0	.	Cleavage.
chr11	111711530	111711533	Q9H6U8	0	-	111711530	111711533	102,0,51	1	3	0	.	Breakpoint	for	translocation.	Pubmed:12030331
chr11	111781170	111781173	P02511	0	-	111781170	111781173	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr11	111782268	111782271	P02511	0	-	111782268	111782271	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr11	111782304	111782307	P02511	0	-	111782304	111782307	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr11	113286274	113286277	P14416	0	-	113286274	113286277	102,0,51	1	3	0	.	Important	for	receptor	activation.
chr11	113286283	113286286	P14416	0	-	113286283	113286286	102,0,51	1	3	0	.	Important	for	receptor	activation.
chr11	113565330	113565336	Q9H3S3	0	-	113565330	113565336	102,0,51	1	6	0	.	Cleavage.
chr11	113935201	113935207	Q05516	0	+	113935201	113935207	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PLZF-RAR-alpha	oncogene.
chr11	116701541	116701544	P02656	0	+	116701541	116701544	102,0,51	1	3	0	.	May	interact	with	the	LDL	receptor.	Pubmed:18408013
chr11	116701553	116701556	P02656	0	+	116701553	116701556	102,0,51	1	3	0	.	May	interact	with	the	LDL	receptor.	Pubmed:18408013
chr11	116701562	116701565	P02656	0	+	116701562	116701565	102,0,51	1	3	0	.	May	interact	with	the	LDL	receptor.	Pubmed:18408013
chr11	117100134	117100140	Q16549	0	-	117100134	117100140	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr11	117982481	117982487	Q9NRS4	0	+	117982481	117982487	102,0,51	1	6	0	.	Cleavage.
chr11	118352794	118352800	Q03164	0	+	118352794	118352800	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KMT2A-ZFYVE19	oncogene.
chr11	118353207	118353210	Q03164	0	+	118353207	118353210	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	KMT2A-FRYL	fusion	protein.
chr11	118353207	118354900	Q03164	0	+	118353207	118354900	102,0,51	1	1693	0	.	Breakpoint	for	translocation	to	form	KMT2A-AF3P21	and	KMT2A-KNL1	oncogenes.
chr11	118353207	118354900	Q03164	0	+	118353207	118354900	102,0,51	1	1693	0	.	Breakpoint	for	translocation	to	form	KMT2A-CENPK	oncogene.
chr11	118355026	118355579	Q03164	0	+	118355026	118355579	102,0,51	1	553	0	.	Breakpoint	for	translocation	to	form	KMT2A-AFF4	fusion	protein.
chr11	118355687	118359331	Q03164	0	+	118355687	118359331	102,0,51	1	3644	0	.	Breakpoint	for	translocation	to	form	KMT2A-GAS7	oncogene.
chr11	118355687	118359331	Q03164	0	+	118355687	118359331	102,0,51	1	3644	0	.	Breakpoint	for	translocation	to	form	KMT2A-LPP.
chr11	118374611	118374617	Q03164	0	+	118374611	118374617	102,0,51	1	6	0	.	Cleavage;	by	TASP1,	site	1.	Pubmed:14636557
chr11	118374767	118374773	Q03164	0	+	118374767	118374773	102,0,51	1	6	0	.	Cleavage;	by	TASP1,	site	2.	Pubmed:14636557
chr11	118390487	118390490	Q03164	0	+	118390487	118390490	102,0,51	1	3	0	.	Important	for	WDR5-recognition	and	binding.	Pubmed:19556245
chr11	120302617	120308019	Q9NZN5	0	+	120302617	120308019	102,0,51	1	5402	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-ARHGEF12	oncogene.
chr11	124615494	124615497	Q92686	0	+	124615494	124615497	102,0,51	1	3	0	.	Crucial	for	interaction	with	calmodulin.
chr11	128709682	128709685	A0A024R3K6	0	-	128709682	128709685	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr11	128709682	128709685	P48048	0	-	128709682	128709685	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr11	128781702	128781705	P48544	0	+	128781702	128781705	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr11	129993541	129993547	Q06481	0	+	129993541	129993547	102,0,51	1	6	0	.	Reactive	bond.
chr11	134251873	134251876	Q9P2W7	0	-	134251873	134251876	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr11	134252837	134252840	Q9P2W7	0	-	134252837	134252840	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr12	1292584	1299027	Q8IUD2	0	+	1292584	1299027	102,0,51	1	6443	0	.	Breakpoint	for	translocation	to	form	ERC1-RET	oncogene.
chr12	1299512	1305955	Q8IUD2	0	+	1299512	1305955	102,0,51	1	6443	0	.	Breakpoint	for	translocation	to	form	ERC1-RET	oncogene.
chr12	4461635	4461638	Q9NQ88	0	+	4461635	4461638	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr12	4479724	4479730	Q9GZV9	0	-	4479724	4479730	102,0,51	1	6	0	.	Cleavage;	by	proprotein	convertases.
chr12	6646758	6646761	P04406	0	+	6646758	6646761	102,0,51	1	3	0	.	Activates	thiol	group	during	catalysis.
chr12	6646758	6646761	V9HVZ4	0	+	6646758	6646761	102,0,51	1	3	0	.	Activates	thiol	group	during	catalysis.
chr12	7044754	7044760	P54259	0	+	7044754	7044760	102,0,51	1	6	0	.	Cleavage.
chr12	7083581	7083584	Q92979	0	+	7083581	7083584	102,0,51	1	3	0	.	Interaction	with	substrate	rRNA.
chr12	7083587	7083590	Q92979	0	+	7083587	7083590	102,0,51	1	3	0	.	Stabilizes	Arg-84.
chr12	7083815	7083818	Q92979	0	+	7083815	7083818	102,0,51	1	3	0	.	Interaction	with	substrate	rRNA.
chr12	7083824	7083827	Q92979	0	+	7083824	7083827	102,0,51	1	3	0	.	Interaction	with	substrate	rRNA.
chr12	7083836	7083839	Q92979	0	+	7083836	7083839	102,0,51	1	3	0	.	Interaction	with	substrate	rRNA.
chr12	7649424	7649430	Q86VB7	0	-	7649424	7649430	102,0,51	1	6	0	.	Cleavage;	in	calcium-free	condition.
chr12	7649505	7649511	Q86VB7	0	-	7649505	7649511	102,0,51	1	6	0	.	Cleavage;	in	calcium-free	condition.
chr12	7649661	7649667	Q86VB7	0	-	7649661	7649667	102,0,51	1	6	0	.	Cleavage;	in	calcium-free	condition.
chr12	7649697	7649703	Q86VB7	0	-	7649697	7649703	102,0,51	1	6	0	.	Cleavage;	in	calcium-free	condition.
chr12	10313399	10313402	P78380	0	-	10313399	10313402	102,0,51	1	3	0	.	Not	glycosylated.
chr12	10374439	10374445	Q9H0R8	0	+	10374439	10374445	102,0,51	1	6	0	.	Cleavage;	by	RavZ.
chr12	10374442	10374448	Q9H0R8	0	+	10374442	10374448	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr12	11803091	11905386	P41212	0	+	11803091	11905386	102,0,51	1	102295	0	.	Breakpoint	for	translocation	to	form	CHIC2-ETV6	in	AML.
chr12	11905509	11992075	P41212	0	+	11905509	11992075	102,0,51	1	86566	0	.	Breakpoint	for	translocation	to	form	ETV6-MDS2	in	MDS.
chr12	11992072	11992078	P41212	0	+	11992072	11992078	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PAX5-ETV6.
chr12	12022899	12037380	P41212	0	+	12022899	12037380	102,0,51	1	14481	0	.	Breakpoint	for	translocation	to	form	ETV6-AML1	in	ALL.
chr12	13761701	13761704	Q13224	0	-	13761701	13761704	102,0,51	1	3	0	.	Functional	determinant	of	NMDA	receptors.
chr12	14827571	14827574	P25092	0	-	14827571	14827574	102,0,51	1	3	0	.	Not	glycosylated.
chr12	16510559	16510562	P10620	0	+	16510559	16510562	102,0,51	1	3	0	.	Activates	the	enzyme	when	modified.
chr12	21680083	21680089	Q9BT56	0	+	21680083	21680089	102,0,51	1	6	0	.	Cleavage;	by	prohormone	convertase	2.
chr12	21680668	21680674	Q9BT56	0	+	21680668	21680674	102,0,51	1	6	0	.	Cleavage;	by	prohormone	convertase	2.
chr12	21681939	21681945	Q9BT56	0	+	21681939	21681945	102,0,51	1	6	0	.	Cleavage;	by	prohormone	convertase	2.
chr12	21919421	21919424	A0A024RAV6	0	-	21919421	21919424	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr12	21919421	21919424	Q15842	0	-	21919421	21919424	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr12	27110673	27113450	Q9NVK5	0	+	27110673	27113450	102,0,51	1	2777	0	.	Breakpoint	for	translocation	to	form	FGFR1OP2-FGFR1.
chr12	48179594	48179597	J3KPH8	0	-	48179594	48179597	102,0,51	1	3	0	.	Contributes	to	catalysis.
chr12	48179594	48179597	Q8WUI4	0	-	48179594	48179597	102,0,51	1	3	0	.	Contributes	to	catalysis.
chr12	48369259	48369265	P02458	0	-	48369259	48369265	102,0,51	1	6	0	.	Cleavage;	by	procollagen	C-endopeptidase.
chr12	48390393	48390399	P02458	0	-	48390393	48390399	102,0,51	1	6	0	.	Cleavage;	by	procollagen	N-endopeptidase.
chr12	49088213	49088216	O60563	0	-	49088213	49088216	102,0,51	1	3	0	.	Essential	for	interacting	with	HIV-1	Tat.
chr12	49484019	49484022	O43323	0	-	49484019	49484022	102,0,51	1	3	0	.	Essential	for	auto-cleavage.
chr12	49484028	49484031	O43323	0	-	49484028	49484031	102,0,51	1	3	0	.	Involved	in	auto-cleavage.
chr12	49484100	49484103	O43323	0	-	49484100	49484103	102,0,51	1	3	0	.	Involved	in	cholesterol	transfer.
chr12	49484235	49484241	O43323	0	-	49484235	49484241	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr12	49521743	49521746	P68363	0	-	49521743	49521746	102,0,51	1	3	0	.	Involved	in	polymerization.
chr12	49578795	49578798	Q71U36	0	-	49578795	49578798	102,0,51	1	3	0	.	Involved	in	polymerization.
chr12	49667004	49667007	Q9BQE3	0	+	49667004	49667007	102,0,51	1	3	0	.	Involved	in	polymerization.
chr12	50452759	50452762	P78348	0	+	50452759	50452762	102,0,51	1	3	0	.	Important	for	channel	gating.
chr12	50452783	50452786	P78348	0	+	50452783	50452786	102,0,51	1	3	0	.	Important	for	channel	desensitizing.
chr12	50472224	50472227	P78348	0	+	50472224	50472227	102,0,51	1	3	0	.	Important	for	channel	gating.
chr12	51207791	51207794	P18846	0	+	51207791	51207794	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	chimeric	EWSR1/ATF1	protein.
chr12	51207797	51207800	P18846	0	+	51207797	51207800	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	chimeric	FUS/ATF1	protein.
chr12	52566157	52566160	Q6KB66	0	-	52566157	52566160	102,0,51	1	3	0	.	Stutter.
chr12	52639237	52639240	P08729	0	+	52639237	52639240	102,0,51	1	3	0	.	Stutter.
chr12	52822221	52822224	O95678	0	-	52822221	52822224	102,0,51	1	3	0	.	Stutter.
chr12	52841743	52841746	P04259	0	-	52841743	52841746	102,0,51	1	3	0	.	Stutter.
chr12	52863635	52863638	P48668	0	-	52863635	52863638	102,0,51	1	3	0	.	Stutter.
chr12	52882293	52882296	P02538	0	-	52882293	52882296	102,0,51	1	3	0	.	Stutter.
chr12	52910602	52910605	P13647	0	-	52910602	52910605	102,0,51	1	3	0	.	Stutter.
chr12	52940251	52940254	Q3SY84	0	-	52940251	52940254	102,0,51	1	3	0	.	Stutter.
chr12	52962134	52962137	Q7RTS7	0	-	52962134	52962137	102,0,51	1	3	0	.	Stutter.
chr12	52981596	52981599	Q14CN4	0	-	52981596	52981599	102,0,51	1	3	0	.	Stutter.
chr12	53004580	53004583	Q86Y46	0	-	53004580	53004583	102,0,51	1	3	0	.	Stutter.
chr12	53040705	53040708	P35908	0	-	53040705	53040708	102,0,51	1	3	0	.	Stutter.
chr12	53070234	53070237	P04264	0	-	53070234	53070237	102,0,51	1	3	0	.	Stutter.
chr12	53086377	53086380	Q7Z794	0	-	53086377	53086380	102,0,51	1	3	0	.	Stutter.
chr12	53216981	53216984	Q5XKE5	0	-	53216981	53216984	102,0,51	1	3	0	.	Stutter.
chr12	53233729	53233732	Q8N1N4	0	-	53233729	53233732	102,0,51	1	3	0	.	Stutter.
chr12	53292638	53292641	P05787	0	-	53292638	53292641	102,0,51	1	3	0	.	Stutter.
chr12	53345318	53345324	P05783	0	+	53345318	53345324	102,0,51	1	6	0	.	Cleavage;	by	caspase-3,	caspase-6	or	caspase-7.
chr12	53345417	53345420	P05783	0	+	53345417	53345420	102,0,51	1	3	0	.	Stutter.
chr12	53345944	53345947	P05783	0	+	53345944	53345947	102,0,51	1	3	0	.	Stutter.
chr12	53682094	53682100	Q14674	0	+	53682094	53682100	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr12	53682377	53682383	Q14674	0	+	53682377	53682383	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr12	53775917	53775923	P08047	0	+	53775917	53775923	102,0,51	1	6	0	.	Cleavage.
chr12	53861034	53861040	Q15366	0	+	53861034	53861040	102,0,51	1	6	0	.	Cleavage,	by	viral	proteinase	3CD.	Pubmed:24371074
chr12	54059151	54059154	Q06055	0	-	54059151	54059154	102,0,51	1	3	0	.	Reversibly	protonated	during	proton	transport.
chr12	56090141	56090147	Q13683	0	-	56090141	56090147	102,0,51	1	6	0	.	Cleavage;	by	urokinase.
chr12	56360816	56360819	P24941	0	+	56360816	56360819	102,0,51	1	3	0	.	CDK7	binding.
chr12	56361899	56361905	P24941	0	+	56361899	56361905	102,0,51	1	6	0	.	CDK7	binding.
chr12	56363267	56363270	P24941	0	+	56363267	56363270	102,0,51	1	3	0	.	CDK7	binding.
chr12	56847452	56847455	P30301	0	-	56847452	56847455	102,0,51	1	3	0	.	Important	for	water	channel	gating.
chr12	58217773	58217776	O14595	0	-	58217773	58217776	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr12	58218024	58218027	O14595	0	-	58218024	58218027	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr12	69260784	69260787	P14384	0	-	69260784	69260787	102,0,51	1	3	0	.	Probable	structural	role.	Pubmed:12457462
chr12	72893406	72893409	Q9UKU6	0	+	72893406	72893409	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr12	88912545	88912548	P21583	0	-	88912545	88912548	102,0,51	1	3	0	.	Not	glycosylated.
chr12	96408699	96408702	P09960	0	-	96408699	96408702	102,0,51	1	3	0	.	Covalently	modified	during	suicide	inhibition	by	leukotrienes.
chr12	96408708	96408711	P09960	0	-	96408708	96408711	102,0,51	1	3	0	.	Essential	for	epoxide	hydrolase	activity,	but	not	for	aminopeptidase	activity.
chr12	102155469	102155475	Q3T906	0	-	102155469	102155475	102,0,51	1	6	0	.	Cleavage;	by	MBTPS1.
chr12	105462598	105462601	Q3SY69	0	-	105462598	105462601	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr12	105597479	105597485	Q8NEU8	0	-	105597479	105597485	102,0,51	1	6	0	.	Breakpoint	for	chromosomal	translocation.	Pubmed:11431708
chr12	110897602	110897605	Q9UHW5	0	-	110897602	110897605	102,0,51	1	3	0	.	Stabilizes	the	phosphate	intermediate;	shared	with	dimeric	partner.
chr12	111160002	111160005	P36873	0	-	111160002	111160005	102,0,51	1	3	0	.	Inhibition	by	microcystin	toxin	binding.
chr12	112228240	112228243	P05091	0	+	112228240	112228243	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr12	113348857	113348860	P00973	0	+	113348857	113348860	102,0,51	1	3	0	.	Interaction	with	dsRNA.
chr12	113382282	113382285	Q9Y6K5	0	+	113382282	113382285	102,0,51	1	3	0	.	Interaction	with	dsRNA.	Pubmed:25775560
chr12	113384640	113384643	Q9Y6K5	0	+	113384640	113384643	102,0,51	1	3	0	.	Interaction	with	dsRNA.	Pubmed:25775560
chr12	117014104	117014110	A6NCE7	0	+	117014104	117014110	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr12	120884052	120884055	O43715	0	-	120884052	120884055	102,0,51	1	3	0	.	Important	for	interaction	with	PRELID3A.	Pubmed:26071602
chr12	120884094	120884097	O43715	0	-	120884094	120884097	102,0,51	1	3	0	.	Important	for	interaction	with	PRELID3A.	Pubmed:26071602
chr12	121858104	121858110	Q969K3	0	+	121858104	121858110	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.	Pubmed:12118383
chr12	125398113	125398116	P0CG48	0	-	125398113	125398116	102,0,51	1	3	0	.	Essential	for	function.
chr12	130839177	130839180	Q96J94	0	+	130839177	130839180	102,0,51	1	3	0	.	Required	for	binding	2'-O-methylated	3'-end	of	piRNAs.
chr12	133384718	133384724	Q08378	0	-	133384718	133384724	102,0,51	1	6	0	.	Cleavage;	by	caspase-7.
chr12	133389991	133389997	Q08378	0	-	133389991	133389997	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr12	133393351	133393357	Q08378	0	-	133393351	133393357	102,0,51	1	6	0	.	Cleavage;	by	caspase-2.
chr13	19748005	19748008	Q13748	0	-	19748005	19748008	102,0,51	1	3	0	.	Involved	in	polymerization.
chr13	20208062	20208065	Q99549	0	+	20208062	20208065	102,0,51	1	3	0	.	Interaction	with	histone	H3K9me3.	Pubmed:21419134
chr13	20633699	20635195	Q9UBW7	0	+	20633699	20635195	102,0,51	1	1496	0	.	Breakpoint	for	translocation	to	form	ZMYM2-FGFR1.
chr13	21013734	21013737	A0A024RDM2	0	-	21013734	21013737	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr13	21013734	21013737	V9HWG2	0	-	21013734	21013737	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr13	28919632	28919638	P17948	0	-	28919632	28919638	102,0,51	1	6	0	.	Cleavage;	by	PSEN1.
chr13	31037435	31037441	P09429	0	-	31037435	31037441	102,0,51	1	6	0	.	Cleavage;	by	CASP1.	Pubmed:24474694
chr13	31037784	31037790	P09429	0	-	31037784	31037790	102,0,51	1	6	0	.	Cleavage;	by	thrombin:thrombomodulin.
chr13	41134952	41134955	Q12778	0	-	41134952	41134955	102,0,51	1	3	0	.	DNA-binding.
chr13	41239854	41239857	Q12778	0	-	41239854	41239857	102,0,51	1	3	0	.	DNA-binding.
chr13	41239875	41239878	Q12778	0	-	41239875	41239878	102,0,51	1	3	0	.	DNA-binding.
chr13	43174914	43174920	O14788	0	+	43174914	43174920	102,0,51	1	6	0	.	Cleavage.
chr13	46632337	46632343	Q96IY4	0	-	46632337	46632343	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr13	48562723	48562726	Q9P2R7	0	-	48562723	48562726	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr13	48563105	48563108	Q9P2R7	0	-	48563105	48563108	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr13	48835285	48835291	Q9Y287	0	+	48835285	48835291	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr13	51935962	51935968	A8MV23	0	+	51935962	51935968	102,0,51	1	6	0	.	Reactive	bond.
chr13	76178903	76178906	P15374	0	+	76178903	76178906	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr13	80107525	80107528	Q9NV92	0	+	80107525	80107528	102,0,51	1	3	0	.	Not	phosphorylated	by	SRC.
chr13	80911405	80911411	O43597	0	-	80911405	80911411	102,0,51	1	6	0	.	Cleavage;	by	FAP.	Pubmed:21288888
chr13	99114138	99114144	Q9Y6E0	0	-	99114138	99114144	102,0,51	1	6	0	.	Cleavage;	by	caspase-3,	caspase-7	and	caspase-8.
chr13	103698545	103698548	Q12908	0	-	103698545	103698548	102,0,51	1	3	0	.	Not	glycosylated.
chr13	108922744	108922750	Q9Y275	0	+	108922744	108922750	102,0,51	1	6	0	.	Cleavage.
chr13	113768180	113768183	P08709	0	+	113768180	113768183	102,0,51	1	3	0	.	Important	for	S-112	for	O-xylosylation.
chr13	113771141	113771147	P08709	0	+	113771141	113771147	102,0,51	1	6	0	.	Cleavage;	by	factor	Xa,	factor	XIIa,	factor	IXa,	or	thrombin.
chr14	20924104	20924110	P27695	0	+	20924104	20924110	102,0,51	1	6	0	.	Cleavage;	by	granzyme	A.
chr14	20925343	20925346	P27695	0	+	20925343	20925346	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr14	20925556	20925559	P27695	0	+	20925556	20925559	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr14	20925634	20925637	P27695	0	+	20925634	20925637	102,0,51	1	3	0	.	Interaction	with	DNA	substrate.
chr14	21360022	21360025	P12724	0	+	21360022	21360025	102,0,51	1	3	0	.	May	be	involved	in	LPS-binding.
chr14	21360028	21360031	P12724	0	+	21360028	21360031	102,0,51	1	3	0	.	May	be	involved	in	LPS-	and	LTA-binding.
chr14	23393876	23393879	O14744	0	-	23393876	23393879	102,0,51	1	3	0	.	Critical	for	specifying	symmetric	addition	of	methyl	groups.
chr14	23530822	23530828	Q9UKV3	0	-	23530822	23530828	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr14	24687355	24687358	Q15843	0	-	24687355	24687358	102,0,51	1	3	0	.	Interaction	with	UBE1C.
chr14	24687631	24687634	Q15843	0	-	24687631	24687634	102,0,51	1	3	0	.	Interaction	with	UBE1C.
chr14	25100336	25100339	P10144	0	-	25100336	25100339	102,0,51	1	3	0	.	Mediates	preference	for	Asp-containing	substrates.
chr14	51398450	51398453	P06737	0	-	51398450	51398453	102,0,51	1	3	0	.	May	be	involved	in	allosteric	control.
chr14	51398489	51398492	P06737	0	-	51398489	51398492	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr14	51404471	51404474	P06737	0	-	51404471	51404474	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr14	65482363	65482366	P49356	0	+	65482363	65482366	102,0,51	1	3	0	.	Important	for	selectivity	against	geranylgeranyl	diphosphate.
chr14	68353918	68758603	O15315	0	+	68353918	68758603	102,0,51	1	404685	0	.	Breakpoint	for	translocation	to	form	HMGA2-RAD51B.
chr14	73673095	73673101	P49768	0	+	73673095	73673101	102,0,51	1	6	0	.	Cleavage;	alternate.	Pubmed:9173929
chr14	73673098	73673104	P49768	0	+	73673098	73673104	102,0,51	1	6	0	.	Cleavage;	alternate.	Pubmed:9173929
chr14	73673116	73673122	P49768	0	+	73673116	73673122	102,0,51	1	6	0	.	Cleavage.	Pubmed:9173929
chr14	73678553	73678559	P49768	0	+	73678553	73678559	102,0,51	1	6	0	.	Cleavage;	by	caspase.	Pubmed:9485372
chr14	76948396	76948399	O95718	0	+	76948396	76948399	102,0,51	1	3	0	.	Important	for	stabilizing	DNA-binding.
chr14	77229248	77229254	Q7L8A9	0	+	77229248	77229254	102,0,51	1	6	0	.	Cleavage.
chr14	77229389	77229395	Q7L8A9	0	+	77229389	77229395	102,0,51	1	6	0	.	Cleavage.
chr14	78161136	78161139	Q13686	0	-	78161136	78161139	102,0,51	1	3	0	.	Primary	catalytic	residue	forming	the	imine	linkage	with	DNA.	Pubmed:23577621
chr14	78161136	78161139	Q13686	0	-	78161136	78161139	102,0,51	1	3	0	.	Secondary	catalytic	residue	forming	the	imine	linkage	with	DNA.	Pubmed:23577621
chr14	81658970	81658976	P52655	0	-	81658970	81658976	102,0,51	1	6	0	.	Cleavage;	by	TASP1.
chr14	90485669	90485672	Q9NUW8	0	+	90485669	90485672	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:12470949
chr14	92442528	92442534	Q15643	0	-	92442528	92442534	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	TRIP11-PDGFRB.
chr14	93176064	93176070	Q99538	0	-	93176064	93176070	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr14	93282763	93286055	Q8TBA6	0	+	93282763	93286055	102,0,51	1	3292	0	.	Breakpoint	for	translocation	to	form	RET-GOLGA5	oncogene.
chr14	94512238	94512241	Q96DC9	0	+	94512238	94512241	102,0,51	1	3	0	.	Required	to	orient	and	stabilize	the	active	site	H-224.	Pubmed:15258613
chr14	94750409	94750415	Q9UK55	0	-	94750409	94750415	102,0,51	1	6	0	.	Reactive	bond.
chr14	94754672	94754675	Q9UK55	0	-	94754672	94754675	102,0,51	1	3	0	.	Essential	for	interaction	with	PROZ.
chr14	94754831	94754834	Q9UK55	0	-	94754831	94754834	102,0,51	1	3	0	.	Essential	for	interaction	with	PROZ.
chr14	94776206	94776209	P08185	0	-	94776206	94776209	102,0,51	1	3	0	.	Conserved	cysteine	within	steroid	binding	domain.
chr14	94844893	94844899	P01009	0	-	94844893	94844899	102,0,51	1	6	0	.	Reactive	bond.
chr14	95035809	95035815	P29622	0	+	95035809	95035815	102,0,51	1	6	0	.	Reactive	bond.
chr14	95058471	95058477	P05154	0	+	95058471	95058477	102,0,51	1	6	0	.	Reactive	bond.
chr14	95090025	95090031	P01011	0	+	95090025	95090031	102,0,51	1	6	0	.	Reactive	bond.
chr14	95557648	95557651	Q9UPY3	0	-	95557648	95557651	102,0,51	1	3	0	.	Important	for	activity.
chr14	96994304	96994307	P51003	0	+	96994304	96994307	102,0,51	1	3	0	.	Interaction	with	RNA.
chr14	96994319	96994322	P51003	0	+	96994319	96994322	102,0,51	1	3	0	.	Interaction	with	RNA.
chr14	97002287	97002290	P51003	0	+	97002287	97002290	102,0,51	1	3	0	.	Interaction	with	RNA.
chr14	97009135	97009138	P51003	0	+	97009135	97009138	102,0,51	1	3	0	.	Interaction	with	RNA.
chr14	97018864	97018867	P51003	0	+	97018864	97018867	102,0,51	1	3	0	.	Interaction	with	RNA.
chr14	106110149	106110152	P01859	0	-	106110149	106110152	102,0,51	1	3	0	.	At	or	near	the	complement-binding	site.
chr14	106110920	106110923	P01859	0	-	106110920	106110923	102,0,51	1	3	0	.	At	or	near	the	complement-binding	site.
chr15	34129184	34129187	Q15413	0	+	34129184	34129187	102,0,51	1	3	0	.	Important	for	activation	by	Ca(2+).
chr15	34638232	34640171	Q86Y26	0	+	34638232	34640171	102,0,51	1	1939	0	.	Breakpoint	for	translocation	to	form	BRD4-NUT	and	BRD3-NUT	fusion	proteins.
chr15	40498384	40498390	O60566	0	+	40498384	40498390	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr15	40498477	40498483	O60566	0	+	40498477	40498483	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr15	40917835	40920270	Q8NG31	0	+	40917835	40920270	102,0,51	1	2435	0	.	Breakpoint	for	translocation	to	form	KMT2A-KNL1.	Pubmed:12618766
chr15	41101636	41101642	Q96K21	0	+	41101636	41101642	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-ZFYVE19.
chr15	41145943	41145949	O43278	0	+	41145943	41145949	102,0,51	1	6	0	.	Reactive	bond.
chr15	41148124	41148130	O43278	0	+	41148124	41148130	102,0,51	1	6	0	.	Reactive	bond.
chr15	41222305	41222308	Q9NR61	0	+	41222305	41222308	102,0,51	1	3	0	.	Interaction	with	Notch1.
chr15	41223951	41223954	Q9NR61	0	+	41223951	41223954	102,0,51	1	3	0	.	Interaction	with	Notch1.
chr15	43641164	43641167	Q6DHV7	0	+	43641164	43641167	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr15	44046025	44046028	P30101	0	+	44046025	44046028	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr15	44046028	44046031	P30101	0	+	44046028	44046031	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr15	44048954	44048957	P30101	0	+	44048954	44048957	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	first	active	site.
chr15	44061796	44061799	P30101	0	+	44061796	44061799	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr15	44061799	44061802	P30101	0	+	44061799	44061802	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr15	44063308	44063311	P30101	0	+	44063308	44063311	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	second	active	site.
chr15	49493431	49493434	Q01415	0	+	49493431	49493434	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr15	51634160	51634166	Q6ZMI3	0	+	51634160	51634166	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr15	51692408	51692414	Q6ZMI3	0	+	51692408	51692414	102,0,51	1	6	0	.	Cleavage;	by	BMP1.
chr15	58285265	58285268	O94788	0	-	58285265	58285268	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr15	66679706	66679712	Q02750	0	+	66679706	66679712	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr15	67358609	67358612	P84022	0	+	67358609	67358612	102,0,51	1	3	0	.	Required	for	trimerization.
chr15	67358612	67358615	P84022	0	+	67358612	67358615	102,0,51	1	3	0	.	Required	for	interaction	with	DNA	and	JUN	and	for	functional	cooperation	with	JUN.
chr15	68582719	68582725	Q9UK73	0	+	68582719	68582725	102,0,51	1	6	0	.	Cleavage;	by	a	caspase-3-like	protease.
chr15	72494802	72494805	P14618	0	-	72494802	72494805	102,0,51	1	3	0	.	Crucial	for	phosphotyrosine	binding.
chr15	72500987	72500990	P14618	0	-	72500987	72500990	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr15	74177123	74177126	Q8IYX1	0	+	74177123	74177126	102,0,51	1	3	0	.	Arginine	finger.
chr15	74177351	74177354	Q8IYX1	0	+	74177351	74177354	102,0,51	1	3	0	.	Glutamine	finger.
chr15	74315745	74317199	P29590	0	+	74315745	74317199	102,0,51	1	1454	0	.	Breakpoint	for	translocation	to	form	PML-RARA	oncogene	in	type	A	APL.
chr15	74325751	74326820	P29590	0	+	74325751	74326820	102,0,51	1	1069	0	.	Breakpoint	for	translocation	to	form	PML-RARA	oncogene	in	type	B	APL.
chr15	75890953	75890956	O95149	0	-	75890953	75890956	102,0,51	1	3	0	.	Interaction	with	m3G-cap	structure.	Pubmed:15920472
chr15	75901968	75901971	O95149	0	-	75901968	75901971	102,0,51	1	3	0	.	Interaction	with	m3G-cap	structure.	Pubmed:15920472
chr15	75902323	75902326	O95149	0	-	75902323	75902326	102,0,51	1	3	0	.	Interaction	with	m3G-cap	structure.	Pubmed:15920472
chr15	78454089	78454092	P50213	0	+	78454089	78454092	102,0,51	1	3	0	.	Critical	for	catalysis.
chr15	78454695	78454698	P50213	0	+	78454695	78454698	102,0,51	1	3	0	.	Critical	for	catalysis.
chr15	78922244	78922247	P30926	0	-	78922244	78922247	102,0,51	1	3	0	.	Key	residue	for	a	low	dissociation	(K(off))	from	the	conotoxin	BuIA.
chr15	78923632	78923635	P30926	0	-	78923632	78923635	102,0,51	1	3	0	.	Key	residue	that	facilitates	effective	access	of	the	conotoxin	BuIA	to	the	channel	binding	site.
chr15	88420183	88420186	Q16288	0	-	88420183	88420186	102,0,51	1	3	0	.	Interaction	with	PLC-gamma-1.
chr15	88576124	88576127	Q16288	0	-	88576124	88576127	102,0,51	1	3	0	.	Interaction	with	SHC1.
chr15	90346883	90346886	P15144	0	-	90346883	90346886	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:22932899
chr15	90630732	90630735	P48735	0	-	90630732	90630735	102,0,51	1	3	0	.	Critical	for	catalysis.
chr15	90631731	90631734	P48735	0	-	90631731	90631734	102,0,51	1	3	0	.	Critical	for	catalysis.
chr15	91419529	91419535	P09958	0	+	91419529	91419535	102,0,51	1	6	0	.	Cleavage,	second;	by	autolysis.
chr15	91419733	91419739	P09958	0	+	91419733	91419739	102,0,51	1	6	0	.	Cleavage,	first;	by	autolysis.
chr15	101434161	101434164	P47895	0	+	101434161	101434164	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr15	101972257	101972263	P29122	0	-	101972257	101972263	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr16	222944	222947	P69905	0	+	222944	222947	102,0,51	1	3	0	.	Not	glycated.
chr16	223196	223199	P69905	0	+	223196	223199	102,0,51	1	3	0	.	Not	glycated.
chr16	223208	223211	P69905	0	+	223208	223211	102,0,51	1	3	0	.	Not	glycated.
chr16	223298	223301	P69905	0	+	223298	223301	102,0,51	1	3	0	.	Not	glycated.
chr16	223325	223328	P69905	0	+	223325	223328	102,0,51	1	3	0	.	Not	glycated.
chr16	226748	226751	P69905	0	+	226748	226751	102,0,51	1	3	0	.	Not	glycated.
chr16	227000	227003	P69905	0	+	227000	227003	102,0,51	1	3	0	.	Not	glycated.
chr16	227012	227015	P69905	0	+	227012	227015	102,0,51	1	3	0	.	Not	glycated.
chr16	227102	227105	P69905	0	+	227102	227105	102,0,51	1	3	0	.	Not	glycated.
chr16	227129	227132	P69905	0	+	227129	227132	102,0,51	1	3	0	.	Not	glycated.
chr16	334400	334403	Q13087	0	+	334400	334403	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr16	334403	334406	Q13087	0	+	334403	334406	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr16	334663	334666	Q13087	0	+	334663	334666	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	first	active	site.
chr16	336567	336570	Q13087	0	+	336567	336570	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr16	336570	336573	Q13087	0	+	336570	336573	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr16	336855	336858	Q13087	0	+	336855	336858	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	second	active	site.
chr16	682773	682779	Q96NZ8	0	+	682773	682779	102,0,51	1	6	0	.	Reactive	bond.
chr16	1250727	1250730	O95180	0	+	1250727	1250730	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr16	1257286	1257289	O95180	0	+	1257286	1257289	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr16	1261748	1261751	O95180	0	+	1261748	1261751	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr16	1268016	1268019	O95180	0	+	1268016	1268019	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr16	1364040	1364043	P63279	0	+	1364040	1364043	102,0,51	1	3	0	.	Interaction	with	RANBP2.
chr16	1364299	1364302	P63279	0	+	1364299	1364302	102,0,51	1	3	0	.	Interaction	with	RANBP2.
chr16	1365672	1365675	P63279	0	+	1365672	1365675	102,0,51	1	3	0	.	Interaction	with	RANBP2.
chr16	1370248	1370254	P63279	0	+	1370248	1370254	102,0,51	1	6	0	.	Substrate	binding.
chr16	1505770	1505773	P51798	0	-	1505770	1505773	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	protein	to	the	inner	aqueous	phase.
chr16	1507335	1507338	P51798	0	-	1507335	1507338	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	outer	aqueous	phase	to	the	interior	of	the	protein;	involved	in	linking	H(+)	and	Cl(-)	transport.
chr16	1551769	1551772	Q9Y4R8	0	+	1551769	1551772	102,0,51	1	3	0	.	Interaction	with	PIH1D1.
chr16	1551772	1551775	Q9Y4R8	0	+	1551772	1551775	102,0,51	1	3	0	.	Interaction	with	PIH1D1.
chr16	1552048	1552051	Q9Y4R8	0	+	1552048	1552051	102,0,51	1	3	0	.	Interaction	with	PIH1D1.
chr16	2090231	2090234	E5KTI5	0	-	2090231	2090234	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr16	2090231	2090234	P78549	0	-	2090231	2090234	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr16	2152435	2152441	P98161	0	-	2152435	2152441	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr16	2264166	2264169	A6NDG6	0	-	2264166	2264169	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr16	2293347	2293350	P42126	0	-	2293347	2293350	102,0,51	1	3	0	.	Important	for	catalytic	activity.	Pubmed:15351645
chr16	2569692	2569695	P27449	0	+	2569692	2569695	102,0,51	1	3	0	.	Essential	for	proton	translocation.
chr16	3299697	3299703	O15553	0	-	3299697	3299703	102,0,51	1	6	0	.	Cleavage;	by	CASP1.
chr16	3526326	3526329	Q9H7X0	0	+	3526326	3526329	102,0,51	1	3	0	.	Required	to	recognizing	and	positioning	the	ethanethioate	moiety	ofacetyl-CoA	to	the	right	location	to	facilitate	acetyl-transfer.	Pubmed:27550639
chr16	3860777	3900300	Q92793	0	-	3860777	3900300	102,0,51	1	39523	0	.	Breakpoint	for	translocation	to	form	KAT6A-CREBBP.
chr16	3901005	3901011	Q92793	0	-	3901005	3901011	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6B-CREBBP.
chr16	4386808	4386814	Q9BZE0	0	+	4386808	4386814	102,0,51	1	6	0	.	Cleavage.
chr16	7629859	7629862	A0A087X2B1	0	+	7629859	7629862	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629859	7629862	B7Z1U7	0	+	7629859	7629862	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629859	7629862	F8VZG9	0	+	7629859	7629862	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629859	7629862	J3KNW3	0	+	7629859	7629862	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629859	7629862	Q9NWB1	0	+	7629859	7629862	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629883	7629886	A0A087X2B1	0	+	7629883	7629886	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629883	7629886	B7Z1U7	0	+	7629883	7629886	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629883	7629886	F8VZG9	0	+	7629883	7629886	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629883	7629886	J3KNW3	0	+	7629883	7629886	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629883	7629886	Q9NWB1	0	+	7629883	7629886	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629886	7629889	A0A087X2B1	0	+	7629886	7629889	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629886	7629889	B7Z1U7	0	+	7629886	7629889	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629886	7629889	F8VZG9	0	+	7629886	7629889	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629886	7629889	J3KNW3	0	+	7629886	7629889	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7629886	7629889	Q9NWB1	0	+	7629886	7629889	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637284	7637287	A0A087X2B1	0	+	7637284	7637287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637284	7637287	B7Z1U7	0	+	7637284	7637287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637284	7637287	F8VZG9	0	+	7637284	7637287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637284	7637287	J3KNW3	0	+	7637284	7637287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637284	7637287	Q9NWB1	0	+	7637284	7637287	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637299	7637302	A0A087X2B1	0	+	7637299	7637302	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637299	7637302	B7Z1U7	0	+	7637299	7637302	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637299	7637302	F8VZG9	0	+	7637299	7637302	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637299	7637302	J3KNW3	0	+	7637299	7637302	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7637299	7637302	Q9NWB1	0	+	7637299	7637302	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645559	7645562	A0A087X2B1	0	+	7645559	7645562	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645559	7645562	B7Z1U7	0	+	7645559	7645562	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645559	7645562	F8VZG9	0	+	7645559	7645562	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645559	7645562	J3KNW3	0	+	7645559	7645562	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645559	7645562	Q9NWB1	0	+	7645559	7645562	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645631	7645634	A0A087X2B1	0	+	7645631	7645634	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645631	7645634	B7Z1U7	0	+	7645631	7645634	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645631	7645634	F8VZG9	0	+	7645631	7645634	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645631	7645634	J3KNW3	0	+	7645631	7645634	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7645631	7645634	Q9NWB1	0	+	7645631	7645634	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7647390	7647393	A0A087X2B1	0	+	7647390	7647393	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7647390	7647393	B7Z1U7	0	+	7647390	7647393	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7647390	7647393	F8VZG9	0	+	7647390	7647393	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7647390	7647393	J3KNW3	0	+	7647390	7647393	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	7647390	7647393	Q9NWB1	0	+	7647390	7647393	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	9923444	9923447	Q12879	0	-	9923444	9923447	102,0,51	1	3	0	.	Functional	determinant	of	NMDA	receptors.
chr16	12059187	12059193	Q02223	0	+	12059187	12059193	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	IL2/TNFRSF17	oncogene.
chr16	14678632	14678635	O95453	0	-	14678632	14678635	102,0,51	1	3	0	.	Interaction	with	poly(A).	Pubmed:16281054
chr16	15141736	15141739	Q96AB6	0	-	15141736	15141739	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr16	15142796	15142799	Q96AB6	0	+	15142796	15142799	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr16	20348025	20348031	P07911	0	-	20348025	20348031	102,0,51	1	6	0	.	Cleavage.	Pubmed:18375198
chr16	21210894	21210900	Q05996	0	-	21210894	21210900	102,0,51	1	6	0	.	Cleavage.
chr16	21217060	21217066	Q05996	0	-	21217060	21217066	102,0,51	1	6	0	.	Cleavage;	by	ASTL.
chr16	27353482	27353485	P24394	0	+	27353482	27353485	102,0,51	1	3	0	.	Major	IL4	binding	determinant.
chr16	27353560	27353563	P24394	0	+	27353560	27353563	102,0,51	1	3	0	.	Minor	IL4	binding	determinant.
chr16	27353566	27353569	P24394	0	+	27353566	27353569	102,0,51	1	3	0	.	Minor	IL4	binding	determinant.
chr16	27356253	27356256	P24394	0	+	27356253	27356256	102,0,51	1	3	0	.	Minor	IL4	binding	determinant.
chr16	27356259	27356262	P24394	0	+	27356259	27356262	102,0,51	1	3	0	.	Minor	IL4	binding	determinant.
chr16	27356268	27356271	P24394	0	+	27356268	27356271	102,0,51	1	3	0	.	Major	IL4	binding	determinant.
chr16	27357879	27357882	P24394	0	+	27357879	27357882	102,0,51	1	3	0	.	Minor	IL4	binding	determinant.
chr16	27363968	27363971	P24394	0	+	27363968	27363971	102,0,51	1	3	0	.	Major	IL4	binding	determinant.
chr16	30081527	30081530	P04075	0	+	30081527	30081530	102,0,51	1	3	0	.	Necessary	for	preference	for	fructose	1,6-bisphosphate	over	fructose	1-phosphate.
chr16	30392667	30392670	J3KNL2	0	-	30392667	30392670	102,0,51	1	3	0	.	Important	for	dimerization.
chr16	30456859	30456862	Q99611	0	-	30456859	30456862	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr16	31196258	31196261	P35637	0	+	31196258	31196261	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	chimeric	FUS/ATF1	protein.
chr16	31198153	31199647	P35637	0	+	31198153	31199647	102,0,51	1	1494	0	.	Breakpoint	for	translocation	to	form	FUS/TLS-CHOP	oncogene.
chr16	31494574	31494577	P31639	0	+	31494574	31494577	102,0,51	1	3	0	.	Implicated	in	sodium	coupling.
chr16	31499370	31499373	P31639	0	+	31499370	31499373	102,0,51	1	3	0	.	Implicated	in	sodium	coupling.
chr16	56468280	56468283	O43809	0	-	56468280	56468283	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	56481828	56481831	O43809	0	-	56481828	56481831	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	56481852	56481855	O43809	0	-	56481852	56481855	102,0,51	1	3	0	.	Interaction	with	RNA.
chr16	57416764	57416770	P78423	0	+	57416764	57416770	102,0,51	1	6	0	.	Cleavage;	to	produce	soluble	form.
chr16	57600639	57600645	Q8IZF4	0	+	57600639	57600645	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:25713288
chr16	57690505	57690511	Q9Y653	0	+	57690505	57690511	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:22333914
chr16	66851378	66851381	Q13564	0	-	66851378	66851381	102,0,51	1	3	0	.	Interaction	with	UBA3.
chr16	67116208	67116214	Q13951	0	+	67116208	67116214	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	CBF-beta-MYH11	oncogene	in	AML,	subtype	M4EO.
chr16	67516688	67516694	O00253	0	-	67516688	67516694	102,0,51	1	6	0	.	Cleavage;	by	PCSK1.	Pubmed:16384863
chr16	67970324	67970330	P40306	0	-	67970324	67970330	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr16	67976577	67976580	P04180	0	-	67976577	67976580	102,0,51	1	3	0	.	Determinant	for	substrate	specificity.	Pubmed:14636062
chr16	68398672	68398675	Q9NY59	0	-	68398672	68398675	102,0,51	1	3	0	.	Important	for	substrate	recognition.
chr16	68857462	68857468	P12830	0	+	68857462	68857468	102,0,51	1	6	0	.	Cleavage;	by	a	metalloproteinase.
chr16	68862102	68862108	P12830	0	+	68862102	68862108	102,0,51	1	6	0	.	Cleavage;	by	gamma-secretase/PS1.
chr16	68862159	68862165	P12830	0	+	68862159	68862165	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr16	74729397	74729400	Q8NB16	0	-	74729397	74729400	102,0,51	1	3	0	.	Target	of	necrosulfonamide	inhibitor.
chr16	75611258	75611264	P60520	0	+	75611258	75611264	102,0,51	1	6	0	.	Cleavage;	by	ATG4.
chr16	83940693	83940696	O95822	0	+	83940693	83940696	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr16	84129270	84129276	Q14703	0	-	84129270	84129276	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr16	87436682	87436688	Q9GZQ8	0	+	87436682	87436688	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr16	88958888	88958894	O75081	0	-	88958888	88958894	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	type-2	RUNX1-CBFA2T3	fusion	protein.
chr16	88968059	88968065	O75081	0	-	88968059	88968065	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	type-1	RUNX1-CBFA2T3	fusion	protein.
chr17	1167352	1167355	P62258	0	-	1167352	1167355	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr17	1171024	1171027	P62258	0	-	1171024	1171027	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr17	1264573	1264576	P62258	0	-	1264573	1264576	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr17	1268245	1268248	P62258	0	-	1268245	1268248	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr17	1339979	1339982	P46108	0	-	1339979	1339982	102,0,51	1	3	0	.	Proline	switch.
chr17	1648638	1648644	P08697	0	+	1648638	1648644	102,0,51	1	6	0	.	Cleavage;	by	prolyl	endopeptidase	FAP,	antiplasmin-cleaving	enzyme	FAP	soluble	form.	Pubmed:14751930,	Pubmed:16223769
chr17	1657558	1657564	P08697	0	+	1657558	1657564	102,0,51	1	6	0	.	Reactive	bond	for	plasmin.
chr17	1657561	1657567	P08697	0	+	1657561	1657567	102,0,51	1	6	0	.	Reactive	bond	for	chymotrypsin.
chr17	3480933	3480936	Q8NER1	0	-	3480933	3480936	102,0,51	1	3	0	.	Important	for	agonist	binding.
chr17	5424984	5424990	Q9C000	0	-	5424984	5424990	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:22665479
chr17	5425068	5425071	Q9C000	0	-	5425068	5425071	102,0,51	1	3	0	.	Trigger	for	autolytic	processing.	Pubmed:22665479
chr17	6544531	6544534	Q9BRA2	0	+	6544531	6544534	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.	Pubmed:15355959
chr17	6544534	6544537	Q9BRA2	0	+	6544534	6544537	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.	Pubmed:15355959
chr17	7139882	7139888	Q9BUL5	0	-	7139882	7139888	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	NUP98-PHF23	oncogene.
chr17	7144175	7144181	O95166	0	-	7144175	7144181	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr17	7453505	7453511	O43508	0	+	7453505	7453511	102,0,51	1	6	0	.	Cleavage.
chr17	7462991	7462997	O75888	0	+	7462991	7462997	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr17	7579326	7579329	P04637	0	-	7579326	7579329	102,0,51	1	3	0	.	Interaction	with	DNA.
chr17	11958222	11958228	P45985	0	+	11958222	11958228	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr17	11958261	11958267	P45985	0	+	11958261	11958267	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr17	16285422	16285425	P0CG47	0	+	16285422	16285425	102,0,51	1	3	0	.	Essential	for	function.
chr17	17720582	17720588	P36956	0	-	17720582	17720588	102,0,51	1	6	0	.	Cleavage;	by	S1P.
chr17	17720702	17720708	P36956	0	-	17720702	17720708	102,0,51	1	6	0	.	Cleavage;	by	S2P.
chr17	17721030	17721036	P36956	0	-	17721030	17721036	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	and	caspase-7.
chr17	21319170	21319173	Q14500	0	+	21319170	21319173	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr17	26694862	26694868	P04004	0	-	26694862	26694868	102,0,51	1	6	0	.	Cleavage.
chr17	26900546	26900549	P09972	0	-	26900546	26900549	102,0,51	1	3	0	.	Necessary	for	preference	for	fructose	1,6-bisphosphate	over	fructose	1-phosphate.
chr17	30267306	30267312	Q15022	0	+	30267306	30267312	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	JAZF1-SUZ12	oncogene.
chr17	30814929	30814935	Q15078	0	+	30814929	30814935	102,0,51	1	6	0	.	Cleavage;	by	calpain.
chr17	31322650	31322656	Q8IXA5	0	+	31322650	31322656	102,0,51	1	6	0	.	Cleavage;	to	produce	processed	form.
chr17	32583254	32583257	P13500	0	+	32583254	32583257	102,0,51	1	3	0	.	Involved	in	dimerization.
chr17	32583269	32583272	P13500	0	+	32583269	32583272	102,0,51	1	3	0	.	Involved	in	dimerization,	receptor	binding	and	signaling.
chr17	32583284	32583287	P13500	0	+	32583284	32583287	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	32583287	32583290	P13500	0	+	32583287	32583290	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	32583302	32583305	P13500	0	+	32583302	32583305	102,0,51	1	3	0	.	Involved	in	GAG	binding	and	receptor	binding.
chr17	32583335	32583338	P13500	0	+	32583335	32583338	102,0,51	1	3	0	.	Involved	in	dimerization.
chr17	32583344	32583347	P13500	0	+	32583344	32583347	102,0,51	1	3	0	.	Involved	in	dimerization.
chr17	32583759	32583762	P13500	0	+	32583759	32583762	102,0,51	1	3	0	.	Involved	in	GAG	binding	and	receptor	binding.
chr17	32583786	32583789	P13500	0	+	32583786	32583789	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	32583810	32583813	P13500	0	+	32583810	32583813	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34205641	34207237	P13501	0	-	34205641	34207237	102,0,51	1	1596	0	.	Cleavage;	by	DPP4.
chr17	34416086	34416089	P10147	0	-	34416086	34416089	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34416092	34416095	P10147	0	-	34416092	34416095	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34416428	34416431	P10147	0	-	34416428	34416431	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34416434	34416437	P10147	0	-	34416434	34416437	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34416596	34416599	P10147	0	-	34416596	34416599	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34416938	34416941	P10147	0	-	34416938	34416941	102,0,51	1	3	0	.	Involved	in	GAG	binding.
chr17	34523309	34524000	P16619	0	-	34523309	34524000	102,0,51	1	691	0	.	Cleavage;	by	DPP4.
chr17	34523346	34524037	P16619	0	-	34523346	34524037	102,0,51	1	691	0	.	Cleavage;	by	DPP4.
chr17	34523681	34524372	P16619	0	-	34523681	34524372	102,0,51	1	691	0	.	Cleavage;	by	DPP4.
chr17	36374272	36374963	P16619	0	+	36374272	36374963	102,0,51	1	691	0	.	Cleavage;	by	DPP4.
chr17	37900373	37900376	Q14451	0	+	37900373	37900376	102,0,51	1	3	0	.	Important	for	lipid	binding	and	for	stimulation	of	cell	migration.
chr17	37903081	37903084	Q14451	0	+	37903081	37903084	102,0,51	1	3	0	.	Important	for	dimerization	and	for	HRAS	activation.
chr17	38504566	38504572	P10276	0	+	38504566	38504572	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PLZF-RAR-alpha,	RAR-alpha1-PLZF	and	PML-RAR-alpha	oncogenes.
chr17	38556786	38556789	P11388	0	-	38556786	38556789	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38557197	38557200	P11388	0	-	38557197	38557200	102,0,51	1	3	0	.	Important	for	DNA	bending;	intercalates	between	base	pairs	of	target	DNA.
chr17	38559177	38559180	P11388	0	-	38559177	38559180	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	38559300	38559303	P11388	0	-	38559300	38559303	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38560415	38560418	P11388	0	-	38560415	38560418	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38560517	38560520	P11388	0	-	38560517	38560520	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38561102	38561105	P11388	0	-	38561102	38561105	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38561105	38561108	P11388	0	-	38561105	38561108	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38564242	38564245	P11388	0	-	38564242	38564245	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:22841979
chr17	38564251	38564254	P11388	0	-	38564251	38564254	102,0,51	1	3	0	.	Interaction	with	DNA.
chr17	38636979	38636985	Q8IZW8	0	-	38636979	38636985	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr17	39036456	39036462	P35900	0	-	39036456	39036462	102,0,51	1	6	0	.	Cleavage;	by	caspases.
chr17	39116714	39116717	Q6A163	0	-	39116714	39116717	102,0,51	1	3	0	.	Stutter.
chr17	39116841	39116844	Q6A163	0	-	39116841	39116844	102,0,51	1	3	0	.	Stutter.
chr17	39135237	39135240	Q6A162	0	-	39135237	39135240	102,0,51	1	3	0	.	Stutter.
chr17	39135364	39135367	Q6A162	0	-	39135364	39135367	102,0,51	1	3	0	.	Stutter.
chr17	39502881	39502884	O76009	0	-	39502881	39502884	102,0,51	1	3	0	.	Stutter.
chr17	39521212	39521215	Q14525	0	-	39521212	39521215	102,0,51	1	3	0	.	Stutter.
chr17	39535389	39535392	O76011	0	-	39535389	39535392	102,0,51	1	3	0	.	Stutter.
chr17	39551281	39551284	Q15323	0	-	39551281	39551284	102,0,51	1	3	0	.	Stutter.
chr17	39558581	39558584	Q15323	0	-	39558581	39558584	102,0,51	1	3	0	.	Stutter.
chr17	39577800	39577803	O76014	0	-	39577800	39577803	102,0,51	1	3	0	.	Stutter.
chr17	39585125	39585128	O76014	0	-	39585125	39585128	102,0,51	1	3	0	.	Stutter.
chr17	39594526	39594529	O76015	0	-	39594526	39594529	102,0,51	1	3	0	.	Stutter.
chr17	39619263	39619266	Q14532	0	-	39619263	39619266	102,0,51	1	3	0	.	Stutter.
chr17	39633951	39633954	Q92764	0	-	39633951	39633954	102,0,51	1	3	0	.	Stutter.
chr17	39643383	39643386	O76013	0	-	39643383	39643386	102,0,51	1	3	0	.	Stutter.
chr17	39680216	39680219	P08727	0	-	39680216	39680219	102,0,51	1	3	0	.	Stutter.
chr17	39680651	39680654	P08727	0	-	39680651	39680654	102,0,51	1	3	0	.	Stutter.
chr17	39739668	39739671	P02533	0	-	39739668	39739671	102,0,51	1	3	0	.	Stutter.
chr17	39871805	39871811	P01350	0	+	39871805	39871811	102,0,51	1	6	0	.	Cleavage.
chr17	39871859	39871865	P01350	0	+	39871859	39871865	102,0,51	1	6	0	.	Cleavage.
chr17	39872040	39872046	P01350	0	+	39872040	39872046	102,0,51	1	6	0	.	Cleavage.
chr17	39872100	39872106	P01350	0	+	39872100	39872106	102,0,51	1	6	0	.	Cleavage.
chr17	42030758	42030764	P10082	0	-	42030758	42030764	102,0,51	1	6	0	.	Cleavage;	by	FAP.	Pubmed:21314817
chr17	42331877	42331880	P02730	0	-	42331877	42331880	102,0,51	1	3	0	.	Important	for	anion-proton	cotransport.
chr17	42333070	42333073	P02730	0	-	42333070	42333073	102,0,51	1	3	0	.	Important	for	anion	transport.
chr17	44039772	44039775	P10636	0	+	44039772	44039775	102,0,51	1	3	0	.	Not	glycated.
chr17	44039832	44039835	P10636	0	+	44039832	44039835	102,0,51	1	3	0	.	Not	glycated.
chr17	44049289	44049292	P10636	0	+	44049289	44049292	102,0,51	1	3	0	.	Not	glycated.
chr17	44064419	44064422	P10636	0	+	44064419	44064422	102,0,51	1	3	0	.	Not	glycated.
chr17	44064449	44064452	P10636	0	+	44064449	44064452	102,0,51	1	3	0	.	Not	glycated.
chr17	44064452	44064455	P10636	0	+	44064452	44064455	102,0,51	1	3	0	.	Not	glycated.
chr17	44064458	44064461	P10636	0	+	44064458	44064461	102,0,51	1	3	0	.	Not	glycated.
chr17	44068837	44068840	P10636	0	+	44068837	44068840	102,0,51	1	3	0	.	Not	glycated.
chr17	44068933	44068936	P10636	0	+	44068933	44068936	102,0,51	1	3	0	.	Not	glycated.
chr17	44073775	44073778	P10636	0	+	44073775	44073778	102,0,51	1	3	0	.	Not	glycated.
chr17	44073877	44073880	P10636	0	+	44073877	44073880	102,0,51	1	3	0	.	Not	glycated.
chr17	44073925	44073928	P10636	0	+	44073925	44073928	102,0,51	1	3	0	.	Not	glycated.
chr17	44073967	44073970	P10636	0	+	44073967	44073970	102,0,51	1	3	0	.	Not	glycated.
chr17	44073976	44073979	P10636	0	+	44073976	44073979	102,0,51	1	3	0	.	Not	glycated.
chr17	44074006	44074009	P10636	0	+	44074006	44074009	102,0,51	1	3	0	.	Not	glycated.
chr17	44074027	44074030	P10636	0	+	44074027	44074030	102,0,51	1	3	0	.	Not	glycated.
chr17	44087720	44087723	P10636	0	+	44087720	44087723	102,0,51	1	3	0	.	Not	glycated.
chr17	44087732	44087735	P10636	0	+	44087732	44087735	102,0,51	1	3	0	.	Not	glycated.
chr17	44087744	44087747	P10636	0	+	44087744	44087747	102,0,51	1	3	0	.	Not	glycated.
chr17	44091623	44091626	P10636	0	+	44091623	44091626	102,0,51	1	3	0	.	Not	glycated.
chr17	44091641	44091644	P10636	0	+	44091641	44091644	102,0,51	1	3	0	.	Not	glycated.
chr17	44091653	44091656	P10636	0	+	44091653	44091656	102,0,51	1	3	0	.	Not	glycated.
chr17	44091683	44091686	P10636	0	+	44091683	44091686	102,0,51	1	3	0	.	Not	glycated.
chr17	44096003	44096006	P10636	0	+	44096003	44096006	102,0,51	1	3	0	.	Not	glycated.
chr17	44096012	44096015	P10636	0	+	44096012	44096015	102,0,51	1	3	0	.	Not	glycated.
chr17	44096093	44096096	P10636	0	+	44096093	44096096	102,0,51	1	3	0	.	Not	glycated.
chr17	44101333	44101336	P10636	0	+	44101333	44101336	102,0,51	1	3	0	.	Not	glycated.
chr17	44101357	44101360	P10636	0	+	44101357	44101360	102,0,51	1	3	0	.	Not	glycated.
chr17	44101363	44101366	P10636	0	+	44101363	44101366	102,0,51	1	3	0	.	Not	glycated.
chr17	44101393	44101396	P10636	0	+	44101393	44101396	102,0,51	1	3	0	.	Not	glycated.
chr17	44101522	44101525	P10636	0	+	44101522	44101525	102,0,51	1	3	0	.	Not	glycated.
chr17	45669372	45669375	P55786	0	+	45669372	45669375	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	46973074	46973077	P05496	0	+	46973074	46973077	102,0,51	1	3	0	.	Reversibly	protonated	during	proton	transport.
chr17	48650393	48650396	O43497	0	+	48650393	48650396	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr17	48669312	48669315	O43497	0	+	48669312	48669315	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr17	48683354	48683357	O43497	0	+	48683354	48683357	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr17	48695584	48695587	O43497	0	+	48695584	48695587	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr17	48917066	48917072	Q8TEU8	0	+	48917066	48917072	102,0,51	1	6	0	.	Reactive	bond.
chr17	55693441	55704591	Q96DH6	0	+	55693441	55704591	102,0,51	1	11150	0	.	Breakpoint	for	translocation	to	form	MSI2/HOXA9	fusion	protein.
chr17	56164571	56164574	Q96FJ2	0	+	56164571	56164574	102,0,51	1	3	0	.	Interaction	with	myosin	V	motor	complex.
chr17	56276408	56276411	P11678	0	+	56276408	56276411	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	56332179	56332182	P22079	0	+	56332179	56332182	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	56353052	56353055	P05164	0	-	56353052	56353055	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	56599335	56599338	J3KSZ7	0	-	56599335	56599338	102,0,51	1	3	0	.	Important	for	dimerization.
chr17	56599335	56599338	J3QLR2	0	-	56599335	56599338	102,0,51	1	3	0	.	Important	for	dimerization.
chr17	56599335	56599338	J3QRT6	0	-	56599335	56599338	102,0,51	1	3	0	.	Important	for	dimerization.
chr17	59445686	59445692	Q9H6U6	0	+	59445686	59445692	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BCAS4-BCAS3.
chr17	61574327	61574330	P12821	0	+	61574327	61574330	102,0,51	1	3	0	.	Not	glycosylated.
chr17	67501943	67501949	P52564	0	+	67501943	67501949	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr17	68128708	68128711	K7EJR9	0	+	68128708	68128711	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr17	68128708	68128711	Q9NPI9	0	+	68128708	68128711	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr17	68171693	68171696	P63252	0	+	68171693	68171696	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr17	71165722	71165725	P30874	0	+	71165722	71165725	102,0,51	1	3	0	.	Important	for	ligand	binding.
chr17	72519008	72519011	A8K4G0	0	-	72519008	72519011	102,0,51	1	3	0	.	Interaction	with	TYROBP.
chr17	72691965	72691968	Q8TDQ1	0	-	72691965	72691968	102,0,51	1	3	0	.	Phosphatase-binding.
chr17	72843611	72843614	Q14957	0	-	72843611	72843614	102,0,51	1	3	0	.	Functional	determinant	of	NMDA	receptors.
chr17	73761106	73761109	P51570	0	-	73761106	73761109	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr17	73775159	73775162	P84243	0	-	73775159	73775162	102,0,51	1	3	0	.	Interaction	with	ZMYND11.	Pubmed:24590075
chr17	74465785	74465788	Q16613	0	+	74465785	74465788	102,0,51	1	3	0	.	Important	for	the	catalytic	mechanism;	involved	in	substrate	deprotonation.
chr17	74465791	74465794	Q16613	0	+	74465791	74465794	102,0,51	1	3	0	.	Important	for	the	catalytic	mechanism;	involved	in	substrate	deprotonation.
chr17	76991166	76991169	Q8WVQ1	0	-	76991166	76991169	102,0,51	1	3	0	.	Important	for	dimer	formation.	Pubmed:16835225
chr17	76993098	76993101	Q8WVQ1	0	-	76993098	76993101	102,0,51	1	3	0	.	Important	for	dimer	formation.	Pubmed:16835225
chr17	76993104	76993107	Q8WVQ1	0	-	76993104	76993107	102,0,51	1	3	0	.	Important	for	dimer	formation.	Pubmed:16835225
chr17	76993224	76993227	Q8WVQ1	0	-	76993224	76993227	102,0,51	1	3	0	.	Important	for	dimer	formation.	Pubmed:16835225
chr17	77097705	77097708	A6NFN3	0	-	77097705	77097708	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77097705	77097708	J3QRF4	0	-	77097705	77097708	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77099252	77099255	A6NFN3	0	-	77099252	77099255	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77099252	77099255	J3QRF4	0	-	77099252	77099255	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77099324	77099327	A6NFN3	0	-	77099324	77099327	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77099324	77099327	J3QRF4	0	-	77099324	77099327	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77100154	77100157	A6NFN3	0	-	77100154	77100157	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77100154	77100157	J3QRF4	0	-	77100154	77100157	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77100169	77100172	A6NFN3	0	-	77100169	77100172	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77100169	77100172	J3QRF4	0	-	77100169	77100172	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102765	77102768	A6NFN3	0	-	77102765	77102768	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102765	77102768	J3QRF4	0	-	77102765	77102768	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102768	77102771	A6NFN3	0	-	77102768	77102771	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102768	77102771	J3QRF4	0	-	77102768	77102771	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102792	77102795	A6NFN3	0	-	77102792	77102795	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	77102792	77102795	J3QRF4	0	-	77102792	77102795	102,0,51	1	3	0	.	Interaction	with	RNA.
chr17	78395669	78395672	Q8N8Q3	0	+	78395669	78395672	102,0,51	1	3	0	.	Interaction	with	target	RNA.
chr17	79803082	79803085	P07237	0	-	79803082	79803085	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	second	active	site.
chr17	79803598	79803601	P07237	0	-	79803598	79803601	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr17	79803601	79803604	P07237	0	-	79803601	79803604	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr17	79813454	79813457	P07237	0	-	79813454	79813457	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	first	active	site.
chr17	79817243	79817246	P07237	0	-	79817243	79817246	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr17	79817246	79817249	P07237	0	-	79817246	79817249	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr17	79954719	79966915	Q9BZE9	0	+	79954719	79966915	102,0,51	1	12196	0	.	Breakpoint	for	translocation	to	form	ASPSCR1-TFE3.
chr18	12420396	12420399	Q96N28	0	+	12420396	12420399	102,0,51	1	3	0	.	Important	for	interaction	with	TRIAP1.	Pubmed:26071602
chr18	12420435	12420438	Q96N28	0	+	12420435	12420438	102,0,51	1	3	0	.	Important	for	interaction	with	TRIAP1.	Pubmed:26071602
chr18	13737076	13737079	O43148	0	+	13737076	13737079	102,0,51	1	3	0	.	mRNA	cap	binding.
chr18	13737094	13737097	O43148	0	+	13737094	13737097	102,0,51	1	3	0	.	mRNA	cap	binding.
chr18	13740200	13740203	O43148	0	+	13740200	13740203	102,0,51	1	3	0	.	mRNA	cap	binding.
chr18	18546887	18546893	Q13464	0	-	18546887	18546893	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr18	21148925	21148928	O15118	0	-	21148925	21148928	102,0,51	1	3	0	.	Important	for	cholesterol	binding.
chr18	22901972	22901978	Q96K83	0	-	22901972	22901978	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PAX5-ZNF521.
chr18	23598341	23612365	Q15532	0	-	23598341	23612365	102,0,51	1	14024	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX1	or	SSXT-SSX2	fusion	proteins.	Pubmed:7539744
chr18	23612491	23612497	Q15532	0	-	23612491	23612497	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX1	fusion	protein	(rare).	Pubmed:7539744
chr18	29787378	29787381	Q16820	0	+	29787378	29787381	102,0,51	1	3	0	.	Mediates	preference	for	acidic	residues	at	subsite	P1'.
chr18	43329760	43329763	B3KXJ3	0	+	43329760	43329763	102,0,51	1	3	0	.	Important	for	channel	permeability.
chr18	43329760	43329763	B4DFJ8	0	+	43329760	43329763	102,0,51	1	3	0	.	Important	for	channel	permeability.
chr18	43329760	43329763	F5GWS2	0	+	43329760	43329763	102,0,51	1	3	0	.	Important	for	channel	permeability.
chr18	43329760	43329763	G0W2N5	0	+	43329760	43329763	102,0,51	1	3	0	.	Important	for	channel	permeability.
chr18	43329760	43329763	Q13336	0	+	43329760	43329763	102,0,51	1	3	0	.	Important	for	channel	permeability.
chr18	43666397	43666400	P25705	0	-	43666397	43666400	102,0,51	1	3	0	.	Required	for	activity.
chr18	48446925	48446928	P23368	0	+	48446925	48446928	102,0,51	1	3	0	.	Important	for	activity.
chr18	48604720	48604723	Q13485	0	+	48604720	48604723	102,0,51	1	3	0	.	Necessary	for	heterotrimerization.
chr18	56363596	56363602	Q9UDY8	0	+	56363596	56363602	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BIRC2-MALT1.
chr18	56367819	56376611	Q9UDY8	0	+	56367819	56376611	102,0,51	1	8792	0	.	Breakpoint	for	translocation	to	form	BIRC2-MALT1.
chr18	56381313	56381319	Q9UDY8	0	+	56381313	56381319	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BIRC2-MALT1.
chr18	56381322	56381328	Q9UDY8	0	+	56381322	56381328	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BIRC2-MALT1.
chr18	56383165	56383171	Q9UDY8	0	+	56383165	56383171	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BIRC2-MALT1.
chr18	56998354	56998357	P49257	0	-	56998354	56998357	102,0,51	1	3	0	.	Required	for	ER	export.
chr18	60985794	60985800	P10415	0	-	60985794	60985800	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr18	61170844	61170850	P36952	0	+	61170844	61170850	102,0,51	1	6	0	.	Reactive	bond	homolog.
chr18	61234133	61234139	Q96P63	0	+	61234133	61234139	102,0,51	1	6	0	.	Reactive	bond.
chr18	61264486	61264492	Q9UIV8	0	+	61264486	61264492	102,0,51	1	6	0	.	Reactive	bond.
chr18	61305060	61305066	P48594	0	-	61305060	61305066	102,0,51	1	6	0	.	Reactive	bond.
chr18	61322998	61323004	P29508	0	-	61322998	61323004	102,0,51	1	6	0	.	Reactive	bond.
chr18	61471764	61471770	O75635	0	+	61471764	61471770	102,0,51	1	6	0	.	Reactive	bond.
chr18	61570428	61570434	P05120	0	+	61570428	61570434	102,0,51	1	6	0	.	Reactive	bond.
chr18	61602365	61602371	P48595	0	+	61602365	61602371	102,0,51	1	6	0	.	Reactive	bond.
chr18	61654401	61654407	P50452	0	+	61654401	61654407	102,0,51	1	6	0	.	Reactive	bond.
chr18	72179706	72179709	Q96KP4	0	+	72179706	72179709	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr19	1615818	1619113	P15923	0	-	1615818	1619113	102,0,51	1	3295	0	.	Breakpoint	for	translocation	to	form	TCF3-PBX1	oncogene.
chr19	2405406	2405412	Q7Z410	0	+	2405406	2405412	102,0,51	1	6	0	.	Cleavage.
chr19	2415702	2415708	Q7Z410	0	+	2415702	2415708	102,0,51	1	6	0	.	Cleavage.
chr19	2424115	2424121	Q7Z410	0	+	2424115	2424121	102,0,51	1	6	0	.	Cleavage.
chr19	3905607	3905613	Q86WG3	0	+	3905607	3905613	102,0,51	1	6	0	.	Cleavage;	by	CASP3.
chr19	3978065	3978071	P13639	0	-	3978065	3978071	102,0,51	1	6	0	.	Cleavage.	Pubmed:24648518
chr19	3978122	3978128	P13639	0	-	3978122	3978128	102,0,51	1	6	0	.	Cleavage.	Pubmed:24648518
chr19	4123839	4123845	P36507	0	-	4123839	4123845	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr19	4171666	4171672	Q68CJ9	0	+	4171666	4171672	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr19	4366988	4400323	Q99961	0	-	4366988	4400323	102,0,51	1	33335	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-EEN	oncogene.
chr19	4538077	4538080	P02750	0	-	4538077	4538080	102,0,51	1	3	0	.	Not	glycosylated.
chr19	4947140	4947143	Q96T88	0	+	4947140	4947143	102,0,51	1	3	0	.	Required	to	confer	preferential	recognition	of	cytosine	over	thymine.
chr19	4947170	4947173	Q96T88	0	+	4947170	4947173	102,0,51	1	3	0	.	Required	to	discriminate	between	hemimethylated	DNA	versus	symmetrically	methylated	DNA.
chr19	4947176	4947179	Q96T88	0	+	4947176	4947179	102,0,51	1	3	0	.	Required	for	affinity	and	specificity	for	5-mCpG	sequence.
chr19	5220120	5220126	Q13332	0	-	5220120	5220126	102,0,51	1	6	0	.	Cleavage.
chr19	6667430	6667436	O43557	0	-	6667430	6667436	102,0,51	1	6	0	.	Cleavage.
chr19	6685004	6685010	P01024	0	-	6685004	6685010	102,0,51	1	6	0	.	Cleavage;	by	factor	I.
chr19	6685055	6685061	P01024	0	-	6685055	6685061	102,0,51	1	6	0	.	Cleavage;	by	factor	I.
chr19	6696474	6696607	P01024	0	-	6696474	6696607	102,0,51	1	133	0	.	Cleavage;	by	factor	I.
chr19	6702588	6707090	P01024	0	-	6702588	6707090	102,0,51	1	4502	0	.	Cleavage;	by	C3	convertase.
chr19	6707087	6707093	P01024	0	-	6707087	6707093	102,0,51	1	6	0	.	Cleavage;	by	carboxypeptidases.
chr19	6743591	6743594	Q15642	0	+	6743591	6743594	102,0,51	1	3	0	.	Mediates	end-to-end	attachment	of	dimers.
chr19	7267809	7267812	P06213	0	-	7267809	7267812	102,0,51	1	3	0	.	Insulin-binding.
chr19	7761729	7761735	P06734	0	-	7761729	7761735	102,0,51	1	6	0	.	Cleavage.
chr19	7913944	7913947	Q96CN4	0	+	7913944	7913947	102,0,51	1	3	0	.	Arginine	finger.
chr19	7914177	7914180	Q96CN4	0	+	7914177	7914180	102,0,51	1	3	0	.	Glutamine	finger.
chr19	7974644	7974650	O14733	0	+	7974644	7974650	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr19	7974740	7974746	O14733	0	+	7974740	7974746	102,0,51	1	6	0	.	Cleavage;	by	anthrax	lethal	factor.
chr19	10265649	10265652	P26358	0	-	10265649	10265652	102,0,51	1	3	0	.	Important	for	activity.
chr19	10531644	10531650	P27815	0	+	10531644	10531650	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr19	10574504	10574507	P27815	0	+	10574504	10574507	102,0,51	1	3	0	.	Binds	AMP,	but	not	cAMP.
chr19	10654952	10654958	Q86TL0	0	+	10654952	10654958	102,0,51	1	6	0	.	Cleavage;	by	CASP3.
chr19	11169544	11169550	P51532	0	+	11169544	11169550	102,0,51	1	6	0	.	Required	for	binding	to	'Lys-15'-acetylated	histone	3.
chr19	11488731	11488734	P19235	0	-	11488731	11488734	102,0,51	1	3	0	.	Required	for	CrkL	binding.
chr19	11488818	11488821	P19235	0	-	11488818	11488821	102,0,51	1	3	0	.	Required	for	STAT1/STAT3	activation.
chr19	11488824	11488827	P19235	0	-	11488824	11488827	102,0,51	1	3	0	.	Interaction	with	PTPN6.
chr19	11488908	11488911	P19235	0	-	11488908	11488911	102,0,51	1	3	0	.	Required	for	STAT5/PTPN11/SOCS3	binding.
chr19	11489082	11489085	P19235	0	-	11489082	11489085	102,0,51	1	3	0	.	Interaction	with	APS	and	STAT5,	and	activation.
chr19	11492681	11492684	P19235	0	-	11492681	11492684	102,0,51	1	3	0	.	Required	for	ligand	binding.
chr19	13876897	13876900	Q9BV20	0	+	13876897	13876900	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr19	14268726	14268732	O94910	0	-	14268726	14268732	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr19	14515332	14515338	P48960	0	+	14515332	14515338	102,0,51	1	6	0	.	Cleavage.
chr19	14554280	14554286	Q16512	0	+	14554280	14554286	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr19	14569127	14569133	Q16512	0	+	14569127	14569133	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr19	14574905	14574911	Q16512	0	+	14574905	14574911	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr19	14754952	14754958	Q9BY15	0	-	14754952	14754958	102,0,51	1	6	0	.	Cleavage.
chr19	14865801	14865807	Q9UHX3	0	-	14865801	14865807	102,0,51	1	6	0	.	Cleavage;	by	autolysis.	Pubmed:15150276
chr19	15284898	15284904	Q9UM47	0	-	15284898	15284904	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr19	15355571	15364966	O60885	0	-	15355571	15364966	102,0,51	1	9395	0	.	Breakpoint	for	translocation	to	form	BDR4-NUT	fusion	protein.
chr19	15582702	15582705	Q96PD5	0	-	15582702	15582705	102,0,51	1	3	0	.	Important	for	catalytic	activity;	essential	for	amidase	activity	and	zinc	hydrate	coordination.
chr19	17000412	17000418	Q96RI0	0	+	17000412	17000418	102,0,51	1	6	0	.	Cleavage;	by	thrombin	or	trypsin.
chr19	18322712	18322715	Q08493	0	-	18322712	18322715	102,0,51	1	3	0	.	Binds	AMP,	but	not	cAMP.
chr19	18583689	18583692	P55199	0	-	18583689	18583692	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient).	Pubmed:7991593
chr19	18685690	18685693	P62987	0	+	18685690	18685693	102,0,51	1	3	0	.	Essential	for	function.
chr19	18794635	18853722	Q6UUV9	0	+	18794635	18853722	102,0,51	1	59087	0	.	Breakpoint	for	translocation	to	form	the	MECT1-MAML2	and	MAML2-MECT1	fusion	proteins.	Pubmed:12539049,	Pubmed:14720503
chr19	18888009	18888012	Q6UUV9	0	+	18888009	18888012	102,0,51	1	3	0	.	Required	for	ubiquitination	and	degradation.
chr19	35793373	35793376	P20916	0	+	35793373	35793376	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:7505568
chr19	35842886	35842889	O14842	0	+	35842886	35842889	102,0,51	1	3	0	.	Important	for	receptor	activation.	Pubmed:19068482
chr19	35842967	35842970	O14842	0	+	35842967	35842970	102,0,51	1	3	0	.	Important	for	receptor	activation.	Pubmed:19068482
chr19	36034250	36034253	O14556	0	+	36034250	36034253	102,0,51	1	3	0	.	Activates	thiol	group	during	catalysis.
chr19	36398414	36398417	O43914	0	-	36398414	36398417	102,0,51	1	3	0	.	Important	for	interaction	with	transmembrane	receptors.
chr19	38774301	38774307	O43291	0	+	38774301	38774307	102,0,51	1	6	0	.	Reactive	bond.
chr19	38780793	38780799	O43291	0	+	38780793	38780799	102,0,51	1	6	0	.	Reactive	bond.
chr19	39307136	39307139	Q13011	0	-	39307136	39307139	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr19	39307160	39307163	Q13011	0	-	39307160	39307163	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr19	40222040	40222043	Q05315	0	-	40222040	40222043	102,0,51	1	3	0	.	Not	glycosylated.
chr19	42384993	42384996	P11912	0	+	42384993	42384996	102,0,51	1	3	0	.	Required	for	binding	to	BLNK.
chr19	42937197	42937203	Q6UXB2	0	-	42937197	42937203	102,0,51	1	6	0	.	Cleavage.
chr19	44160766	44160772	Q03405	0	-	44160766	44160772	102,0,51	1	6	0	.	Cleavage;	by	U-PA.
chr19	44160784	44160790	Q03405	0	-	44160784	44160790	102,0,51	1	6	0	.	Cleavage;	by	U-PA.
chr19	47124770	47124773	P43119	0	-	47124770	47124773	102,0,51	1	3	0	.	Not	S-palmitoylated.
chr19	48624426	48624429	P18858	0	-	48624426	48624429	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr19	48624501	48624504	P18858	0	-	48624501	48624504	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr19	48634383	48634386	P18858	0	-	48634383	48634386	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr19	48646798	48646801	P18858	0	-	48646798	48646801	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr19	48922903	48922906	O15399	0	+	48922903	48922906	102,0,51	1	3	0	.	Functional	determinant	of	NMDA	receptors.
chr19	49439296	49439299	Q9UQ10	0	+	49439296	49439299	102,0,51	1	3	0	.	May	play	an	important	role	in	coenzyme	binding.
chr19	49439320	49439323	Q9UQ10	0	+	49439320	49439323	102,0,51	1	3	0	.	May	play	an	important	role	in	coenzyme	binding.
chr19	49439374	49439377	Q9UQ10	0	+	49439374	49439377	102,0,51	1	3	0	.	May	play	an	important	role	in	coenzyme	binding.
chr19	49442864	49442867	Q9UQ10	0	+	49442864	49442867	102,0,51	1	3	0	.	May	play	an	important	role	for	the	adaptation	of	the	alcohol	substrate	into	the	binding	site.
chr19	49442876	49442879	Q9UQ10	0	+	49442876	49442879	102,0,51	1	3	0	.	May	play	an	important	role	in	catalytic	activity.
chr19	49951317	49951320	Q9NWS0	0	-	49951317	49951320	102,0,51	1	3	0	.	Interacts	with	TELO2.
chr19	49952876	49952879	Q9NWS0	0	-	49952876	49952879	102,0,51	1	3	0	.	Interacts	with	TELO2.	Pubmed:24656813
chr19	49952897	49952900	Q9NWS0	0	-	49952897	49952900	102,0,51	1	3	0	.	Interacts	with	TELO2.	Pubmed:24656813
chr19	51466759	51466765	Q92876	0	-	51466759	51466765	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr19	51483637	51483640	P49862	0	-	51483637	51483640	102,0,51	1	3	0	.	Major	binding	site	for	inhibitory	zinc	or	copper.
chr19	54627918	54627921	Q8WWY3	0	+	54627918	54627921	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.
chr19	54627987	54627990	Q8WWY3	0	+	54627987	54627990	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.
chr19	54628043	54628046	Q8WWY3	0	+	54628043	54628046	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.
chr19	54628112	54628115	Q8WWY3	0	+	54628112	54628115	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.
chr19	55666189	55666192	P19429	0	-	55666189	55666192	102,0,51	1	3	0	.	Involved	in	TNI-TNT	interactions.
chr19	55667610	55667613	P19429	0	-	55667610	55667613	102,0,51	1	3	0	.	Involved	in	TNI-TNT	interactions.
chr19	55877470	55877473	P20809	0	-	55877470	55877473	102,0,51	1	3	0	.	Important	for	interaction	with	IL6ST	and	for	the	stimulation	of	cell	proliferation.
chr2	1481223	1481226	P07202	0	+	1481223	1481226	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr2	1652620	1652623	Q92626	0	-	1652620	1652623	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr2	9731557	9731560	P27348	0	-	9731557	9731560	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr2	9770413	9770416	P27348	0	-	9770413	9770416	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr2	10583690	10583693	P11926	0	-	10583690	10583693	102,0,51	1	3	0	.	Stacks	against	the	aromatic	ring	of	pyridoxal	phosphate	and	stabilizes	reaction	intermediates.
chr2	10929946	10929949	Q15084	0	-	10929946	10929949	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	second	active	site.
chr2	10931928	10931931	Q15084	0	-	10931928	10931931	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr2	10931931	10931934	Q15084	0	-	10931931	10931934	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr2	10933320	10933323	Q15084	0	-	10933320	10933323	102,0,51	1	3	0	.	Lowers	pKa	of	C-terminal	Cys	of	first	active	site.
chr2	10937873	10937876	Q15084	0	-	10937873	10937876	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr2	10937876	10937879	Q15084	0	-	10937876	10937879	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr2	11337357	11337363	O75116	0	-	11337357	11337363	102,0,51	1	6	0	.	Cleavage;	by	granzyme	B.
chr2	20402881	20402887	P18827	0	-	20402881	20402887	102,0,51	1	6	0	.	Cleavage.
chr2	24949456	24949462	Q15788	0	+	24949456	24949462	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PAX3-NCOA1	oncogene.
chr2	26068426	26068432	Q76L83	0	-	26068426	26068432	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6A-ASXL2	protein.
chr2	26455081	26455084	P40939	0	-	26455081	26455084	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr2	26457084	26457087	P40939	0	-	26457084	26457087	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr2	27854716	27854719	Q9HCN4	0	+	27854716	27854719	102,0,51	1	3	0	.	Stabilizes	the	phosphate	intermediate;	shared	with	dimeric	partner.
chr2	38298311	38298314	Q16678	0	-	38298311	38298314	102,0,51	1	3	0	.	Major	determinant	of	CYP1B1	17beta-estradiol	hydroxylation	regiospecificity.
chr2	55461978	55461981	P62979	0	+	55461978	55461981	102,0,51	1	3	0	.	Essential	for	function.
chr2	60997607	60997610	Q9BWT3	0	+	60997607	60997610	102,0,51	1	3	0	.	Interaction	with	RNA.
chr2	60997622	60997625	Q9BWT3	0	+	60997622	60997625	102,0,51	1	3	0	.	Interaction	with	RNA.
chr2	61009091	61009094	Q9BWT3	0	+	61009091	61009094	102,0,51	1	3	0	.	Interaction	with	RNA.
chr2	61014106	61014109	Q9BWT3	0	+	61014106	61014109	102,0,51	1	3	0	.	Interaction	with	RNA.
chr2	61019338	61019341	Q9BWT3	0	+	61019338	61019341	102,0,51	1	3	0	.	Interaction	with	RNA.
chr2	73456005	73456008	Q9BSG0	0	-	73456005	73456008	102,0,51	1	3	0	.	Not	glycosylated.
chr2	74076584	74076587	O95630	0	+	74076584	74076587	102,0,51	1	3	0	.	Indirect	zinc-binding.
chr2	85806224	85806227	Q9BV40	0	+	85806224	85806227	102,0,51	1	3	0	.	Interaction	with	STX8.
chr2	86756482	86756485	Q9Y3E7	0	-	86756482	86756485	102,0,51	1	3	0	.	Important	for	autoinhibitory	function.
chr2	100024589	100024592	Q9UBZ9	0	-	100024589	100024592	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr2	100027191	100027194	Q9UBZ9	0	-	100027191	100027194	102,0,51	1	3	0	.	Interaction	with	target	DNA.
chr2	101650005	101650008	O95759	0	-	101650005	101650008	102,0,51	1	3	0	.	Glutamine	finger.
chr2	101650122	101650125	O95759	0	-	101650122	101650125	102,0,51	1	3	0	.	Arginine	finger.
chr2	113590344	113590347	P01584	0	-	113590344	113590347	102,0,51	1	3	0	.	Involved	in	receptor	binding.
chr2	120005734	120005740	Q658P3	0	+	120005734	120005740	102,0,51	1	6	0	.	Cleavage;	by	RHBDL4/RHBDD1.
chr2	127413860	127413863	P04921	0	+	127413860	127413863	102,0,51	1	3	0	.	Not	glycosylated;	in	variant	Webb	antigen.
chr2	128183755	128183761	P04070	0	+	128183755	128183761	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr2	130949406	130949409	Q6PEY2	0	-	130949406	130949409	102,0,51	1	3	0	.	Involved	in	polymerization.
chr2	132240415	132240418	Q13748	0	+	132240415	132240418	102,0,51	1	3	0	.	Involved	in	polymerization.
chr2	155555803	155555806	P48549	0	+	155555803	155555806	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr2	163000634	163000640	P01275	0	-	163000634	163000640	102,0,51	1	6	0	.	Cleavage;	by	PCSK1.
chr2	163002048	163002054	P01275	0	-	163002048	163002054	102,0,51	1	6	0	.	Cleavage;	by	PCSK1.
chr2	163002147	163002153	P01275	0	-	163002147	163002153	102,0,51	1	6	0	.	Cleavage;	by	PCSK1.
chr2	163002165	163002171	P01275	0	-	163002165	163002171	102,0,51	1	6	0	.	Cleavage;	by	PCSK1.
chr2	163003864	163003870	P01275	0	-	163003864	163003870	102,0,51	1	6	0	.	Cleavage;	by	PCSK1	and	PCSK2.
chr2	163003957	163003963	P01275	0	-	163003957	163003963	102,0,51	1	6	0	.	Cleavage;	by	PCSK2.
chr2	163099436	163099442	Q12884	0	-	163099436	163099442	102,0,51	1	6	0	.	Cleavage.	Pubmed:14751930
chr2	163163231	163163237	Q9BYX4	0	-	163163231	163163237	102,0,51	1	6	0	.	Cleavage.
chr2	163163336	163163342	Q9BYX4	0	-	163163336	163163342	102,0,51	1	6	0	.	Cleavage.
chr2	163163360	163163366	Q9BYX4	0	-	163163360	163163366	102,0,51	1	6	0	.	Cleavage.
chr2	166237620	166237623	Q99250	0	+	166237620	166237623	102,0,51	1	3	0	.	Important	for	channel	closure.
chr2	173349920	173349926	P23229	0	+	173349920	173349926	102,0,51	1	6	0	.	Cleavage;	by	PLAU	in	invasive	prostate	cancer.	Pubmed:17303120
chr2	176043069	176043072	P48201	0	-	176043069	176043072	102,0,51	1	3	0	.	Reversibly	protonated	during	proton	transport.
chr2	178357896	178357899	O00116	0	+	178357896	178357899	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr2	182374459	182374465	P13612	0	+	182374459	182374465	102,0,51	1	6	0	.	Cleavage.
chr2	188332519	188332522	P10646	0	-	188332519	188332522	102,0,51	1	3	0	.	Not	glycosylated.
chr2	188332603	188332609	P10646	0	-	188332603	188332609	102,0,51	1	6	0	.	Reactive	bond.
chr2	188349664	188349670	P10646	0	-	188349664	188349670	102,0,51	1	6	0	.	Reactive	bond.
chr2	188361731	188361737	P10646	0	-	188361731	188361737	102,0,51	1	6	0	.	Reactive	bond.
chr2	202901074	202901077	O75084	0	+	202901074	202901077	102,0,51	1	3	0	.	Essential	for	SDCBP-mediated	plasma	membrane	phosphatidylinositol-4,5-bisphosphate	recognition.	Pubmed:27386966
chr2	203079136	203079139	P63165	0	-	203079136	203079139	102,0,51	1	3	0	.	Interaction	with	PIAS2.
chr2	208461695	208461698	P16220	0	+	208461695	208461698	102,0,51	1	3	0	.	Required	for	binding	TORCs.
chr2	209108212	209108215	O75874	0	-	209108212	209108215	102,0,51	1	3	0	.	Critical	for	catalysis.
chr2	209108212	209108215	V9HWJ2	0	-	209108212	209108215	102,0,51	1	3	0	.	Critical	for	catalysis.
chr2	209110145	209110148	O75874	0	-	209110145	209110148	102,0,51	1	3	0	.	Critical	for	catalysis.
chr2	209110145	209110148	V9HWJ2	0	-	209110145	209110148	102,0,51	1	3	0	.	Critical	for	catalysis.
chr2	216197211	216197214	P31939	0	+	216197211	216197214	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr2	216236748	216236751	P02751	0	-	216236748	216236751	102,0,51	1	3	0	.	Not	glycosylated.
chr2	216274780	216274783	P02751	0	-	216274780	216274783	102,0,51	1	3	0	.	Important	for	superfibronectin	formation.
chr2	216274789	216274792	P02751	0	-	216274789	216274792	102,0,51	1	3	0	.	Important	for	superfibronectin	formation.
chr2	219267832	219267835	Q9GZU7	0	+	219267832	219267835	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:15304220
chr2	219268050	219268053	Q9GZU7	0	+	219268050	219268053	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:15304220
chr2	219849022	219849028	Q99581	0	-	219849022	219849028	102,0,51	1	6	0	.	Breakpoint	for	insertion	to	form	EWS-FEV	fusion	protein.
chr2	219920339	219920342	Q14623	0	-	219920339	219920342	102,0,51	1	3	0	.	Essential	for	auto-cleavage.
chr2	219920348	219920351	Q14623	0	-	219920348	219920351	102,0,51	1	3	0	.	Involved	in	auto-cleavage.
chr2	219920420	219920423	Q14623	0	-	219920420	219920423	102,0,51	1	3	0	.	Involved	in	cholesterol	transfer.
chr2	219920555	219920561	Q14623	0	-	219920555	219920561	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr2	220164795	220164801	Q16849	0	-	220164795	220164801	102,0,51	1	6	0	.	Cleavage.
chr2	220437276	220437282	P05111	0	+	220437276	220437282	102,0,51	1	6	0	.	Cleavage.
chr2	220439840	220439846	P05111	0	+	220439840	220439846	102,0,51	1	6	0	.	Cleavage.
chr2	223085071	223085944	P23760	0	-	223085071	223085944	102,0,51	1	873	0	.	Breakpoint	for	translocation	to	form	PAX3-NCOA1	oncogene.
chr2	224842321	224842327	P07093	0	-	224842321	224842327	102,0,51	1	6	0	.	Reactive	bond.
chr2	227896948	227896954	P53420	0	-	227896948	227896954	102,0,51	1	6	0	.	Cleavage;	by	collagenase.
chr2	228172448	228172454	Q01955	0	+	228172448	228172454	102,0,51	1	6	0	.	Cleavage;	by	collagenase.
chr2	228243942	228243948	Q53R12	0	-	228243942	228243948	102,0,51	1	6	0	.	Cleavage.	Pubmed:27499293
chr2	231742733	231742739	Q9NQX7	0	+	231742733	231742739	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr2	233075081	233075084	Q8IYB7	0	+	233075081	233075084	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr2	233635625	233635628	O60928	0	-	233635625	233635628	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr2	238234326	238234332	P12111	0	-	238234326	238234332	102,0,51	1	6	0	.	Reactive	bond.
chr2	241517147	241517150	Q9HAU8	0	+	241517147	241517150	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr2	242276920	242276923	B5MCX3	0	+	242276920	242276923	102,0,51	1	3	0	.	Important	for	dimerization.
chr2	242276920	242276923	C9J2Q4	0	+	242276920	242276923	102,0,51	1	3	0	.	Important	for	dimerization.
chr2	242276920	242276923	Q15019	0	+	242276920	242276923	102,0,51	1	3	0	.	Important	for	dimerization.
chr20	422592	422595	Q96BZ9	0	-	422592	422595	102,0,51	1	3	0	.	Glutamine	finger.
chr20	425715	425718	Q96BZ9	0	-	425715	425718	102,0,51	1	3	0	.	Arginine	finger.
chr20	2312712	2312718	Q08188	0	+	2312712	2312718	102,0,51	1	6	0	.	Cleavage;	by	CTSL.
chr20	2641113	2641116	O43837	0	-	2641113	2641116	102,0,51	1	3	0	.	Critical	for	catalysis.
chr20	2641360	2641363	O43837	0	-	2641360	2641363	102,0,51	1	3	0	.	Critical	for	catalysis.
chr20	2690220	2690223	Q9BQW3	0	+	2690220	2690223	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	2690247	2690250	Q9BQW3	0	+	2690247	2690250	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	3846449	3846455	Q7Z434	0	+	3846449	3846455	102,0,51	1	6	0	.	Cleavage;	by	HHAV	protein	3ABC.
chr20	3846692	3846698	Q7Z434	0	+	3846692	3846698	102,0,51	1	6	0	.	Cleavage;	by	HCV	and	hepatitis	GB	virus	B	NS3/4A	protease	complex.
chr20	10280045	10280051	P60880	0	+	10280045	10280051	102,0,51	1	6	0	.	Cleavage;	by	BONT/E.
chr20	23618388	23618391	P01034	0	-	23618388	23618391	102,0,51	1	3	0	.	Reactive	site.
chr20	23669510	23669513	P01036	0	-	23669510	23669513	102,0,51	1	3	0	.	Reactive	site.
chr20	23731407	23731410	P01037	0	-	23731407	23731410	102,0,51	1	3	0	.	Reactive	site.
chr20	23807201	23807204	P09228	0	-	23807201	23807204	102,0,51	1	3	0	.	Reactive	site.
chr20	23860217	23860220	P28325	0	-	23860217	23860220	102,0,51	1	3	0	.	Reactive	site.
chr20	24937960	24937963	O76096	0	+	24937960	24937963	102,0,51	1	3	0	.	Reactive	site.
chr20	25229039	25229042	P11216	0	+	25229039	25229042	102,0,51	1	3	0	.	Participates	in	a	stacking	interaction	with	the	adenine	ring	of	AMP.	Pubmed:27402852
chr20	25239953	25239956	P11216	0	+	25239953	25239956	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr20	25252020	25252023	P11216	0	+	25252020	25252023	102,0,51	1	3	0	.	Involved	in	the	association	of	subunits.
chr20	25252059	25252062	P11216	0	+	25252059	25252062	102,0,51	1	3	0	.	May	be	involved	in	allosteric	control.
chr20	30309835	30309841	Q07817	0	-	30309835	30309841	102,0,51	1	6	0	.	Cleavage;	by	caspase-1.
chr20	32162063	32194763	O43439	0	+	32162063	32194763	102,0,51	1	32700	0	.	Breakpoint	for	translocation	to	form	RUNX1-CBFA2T2	in	acute	myeloid	leukemia.	Pubmed:20520637
chr20	33147693	33147699	Q9H492	0	+	33147693	33147699	102,0,51	1	6	0	.	Cleavage;	by	ATG4B.
chr20	33862214	33862220	Q9Y5R2	0	+	33862214	33862220	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr20	39726947	39726950	P11387	0	+	39726947	39726950	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39728809	39728812	P11387	0	+	39728809	39728812	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39729918	39729921	P11387	0	+	39729918	39729921	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39741439	39741442	P11387	0	+	39741439	39741442	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39742657	39742660	P11387	0	+	39742657	39742660	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39742750	39742753	P11387	0	+	39742750	39742753	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39744929	39744932	P11387	0	+	39744929	39744932	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39746879	39746882	P11387	0	+	39746879	39746882	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	39746933	39746936	P11387	0	+	39746933	39746936	102,0,51	1	3	0	.	Interaction	with	DNA.
chr20	43243242	43243245	Q549H9	0	+	43243242	43243245	102,0,51	1	3	0	.	Important	for	inhibition.
chr20	43243251	43243254	Q549H9	0	+	43243251	43243254	102,0,51	1	3	0	.	Important	for	inhibition.
chr20	43243254	43243257	Q549H9	0	+	43243254	43243257	102,0,51	1	3	0	.	Important	for	inhibition.
chr20	43251535	43251538	P00813	0	-	43251535	43251538	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr20	43257719	43257722	P00813	0	-	43257719	43257722	102,0,51	1	3	0	.	Important	for	interaction	with	adenosine	receptors	and	increasing	their	affinity	for	agonists.	Pubmed:23193172
chr20	43257731	43257734	P00813	0	-	43257731	43257734	102,0,51	1	3	0	.	Important	for	interaction	with	adenosine	receptors	and	increasing	their	affinity	for	agonists.	Pubmed:23193172
chr20	43530345	43530348	P31946	0	+	43530345	43530348	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr20	43532717	43532720	P31946	0	+	43532717	43532720	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr20	43629822	43629828	Q13043	0	+	43629822	43629828	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr20	43629891	43629897	Q13043	0	+	43629891	43629897	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr20	43881742	43881748	P03973	0	-	43881742	43881748	102,0,51	1	6	0	.	Reactive	bond	for	chymotrypsin,	trypsin	and	elastase.	Pubmed:24121345,	Pubmed:3366116,	Pubmed:18421166
chr20	44638540	44638546	P14780	0	+	44638540	44638546	102,0,51	1	6	0	.	Cleavage;	by	MMP3.
chr20	44638681	44638687	P14780	0	+	44638681	44638687	102,0,51	1	6	0	.	Cleavage;	by	MMP3.
chr20	49411707	49434750	Q8TDM0	0	+	49411707	49434750	102,0,51	1	23043	0	.	Breakpoint	for	translocation	to	form	BCAS4-BCAS3.
chr20	57876760	57876766	P14138	0	+	57876760	57876766	102,0,51	1	6	0	.	Cleavage;	by	KEL.
chr20	61867601	61867607	Q96CA5	0	+	61867601	61867607	102,0,51	1	6	0	.	Cleavage;	by	CASP3	and	CASP7.
chr20	62729248	62729251	P41146	0	+	62729248	62729251	102,0,51	1	3	0	.	Important	for	G	protein-mediated	signaling.
chr20	62729308	62729311	P41146	0	+	62729308	62729311	102,0,51	1	3	0	.	Important	for	G	protein-mediated	signaling.
chr21	44589209	44589212	P02489	0	+	44589209	44589212	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44589260	44589263	P02489	0	+	44589260	44589263	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44589308	44589311	P02489	0	+	44589308	44589311	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44592279	44592282	P02489	0	+	44592279	44592282	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	27254073	27254079	P05067	0	-	27254073	27254079	102,0,51	1	6	0	.	Cleavage;	by	caspase-6,	caspase-8	or	caspase-9.
chr21	27264081	27264087	P05067	0	-	27264081	27264087	102,0,51	1	6	0	.	Cleavage;	by	gamma-secretase;	site	3.
chr21	27264102	27264108	P05067	0	-	27264102	27264108	102,0,51	1	6	0	.	Cleavage;	by	gamma-secretase;	site	2.
chr21	27264108	27264114	P05067	0	-	27264108	27264114	102,0,51	1	6	0	.	Cleavage;	by	gamma-secretase;	site	1.
chr21	27264126	27264129	P05067	0	-	27264126	27264129	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:10535332
chr21	27264132	27264135	P05067	0	-	27264132	27264135	102,0,51	1	3	0	.	Implicated	in	free	radical	propagation.
chr21	27264171	27264177	P05067	0	-	27264171	27264177	102,0,51	1	6	0	.	Cleavage;	by	theta-secretase.	Pubmed:16816112
chr21	27269884	27269890	P05067	0	-	27269884	27269890	102,0,51	1	6	0	.	Cleavage;	by	alpha-secretase.
chr21	27269929	27269935	P05067	0	-	27269929	27269935	102,0,51	1	6	0	.	Cleavage;	by	caspase-6;	when	associated	with	variant	670-N-L-671.
chr21	27269932	27269938	P05067	0	-	27269932	27269938	102,0,51	1	6	0	.	Cleavage;	by	beta-secretase.
chr21	27372456	27372462	P05067	0	-	27372456	27372462	102,0,51	1	6	0	.	Reactive	bond.
chr21	27425587	27425590	P05067	0	-	27425587	27425590	102,0,51	1	3	0	.	Required	for	Cu(2+)	reduction.
chr21	34876610	34876613	P22102	0	-	34876610	34876613	102,0,51	1	3	0	.	Raises	pKa	of	active	site	His.
chr21	36171757	36206710	Q01196	0	-	36171757	36206710	102,0,51	1	34953	0	.	Breakpoint	for	translocation	to	form	AML1-EAP	in	T-MDS	and	CML,	to	form	type	II	MACROD1-RUNX1	fusion	protein	and	to	form	RUNX1-CBFA2T2	in	acute	myeloid	leukemia.	Pubmed:20520637
chr21	36206896	36231774	Q01196	0	-	36206896	36231774	102,0,51	1	24878	0	.	Breakpoint	for	translocation	to	form	AML1-EMV-1	(or	AML1-EAP)	in	CML	and	T-MDS,	to	form	AML1-MTG8	(ETO)	in	AML-M2,	to	form	AML1-CBFA2T3	in	therapy-related	myeloid	malignancies.
chr21	39086913	39086916	P48051	0	-	39086913	39086916	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr21	39671651	39671654	Q99712	0	+	39671651	39671654	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr21	39755375	39755381	P11308	0	-	39755375	39755381	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	ELF4-ERG	oncogene.
chr21	42845382	42845388	O15393	0	-	42845382	42845388	102,0,51	1	6	0	.	Cleavage.
chr21	43164099	43164105	P57078	0	-	43164099	43164105	102,0,51	1	6	0	.	Cleavage.
chr21	43164213	43164219	P57078	0	-	43164213	43164219	102,0,51	1	6	0	.	Cleavage.
chr21	43803272	43803278	P57727	0	-	43803272	43803278	102,0,51	1	6	0	.	Cleavage.
chr21	44589209	44589212	P02489	0	+	44589209	44589212	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44589260	44589263	P02489	0	+	44589260	44589263	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44589308	44589311	P02489	0	+	44589308	44589311	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	44592279	44592282	P02489	0	+	44592279	44592282	102,0,51	1	3	0	.	Susceptible	to	oxidation.
chr21	45196138	45196141	P04080	0	-	45196138	45196141	102,0,51	1	3	0	.	Reactive	site.
chr21	46685498	46685501	Q9Y2G5	0	-	46685498	46685501	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr22	18222177	18222183	P55957	0	-	18222177	18222183	102,0,51	1	6	0	.	Cleavage.
chr22	18222246	18222252	P55957	0	-	18222246	18222252	102,0,51	1	6	0	.	Cleavage.
chr22	18226605	18226611	P55957	0	-	18226605	18226611	102,0,51	1	6	0	.	Cleavage.
chr22	19707966	19707969	B4DJ62	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	19707966	19707969	C9JM82	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	19707966	19707969	E7EPG2	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	19707966	19707969	E7EQM7	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	19707966	19707969	G3XAH0	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	19707966	19707969	X5DNA9	0	+	19707966	19707969	102,0,51	1	3	0	.	Important	for	dimerization.
chr22	21141240	21141246	P05546	0	+	21141240	21141246	102,0,51	1	6	0	.	Reactive	bond.
chr22	23524422	23595987	P11274	0	+	23524422	23595987	102,0,51	1	71565	0	.	Breakpoint	for	translocation	to	form	BCR-ABL	oncogene.
chr22	26932439	26932442	O60704	0	-	26932439	26932442	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr22	26937122	26937125	O60704	0	-	26937122	26937125	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr22	29192048	29192054	P17861	0	-	29192048	29192054	102,0,51	1	6	0	.	Cleavage;	by	HM13/SPP.	Pubmed:25239945
chr22	29684593	29684596	Q01844	0	+	29684593	29684596	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	chimeric	EWSR1/ATF1	protein.
chr22	29688154	29688478	Q01844	0	+	29688154	29688478	102,0,51	1	324	0	.	Breakpoint	for	insertion	to	form	EWSR1-FEV	fusion	protein.
chr22	30690977	30690980	Q9BXI6	0	-	30690977	30690980	102,0,51	1	3	0	.	Glutamine	finger.
chr22	30691781	30691784	Q9BXI6	0	-	30691781	30691784	102,0,51	1	3	0	.	Arginine	finger.
chr22	30741065	30741068	Q15459	0	-	30741065	30741068	102,0,51	1	3	0	.	Critical	for	binding	to	SF3A3.
chr22	32015693	32015699	A0A024R1K5	0	-	32015693	32015699	102,0,51	1	6	0	.	Cleavage	(non-hydrolytic);	by	autocatalysis.
chr22	32015693	32015699	Q9UG56	0	-	32015693	32015699	102,0,51	1	6	0	.	Cleavage	(non-hydrolytic);	by	autocatalysis.
chr22	32352206	32352209	Q04917	0	+	32352206	32352209	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr22	32352431	32352434	Q04917	0	+	32352431	32352434	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr22	32439394	32439397	P13866	0	+	32439394	32439397	102,0,51	1	3	0	.	Implicated	in	sodium	coupling.
chr22	32480898	32480901	P13866	0	+	32480898	32480901	102,0,51	1	3	0	.	Implicated	in	sodium	coupling.
chr22	32495266	32495269	P13866	0	+	32495266	32495269	102,0,51	1	3	0	.	Involved	in	sugar-binding/transport	and	inhibitor	binding.
chr22	36161509	36161512	B0QYV1	0	-	36161509	36161512	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36161509	36161512	B0QYY4	0	-	36161509	36161512	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36164312	36164315	B0QYV1	0	-	36164312	36164315	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36164312	36164315	B0QYY4	0	-	36164312	36164315	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36164384	36164387	B0QYV1	0	-	36164384	36164387	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36164384	36164387	B0QYY4	0	-	36164384	36164387	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36167740	36167743	A0A0G2JRA5	0	-	36167740	36167743	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36167740	36167743	B0QYV1	0	-	36167740	36167743	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36167740	36167743	B0QYY4	0	-	36167740	36167743	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170543	36170546	A0A0G2JRA5	0	-	36170543	36170546	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170543	36170546	B0QYV1	0	-	36170543	36170546	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170543	36170546	B0QYY4	0	-	36170543	36170546	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170615	36170618	A0A0G2JRA5	0	-	36170615	36170618	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170615	36170618	B0QYV1	0	-	36170615	36170618	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36170615	36170618	B0QYY4	0	-	36170615	36170618	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36174071	36174074	B0QYV1	0	-	36174071	36174074	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36174071	36174074	B0QYY4	0	-	36174071	36174074	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36174086	36174089	B0QYV1	0	-	36174086	36174089	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36174086	36174089	B0QYY4	0	-	36174086	36174089	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177679	36177682	B0QYV1	0	-	36177679	36177682	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177679	36177682	B0QYY4	0	-	36177679	36177682	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177682	36177685	B0QYV1	0	-	36177682	36177685	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177682	36177685	B0QYY4	0	-	36177682	36177685	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177706	36177709	B0QYV1	0	-	36177706	36177709	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36177706	36177709	B0QYY4	0	-	36177706	36177709	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180302	36180305	A0A0G2JRA5	0	-	36180302	36180305	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180302	36180305	B0QYV1	0	-	36180302	36180305	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180302	36180305	B0QYY4	0	-	36180302	36180305	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180317	36180320	A0A0G2JRA5	0	-	36180317	36180320	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180317	36180320	B0QYV1	0	-	36180317	36180320	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36180317	36180320	B0QYY4	0	-	36180317	36180320	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183910	36183913	A0A0G2JRA5	0	-	36183910	36183913	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183910	36183913	B0QYV1	0	-	36183910	36183913	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183910	36183913	B0QYY4	0	-	36183910	36183913	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183913	36183916	A0A0G2JRA5	0	-	36183913	36183916	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183913	36183916	B0QYV1	0	-	36183913	36183916	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183913	36183916	B0QYY4	0	-	36183913	36183916	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183937	36183940	A0A0G2JRA5	0	-	36183937	36183940	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183937	36183940	B0QYV1	0	-	36183937	36183940	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36183937	36183940	B0QYY4	0	-	36183937	36183940	102,0,51	1	3	0	.	Interaction	with	RNA.
chr22	36872890	36872893	Q99757	0	-	36872890	36872893	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr22	36872893	36872896	Q99757	0	-	36872893	36872896	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr22	36876632	36876635	Q99757	0	-	36876632	36876635	102,0,51	1	3	0	.	Deprotonates	C-terminal	active	site	Cys.
chr22	38823645	38823648	A0A024R1L8	0	-	38823645	38823648	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr22	38823645	38823648	P48050	0	-	38823645	38823648	102,0,51	1	3	0	.	Role	in	the	control	of	polyamine-mediated	channel	gating	and	in	the	blocking	by	intracellular	magnesium.
chr22	39479883	39479886	Q9HC16	0	+	39479883	39479886	102,0,51	1	3	0	.	Interaction	with	DNA.
chr22	39627749	39627752	P01127	0	-	39627749	39627752	102,0,51	1	3	0	.	Involved	in	receptor	binding.
chr22	39627758	39627761	P01127	0	-	39627758	39627761	102,0,51	1	3	0	.	Involved	in	receptor	binding.
chr22	39826161	39826164	Q15750	0	+	39826161	39826164	102,0,51	1	3	0	.	Required	for	interaction	with	MAP3K7.	Pubmed:11323434
chr22	40038813	40038816	Q9P0X4	0	+	40038813	40038816	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr22	40055713	40055716	Q9P0X4	0	+	40055713	40055716	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr22	40064329	40064332	Q9P0X4	0	+	40064329	40064332	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr22	40074089	40074092	Q9P0X4	0	+	40074089	40074092	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr22	40831553	40831559	Q969V6	0	-	40831553	40831559	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	RBM15-MKL1.
chr22	41489098	41513192	Q09472	0	+	41489098	41513192	102,0,51	1	24094	0	.	Breakpoint	for	translocation	to	form	KAT6A-EP300	and	EP300-KAT6A.
chr22	41573976	41573979	Q09472	0	+	41573976	41573979	102,0,51	1	3	0	.	Interaction	with	NCOA2.
chr22	41574138	41574141	Q09472	0	+	41574138	41574141	102,0,51	1	3	0	.	Interaction	with	NCOA2.
chr22	41645332	41645335	P46060	0	-	41645332	41645335	102,0,51	1	3	0	.	Hydrophobic	interaction	with	UBC9.
chr22	41645341	41645344	P46060	0	-	41645341	41645344	102,0,51	1	3	0	.	Hydrophobic	interaction	with	UBC9.
chr22	42273247	42273253	Q12772	0	+	42273247	42273253	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	and	caspase-7.
chr22	42273295	42273301	Q12772	0	+	42273295	42273301	102,0,51	1	6	0	.	Cleavage;	by	S2P.
chr22	42273409	42273415	Q12772	0	+	42273409	42273415	102,0,51	1	6	0	.	Cleavage;	by	S1P.
chr22	43525284	43525290	Q13323	0	+	43525284	43525290	102,0,51	1	6	0	.	Cleavage;	by	RHBDL4/RHBDD1.
chr22	46631166	46631169	Q07869	0	+	46631166	46631169	102,0,51	1	3	0	.	Essential	for	heterodimerization	with	RXRA.
chr22	46742341	46742344	O75648	0	+	46742341	46742344	102,0,51	1	3	0	.	Interaction	with	tRNA.
chr22	46749689	46749692	O75648	0	+	46749689	46749692	102,0,51	1	3	0	.	Interaction	with	tRNA.
chr22	46751966	46751969	O75648	0	+	46751966	46751969	102,0,51	1	3	0	.	Interaction	with	tRNA.
chr22	50720021	50720027	O15031	0	-	50720021	50720027	102,0,51	1	6	0	.	Cleavage;	by	proprotein	convertases.
chr3	430991	430997	O00533	0	+	430991	430997	102,0,51	1	6	0	.	Cleavage;	by	ADAM8.
chr3	439977	439983	O00533	0	+	439977	439983	102,0,51	1	6	0	.	Cleavage;	by	ADAM8.
chr3	17425404	17425407	Q92609	0	-	17425404	17425407	102,0,51	1	3	0	.	Glutamine	finger.
chr3	17444674	17444677	Q92609	0	-	17444674	17444677	102,0,51	1	3	0	.	Arginine	finger.
chr3	18436394	18436400	Q01826	0	-	18436394	18436400	102,0,51	1	6	0	.	Cleavage;	by	caspases.
chr3	25662178	25662181	Q02880	0	-	25662178	25662181	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25665101	25665104	Q02880	0	-	25665101	25665104	102,0,51	1	3	0	.	Important	for	DNA	bending;	intercalates	between	base	pairs	of	target	DNA.
chr3	25665807	25665810	Q02880	0	-	25665807	25665810	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr3	25666184	25666187	Q02880	0	-	25666184	25666187	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25666286	25666289	Q02880	0	-	25666286	25666289	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25668322	25668325	Q02880	0	-	25668322	25668325	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25668325	25668328	Q02880	0	-	25668325	25668328	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25671826	25671829	Q02880	0	-	25671826	25671829	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	25671835	25671838	Q02880	0	-	25671835	25671838	102,0,51	1	3	0	.	Interaction	with	DNA.
chr3	37670680	37670686	Q13797	0	+	37670680	37670686	102,0,51	1	6	0	.	Cleavage.
chr3	38012972	38012975	O15194	0	+	38012972	38012975	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr3	38017295	38017298	O15194	0	+	38017295	38017298	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr3	39452334	39452340	A0A024R2P0	0	+	39452334	39452340	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	1.
chr3	39452334	39452340	A0A0C4DG17	0	+	39452334	39452340	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	1.
chr3	39452334	39452340	P08865	0	+	39452334	39452340	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	1.
chr3	39452388	39452394	A0A024R2P0	0	+	39452388	39452394	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	2.
chr3	39452388	39452394	A0A0C4DG17	0	+	39452388	39452394	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	2.
chr3	39452388	39452394	P08865	0	+	39452388	39452394	102,0,51	1	6	0	.	Cleavage;	by	ST3;	site	2.
chr3	45136977	45136983	Q9H5V8	0	-	45136977	45136983	102,0,51	1	6	0	.	Cleavage;	by	ST14/MT-SP1.
chr3	46495810	46495813	P02788	0	-	46495810	46495813	102,0,51	1	3	0	.	Important	for	iron	binding.
chr3	48361069	48361075	P0C7L1	0	-	48361069	48361075	102,0,51	1	6	0	.	Reactive	bond.
chr3	48451938	48451941	O43157	0	-	48451938	48451941	102,0,51	1	3	0	.	Important	for	interaction	with	RAC1	and	RND1.
chr3	48456632	48456638	O43157	0	-	48456632	48456638	102,0,51	1	6	0	.	Cleavage;	by	proprotein	convertases.
chr3	48561182	48561185	Q16877	0	-	48561182	48561185	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr3	48602372	48602378	Q02388	0	-	48602372	48602378	102,0,51	1	6	0	.	Reactive	bond.
chr3	48720442	48723072	Q9NZQ3	0	-	48720442	48723072	102,0,51	1	2630	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-AF3P21	oncogene.
chr3	49395564	49395567	P07203	0	-	49395564	49395567	102,0,51	1	3	0	.	Subject	to	oxidation	and	hydroselenide	loss	to	dehydroalanine.
chr3	49397653	49397659	P61586	0	-	49397653	49397659	102,0,51	1	6	0	.	Cleavage;	by	yopT.
chr3	49569900	49569906	Q14118	0	+	49569900	49569906	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr3	49570086	49570092	Q14118	0	+	49570086	49570092	102,0,51	1	6	0	.	Cleavage;	by	MMP9.
chr3	52441217	52441220	Q92560	0	-	52441217	52441220	102,0,51	1	3	0	.	Important	for	enzyme	activity.
chr3	52853418	52853424	Q14624	0	-	52853418	52853424	102,0,51	1	6	0	.	Cleavage;	by	kallikrein.
chr3	53213618	53213621	Q05655	0	+	53213618	53213621	102,0,51	1	3	0	.	Interaction	with	phosphotyrosine-containing	peptide.
chr3	53213660	53213663	Q05655	0	+	53213660	53213663	102,0,51	1	3	0	.	Interaction	with	phosphotyrosine-containing	peptide.
chr3	53213675	53213678	Q05655	0	+	53213675	53213678	102,0,51	1	3	0	.	Interaction	with	phosphotyrosine-containing	peptide.
chr3	53215273	53215276	Q05655	0	+	53215273	53215276	102,0,51	1	3	0	.	Interaction	with	phosphotyrosine-containing	peptide.
chr3	53219941	53219947	Q05655	0	+	53219941	53219947	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr3	53265540	53265543	P29401	0	-	53265540	53265543	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	53276254	53276257	P29401	0	-	53276254	53276257	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	53700535	53700538	Q01668	0	+	53700535	53700538	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr3	53760917	53760920	Q01668	0	+	53760917	53760920	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr3	53781461	53781464	Q01668	0	+	53781461	53781464	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr3	53809925	53809928	Q01668	0	+	53809925	53809928	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr3	53919887	53919893	Q9Y6D0	0	-	53919887	53919893	102,0,51	1	6	0	.	Cleavage;	by	CAPN2.
chr3	58413883	58413886	P11177	0	-	58413883	58413886	102,0,51	1	3	0	.	Important	for	interaction	with	DLAT.	Pubmed:20160912
chr3	59908077	59908080	P49789	0	-	59908077	59908080	102,0,51	1	3	0	.	Important	for	induction	of	apoptosis.
chr3	62268539	62268542	P23470	0	+	62268539	62268542	102,0,51	1	3	0	.	Ancestral	active	site.
chr3	67571034	67571037	Q96I99	0	-	67571034	67571037	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr3	67579599	67579602	Q96I99	0	-	67579599	67579602	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr3	69112192	69112195	Q8TBC4	0	-	69112192	69112195	102,0,51	1	3	0	.	Determines	specificity	for	NEDD8.
chr3	71247352	71247358	Q9H334	0	-	71247352	71247358	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PAX5-FOXP1.
chr3	93598153	93598156	P07225	0	-	93598153	93598156	102,0,51	1	3	0	.	Not	glycosylated;	in	variant	Heerlen.
chr3	98304475	98304478	P36551	0	-	98304475	98304478	102,0,51	1	3	0	.	Important	for	dimerization.
chr3	100451512	100455421	Q92734	0	+	100451512	100455421	102,0,51	1	3909	0	.	Breakpoint	for	translocation	to	form	TRK-T3.
chr3	112256992	112256998	Q9NT62	0	-	112256992	112256998	102,0,51	1	6	0	.	Cleavage;	by	CASP8.
chr3	122044148	122044151	P01040	0	+	122044148	122044151	102,0,51	1	3	0	.	Reactive	site.
chr3	125876287	125876290	O75891	0	-	125876287	125876290	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr3	132047134	132047137	P15309	0	+	132047134	132047137	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr3	132051143	132051146	P15309	0	+	132051143	132051146	102,0,51	1	3	0	.	Required	for	homodimerization.
chr3	132051161	132051164	P15309	0	+	132051161	132051164	102,0,51	1	3	0	.	Required	for	homodimerization.
chr3	132061455	132061458	P15309	0	+	132061455	132061458	102,0,51	1	3	0	.	Required	for	structural	stability.
chr3	142840111	142840114	Q9Y4C5	0	+	142840111	142840114	102,0,51	1	3	0	.	Not	glycosylated.
chr3	148714687	148714690	P46976	0	+	148714687	148714690	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	148727067	148727070	P46976	0	+	148727067	148727070	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	158289134	158310226	P58340	0	+	158289134	158310226	102,0,51	1	21092	0	.	Breakpoint	for	translocation	to	form	NPM-MLF1.
chr3	167164246	167164252	O75830	0	-	167164246	167164252	102,0,51	1	6	0	.	Reactive	bond.
chr3	167542277	167542283	Q99574	0	+	167542277	167542283	102,0,51	1	6	0	.	Reactive	bond.
chr3	184040960	184040966	Q04637	0	+	184040960	184040966	102,0,51	1	6	0	.	Cleavage;	by	foot-and-mouth	disease	virus	leader	protease.
chr3	184040981	184040987	Q04637	0	+	184040981	184040987	102,0,51	1	6	0	.	Cleavage;	by	enterovirus/rhinovirus	protease	2A.
chr3	184947310	184947313	Q08426	0	-	184947310	184947313	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	184953116	184953119	Q08426	0	-	184953116	184953119	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr3	186395408	186395414	P04196	0	+	186395408	186395414	102,0,51	1	6	0	.	Cleavage;	by	plasmin.
chr3	186435472	186435475	P01042	0	+	186435472	186435475	102,0,51	1	3	0	.	Not	glycosylated.
chr3	186459319	186459325	P01042	0	+	186459319	186459325	102,0,51	1	6	0	.	Cleavage;	by	kallikrein.
chr3	186459349	186459355	P01042	0	+	186459349	186459355	102,0,51	1	6	0	.	Cleavage;	by	kallikrein.
chr3	186571030	186571033	Q15848	0	+	186571030	186571033	102,0,51	1	3	0	.	Not	hydroxylated.
chr3	186572013	186572016	Q15848	0	+	186572013	186572016	102,0,51	1	3	0	.	Not	hydroxylated.
chr3	186572067	186572070	Q15848	0	+	186572067	186572070	102,0,51	1	3	0	.	Not	hydroxylated.
chr3	186572445	186572448	Q15848	0	+	186572445	186572448	102,0,51	1	3	0	.	Not	glycosylated.
chr3	186947641	186947647	P48740	0	-	186947641	186947647	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr3	188327629	188426057	Q93052	0	+	188327629	188426057	102,0,51	1	98428	0	.	Breakpoint	for	translocation	to	form	HMGA2-LPP.
chr3	188478067	188583990	Q93052	0	+	188478067	188583990	102,0,51	1	105923	0	.	Breakpoint	for	translocation	to	form	HMGA2-LPP	and	KMT2A/MLL1-LPP.
chr3	195800931	195800937	P02786	0	-	195800931	195800937	102,0,51	1	6	0	.	Cleavage;	by	trypsin;	to	produce	soluble	form.
chr3	196534709	196534715	Q13177	0	+	196534709	196534715	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	or	caspase-3-like	proteases.
chr4	3129118	3129124	P42858	0	+	3129118	3129124	102,0,51	1	6	0	.	Cleavage;	by	apopain.
chr4	3129169	3129175	P42858	0	+	3129169	3129175	102,0,51	1	6	0	.	Cleavage;	by	apopain.
chr4	3129235	3129241	P42858	0	+	3129235	3129241	102,0,51	1	6	0	.	Cleavage;	by	apopain.
chr4	3131665	3131671	P42858	0	+	3131665	3131671	102,0,51	1	6	0	.	Cleavage;	by	apopain.
chr4	3768723	3768726	P18825	0	+	3768723	3768726	102,0,51	1	3	0	.	Implicated	in	ligand	binding.
chr4	3768972	3768975	P18825	0	+	3768972	3768975	102,0,51	1	3	0	.	Implicated	in	catechol	agonist	binding	and	receptor	activation.
chr4	3768984	3768987	P18825	0	+	3768984	3768987	102,0,51	1	3	0	.	Implicated	in	catechol	agonist	binding	and	receptor	activation.
chr4	15709142	15709145	Q10588	0	+	15709142	15709145	102,0,51	1	3	0	.	Crucial	for	NAD	binding	and	catalysis.
chr4	15713491	15713494	Q10588	0	+	15713491	15713494	102,0,51	1	3	0	.	Crucial	for	NAD	binding	and	catalysis.
chr4	15717345	15717348	Q10588	0	+	15717345	15717348	102,0,51	1	3	0	.	Crucial	for	NAD	binding	and	catalysis.
chr4	20598077	20598083	O94813	0	+	20598077	20598083	102,0,51	1	6	0	.	Cleavage.
chr4	24801263	24801266	P08294	0	+	24801263	24801266	102,0,51	1	3	0	.	Not	glycated.
chr4	24801416	24801419	P08294	0	+	24801416	24801419	102,0,51	1	3	0	.	Not	glycated.
chr4	24801854	24801857	P08294	0	+	24801854	24801857	102,0,51	1	3	0	.	Not	glycated.
chr4	25160621	25160624	Q9HD40	0	-	25160621	25160624	102,0,51	1	3	0	.	May	act	as	a	substrate	filter	by	repelling	compounds	with	a	negatively	charged	alpha-carboxylate.
chr4	25665948	25667751	O95436	0	+	25665948	25667751	102,0,51	1	1803	0	.	Breakpoint	for	translocation	to	form	a	SLC34A2-ROS1	fusion	protein.
chr4	40350968	40350971	Q9UGM1	0	+	40350968	40350971	102,0,51	1	3	0	.	Key	residue	important	for	potent	inhibition	of	the	CHRNA9-CHRNA10	receptor	by	the	alpha-conotoxin	RgIA	(AC	P0C1D0).
chr4	41258993	41258996	P09936	0	+	41258993	41258996	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	41259008	41259011	P09936	0	+	41259008	41259011	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	41259131	41259134	P09936	0	+	41259131	41259134	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	41263775	41263778	P09936	0	+	41263775	41263778	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	41266118	41266121	P09936	0	+	41266118	41266121	102,0,51	1	3	0	.	Important	for	enzyme	activity.	Pubmed:8639624
chr4	41266127	41266130	P09936	0	+	41266127	41266130	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	41270075	41270078	P09936	0	+	41270075	41270078	102,0,51	1	3	0	.	Susceptible	to	oxidation.	Pubmed:14722078
chr4	47625721	47625727	Q9Y5Q5	0	-	47625721	47625727	102,0,51	1	6	0	.	Cleavage.
chr4	47676482	47676488	Q9Y5Q5	0	-	47676482	47676488	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr4	47765517	47765523	Q9Y5Q5	0	-	47765517	47765523	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr4	48424088	48424091	Q9P270	0	+	48424088	48424091	102,0,51	1	3	0	.	Important	for	interaction	with	CLIP1.
chr4	48485836	48485842	Q96EP9	0	+	48485836	48485842	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr4	48530350	48530353	O94915	0	-	48530350	48530353	102,0,51	1	3	0	.	Breakpoint	for	insertion	to	form	KMT2A/MLL1-AFF4	fusion	protein.
chr4	54292129	54294196	Q6UN15	0	+	54292129	54294196	102,0,51	1	2067	0	.	Breakpoint	for	interstitial	deletion	to	form	the	FIP1L1-PDGFRA	fusion	protein.
chr4	54880280	54880286	Q9UKJ5	0	-	54880280	54880286	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	CHIC2-ETV6	in	AML.
chr4	55141085	55141091	P16234	0	+	55141085	55141091	102,0,51	1	6	0	.	Breakpoint	for	interstitial	deletion	to	form	the	FIP1L1-PDGFRA	fusion	protein.
chr4	55604597	55604600	A0A024RDA0	0	+	55604597	55604600	102,0,51	1	3	0	.	Important	for	interaction	with	phosphotyrosine-binding	proteins.
chr4	55604597	55604600	P10721	0	+	55604597	55604600	102,0,51	1	3	0	.	Important	for	interaction	with	phosphotyrosine-binding	proteins.
chr4	55953910	55953913	P35968	0	-	55953910	55953913	102,0,51	1	3	0	.	Interaction	with	SHB.
chr4	56344985	56344988	O15516	0	-	56344985	56344988	102,0,51	1	3	0	.	Important	for	interaction	with	ARNTL/BMAL1.	Pubmed:23229515
chr4	56345096	56345099	O15516	0	-	56345096	56345099	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr4	56345108	56345111	O15516	0	-	56345108	56345111	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr4	56345120	56345123	O15516	0	-	56345120	56345123	102,0,51	1	3	0	.	Interaction	with	E-box	DNA.	Pubmed:23229515
chr4	57319815	57319818	P22234	0	+	57319815	57319818	102,0,51	1	3	0	.	Essential	for	AIR	carboxylase	activity.
chr4	57677918	57677924	P20155	0	-	57677918	57677924	102,0,51	1	6	0	.	Reactive	bond.
chr4	70897815	70897818	P15516	0	+	70897815	70897818	102,0,51	1	3	0	.	Important	for	candidacidal	activity.
chr4	70898901	70898904	P15516	0	+	70898901	70898904	102,0,51	1	3	0	.	Important	for	candidacidal	activity.
chr4	70898907	70898910	P15516	0	+	70898907	70898910	102,0,51	1	3	0	.	Not	sulfated.
chr4	70898919	70898922	P15516	0	+	70898919	70898922	102,0,51	1	3	0	.	Not	sulfated.
chr4	70898925	70898928	P15516	0	+	70898925	70898928	102,0,51	1	3	0	.	Not	sulfated.
chr4	71114975	71114981	P07498	0	+	71114975	71114981	102,0,51	1	6	0	.	Cleavage;	by	chymosin/rennin.
chr4	74270834	74270837	P02768	0	+	74270834	74270837	102,0,51	1	3	0	.	Not	glycated.
chr4	74270882	74270885	P02768	0	+	74270882	74270885	102,0,51	1	3	0	.	Not	glycated.
chr4	74272400	74272403	P02768	0	+	74272400	74272403	102,0,51	1	3	0	.	Not	glycated.
chr4	74272469	74272472	P02768	0	+	74272469	74272472	102,0,51	1	3	0	.	Not	glycated.
chr4	74274328	74274331	P02768	0	+	74274328	74274331	102,0,51	1	3	0	.	Not	glycated.
chr4	74274388	74274391	P02768	0	+	74274388	74274391	102,0,51	1	3	0	.	Not	glycated.
chr4	74274427	74274430	P02768	0	+	74274427	74274430	102,0,51	1	3	0	.	Not	glycated.
chr4	74274517	74274520	P02768	0	+	74274517	74274520	102,0,51	1	3	0	.	Not	glycated.
chr4	74275135	74275138	P02768	0	+	74275135	74275138	102,0,51	1	3	0	.	Not	glycated.
chr4	74275180	74275183	P02768	0	+	74275180	74275183	102,0,51	1	3	0	.	Not	glycated.
chr4	74275201	74275204	P02768	0	+	74275201	74275204	102,0,51	1	3	0	.	Not	glycated.
chr4	74276052	74276055	P02768	0	+	74276052	74276055	102,0,51	1	3	0	.	Not	glycated.
chr4	74276067	74276070	P02768	0	+	74276067	74276070	102,0,51	1	3	0	.	Not	glycated.
chr4	74276079	74276082	P02768	0	+	74276079	74276082	102,0,51	1	3	0	.	Aspirin-acetylated	lysine.
chr4	74276097	74276100	P02768	0	+	74276097	74276100	102,0,51	1	3	0	.	Not	glycated.
chr4	74276118	74276121	P02768	0	+	74276118	74276121	102,0,51	1	3	0	.	Not	glycated.
chr4	74277788	74277791	P02768	0	+	74277788	74277791	102,0,51	1	3	0	.	Not	glycated.
chr4	74279148	74279151	P02768	0	+	74279148	74279151	102,0,51	1	3	0	.	Not	glycated.
chr4	74279184	74279187	P02768	0	+	74279184	74279187	102,0,51	1	3	0	.	Not	glycated.
chr4	74279220	74279223	P02768	0	+	74279220	74279223	102,0,51	1	3	0	.	Not	glycated.
chr4	74280839	74280842	P02768	0	+	74280839	74280842	102,0,51	1	3	0	.	Not	glycated.
chr4	74280878	74280881	P02768	0	+	74280878	74280881	102,0,51	1	3	0	.	Not	glycated.
chr4	74282017	74282020	P02768	0	+	74282017	74282020	102,0,51	1	3	0	.	Not	glycated.
chr4	74282056	74282059	P02768	0	+	74282056	74282059	102,0,51	1	3	0	.	Not	glycated.
chr4	74283269	74283272	P02768	0	+	74283269	74283272	102,0,51	1	3	0	.	Not	glycated.
chr4	74283323	74283326	P02768	0	+	74283323	74283326	102,0,51	1	3	0	.	Not	glycated.
chr4	74283335	74283338	P02768	0	+	74283335	74283338	102,0,51	1	3	0	.	Not	glycated.
chr4	74283843	74283846	P02768	0	+	74283843	74283846	102,0,51	1	3	0	.	Not	glycated.
chr4	74283870	74283873	P02768	0	+	74283870	74283873	102,0,51	1	3	0	.	Not	glycated.
chr4	74283945	74283948	P02768	0	+	74283945	74283948	102,0,51	1	3	0	.	Not	glycated.
chr4	74284002	74284005	P02768	0	+	74284002	74284005	102,0,51	1	3	0	.	Not	glycated.
chr4	74284017	74284020	P02768	0	+	74284017	74284020	102,0,51	1	3	0	.	Not	glycated.
chr4	74285254	74285257	P02768	0	+	74285254	74285257	102,0,51	1	3	0	.	Not	glycated.
chr4	74285263	74285266	P02768	0	+	74285263	74285266	102,0,51	1	3	0	.	Not	glycated.
chr4	74285311	74285314	P02768	0	+	74285311	74285314	102,0,51	1	3	0	.	Not	glycated.
chr4	74285320	74285323	P02768	0	+	74285320	74285323	102,0,51	1	3	0	.	Not	glycated.
chr4	74285332	74285335	P02768	0	+	74285332	74285335	102,0,51	1	3	0	.	Not	glycated.
chr4	74285976	74285979	P02768	0	+	74285976	74285979	102,0,51	1	3	0	.	Not	glycated.
chr4	74607272	74607278	P10145	0	+	74607272	74607278	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr4	74607275	74607281	P10145	0	+	74607275	74607281	102,0,51	1	6	0	.	Cleavage;	by	MMP9.
chr4	74864029	74864035	P42830	0	-	74864029	74864035	102,0,51	1	6	0	.	Cleavage;	by	cathepsin	G.
chr4	89016737	89016740	Q9UNQ0	0	-	89016737	89016740	102,0,51	1	3	0	.	Not	glycosylated.
chr4	89028358	89028361	Q9UNQ0	0	-	89028358	89028361	102,0,51	1	3	0	.	Not	glycosylated.
chr4	96141187	96141193	O95185	0	-	96141187	96141193	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr4	100002514	100002517	P11766	0	-	100002514	100002517	102,0,51	1	3	0	.	Important	for	FDH	activity	and	activation	by	fatty	acids.
chr4	103517293	103517299	P19838	0	+	103517293	103517299	102,0,51	1	6	0	.	Cleavage	(when	cotranslationally	processed).
chr4	103968259	103968262	Q86UD5	0	-	103968259	103968262	102,0,51	1	3	0	.	Important	for	cation	transport.
chr4	103968262	103968265	Q86UD5	0	-	103968262	103968265	102,0,51	1	3	0	.	Important	for	cation	transport.
chr4	108940783	108940786	A0A140VK76	0	+	108940783	108940786	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr4	108940783	108940786	E9PF18	0	+	108940783	108940786	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr4	108940783	108940786	Q16836	0	+	108940783	108940786	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr4	110221766	110221772	Q9BXS0	0	-	110221766	110221772	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr4	111434696	111434699	Q07075	0	+	111434696	111434699	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr4	119216955	119216961	P56730	0	-	119216955	119216961	102,0,51	1	6	0	.	Reactive	bond	homolog.
chr4	141583046	141583049	Q6ZT07	0	-	141583046	141583049	102,0,51	1	3	0	.	Glutamine	finger.
chr4	141583163	141583166	Q6ZT07	0	-	141583163	141583166	102,0,51	1	3	0	.	Arginine	finger.
chr4	144922371	144922374	P06028	0	-	144922371	144922374	102,0,51	1	3	0	.	Not	glycosylated.
chr4	144922374	144922377	P06028	0	-	144922374	144922377	102,0,51	1	3	0	.	Not	glycosylated.
chr4	154625103	154625106	A0A0S2Z4S4	0	+	154625103	154625106	102,0,51	1	3	0	.	Interaction	with	bacterial	lipopeptide.
chr4	154625103	154625106	O60603	0	+	154625103	154625106	102,0,51	1	3	0	.	Interaction	with	bacterial	lipopeptide.
chr4	155486974	155486980	P02675	0	+	155486974	155486980	102,0,51	1	6	0	.	Cleavage;	by	thrombin;	to	release	fibrinopeptide	B.
chr4	155487787	155487793	P02675	0	+	155487787	155487793	102,0,51	1	6	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	155487811	155487817	P02675	0	+	155487811	155487817	102,0,51	1	6	0	.	Cleavage;	by	hementin;	to	prevent	blood	coagulation.
chr4	155487820	155488746	P02675	0	+	155487820	155488746	102,0,51	1	926	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	155508801	155508807	P02671	0	-	155508801	155508807	102,0,51	1	6	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	155508807	155509948	P02671	0	-	155508807	155509948	102,0,51	1	1141	0	.	Cleavage;	by	hementin;	to	prevent	blood	coagulation.
chr4	155510005	155510011	P02671	0	-	155510005	155510011	102,0,51	1	6	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	155510660	155510666	P02671	0	-	155510660	155510666	102,0,51	1	6	0	.	Cleavage;	by	thrombin;	to	release	fibrinopeptide	A.
chr4	155533048	155533173	P02679	0	-	155533048	155533173	102,0,51	1	125	0	.	Cleavage;	by	hementin;	to	prevent	blood	coagulation.
chr4	155533209	155533215	P02679	0	-	155533209	155533215	102,0,51	1	6	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	155533221	155533227	P02679	0	-	155533221	155533227	102,0,51	1	6	0	.	Cleavage;	by	plasmin;	to	break	down	fibrin	clots.
chr4	157689140	157693841	Q9NRA1	0	-	157689140	157693841	102,0,51	1	4701	0	.	Cleavage.
chr4	157693844	157693850	Q9NRA1	0	-	157693844	157693850	102,0,51	1	6	0	.	Cleavage.
chr4	157693862	157693868	Q9NRA1	0	-	157693862	157693868	102,0,51	1	6	0	.	Cleavage.
chr4	158073883	158073886	P48167	0	+	158073883	158073886	102,0,51	1	3	0	.	Important	for	obstruction	of	the	ion	pore	in	the	closed	conformation.
chr4	164394100	164394103	Q9H0I9	0	-	164394100	164394103	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr4	169923249	169923252	Q8N4T8	0	-	169923249	169923252	102,0,51	1	3	0	.	Important	for	interaction	with	acyl	carrier	protein	(ACP).	Pubmed:25203508
chr4	170613378	170613381	P51790	0	+	170613378	170613381	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	outer	aqueous	phase	to	the	interior	of	the	protein;	involved	in	linking	H(+)	and	Cl(-)	transport.
chr4	170616840	170616843	P51790	0	+	170616840	170616843	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	protein	to	the	inner	aqueous	phase.
chr4	175598273	175598276	O75311	0	-	175598273	175598276	102,0,51	1	3	0	.	Important	for	obstruction	of	the	ion	pore	in	the	closed	conformation.	Pubmed:26416729
chr4	178231110	178231113	Q8TAT5	0	+	178231110	178231113	102,0,51	1	3	0	.	Important	for	monofunctional	glycosylase	activity.
chr4	178243696	178243699	Q8TAT5	0	+	178243696	178243699	102,0,51	1	3	0	.	Required	for	glycosylase	and	lyase	activities.
chr5	1266631	1266634	O14746	0	-	1266631	1266634	102,0,51	1	3	0	.	Required	for	nucleotide	incorporation	and	primer	extension	rate.
chr5	1294493	1294496	O14746	0	-	1294493	1294496	102,0,51	1	3	0	.	Required	for	optimal	binding	of	telomeric	ssDNA	and	incorporation	of	nucleotides	at	the	second	position	of	the	template.
chr5	1441576	1441579	Q01959	0	-	1441576	1441579	102,0,51	1	3	0	.	Contributes	to	high-affinity	binding	to	cocaine.
chr5	1445812	1445815	Q01959	0	-	1445812	1445815	102,0,51	1	3	0	.	Contributes	to	high-affinity	binding	to	cocaine.
chr5	31410874	31410877	Q9NRR4	0	-	31410874	31410877	102,0,51	1	3	0	.	Important	for	activity.
chr5	32091027	32091033	O15018	0	+	32091027	32091033	102,0,51	1	6	0	.	Cleavage;	by	caspases.
chr5	32591743	32591749	P53999	0	+	32591743	32591749	102,0,51	1	6	0	.	Cleavage.
chr5	39315948	39315954	P02748	0	-	39315948	39315954	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr5	42718641	42718644	P10912	0	+	42718641	42718644	102,0,51	1	3	0	.	Required	for	endocytosis	and	down-regulation.
chr5	58271627	58271630	Q08499	0	-	58271627	58271630	102,0,51	1	3	0	.	Binds	AMP,	but	not	cAMP.
chr5	64825023	64838631	Q9BS16	0	-	64825023	64838631	102,0,51	1	13608	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-CENPK	oncogene.
chr5	75914414	75914420	O00254	0	-	75914414	75914420	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr5	76028170	76028176	P25116	0	+	76028170	76028176	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chr5	88018543	88018549	Q06413	0	-	88018543	88018549	102,0,51	1	6	0	.	Cleavage.
chr5	96127769	96127772	Q9NZ08	0	-	96127769	96127772	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr5	96232199	96232202	Q6P179	0	+	96232199	96232202	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr5	96315281	96315287	Q9UIQ6	0	+	96315281	96315287	102,0,51	1	6	0	.	Cleavage;	to	produce	pregnancy	serum	form.
chr5	96333840	96333843	Q9UIQ6	0	+	96333840	96333843	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr5	98115648	98115654	Q6NW40	0	+	98115648	98115654	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr5	115335590	115335593	Q6Q4G3	0	+	115335590	115335593	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr5	125912835	125912838	P49419	0	-	125912835	125912838	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr5	131877742	131877745	P05113	0	-	131877742	131877745	102,0,51	1	3	0	.	Not	glycosylated.
chr5	132240093	132262815	Q9UHB7	0	-	132240093	132262815	102,0,51	1	22722	0	.	Breakpoint	for	insertion	to	form	KMT2A/MLL1-AFF4	fusion	protein.
chr5	133326743	133326746	P21796	0	-	133326743	133326746	102,0,51	1	3	0	.	Involved	in	hexokinase	binding.
chr5	137803143	137803146	P18146	0	+	137803143	137803146	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25258363
chr5	137803176	137803179	P18146	0	+	137803176	137803179	102,0,51	1	3	0	.	Interaction	with	DNA.
chr5	137803188	137803191	P18146	0	+	137803188	137803191	102,0,51	1	3	0	.	Interaction	with	DNA.
chr5	137803206	137803209	P18146	0	+	137803206	137803209	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25258363
chr5	137803260	137803263	P18146	0	+	137803260	137803263	102,0,51	1	3	0	.	Interaction	with	DNA.
chr5	137803272	137803275	P18146	0	+	137803272	137803275	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25258363
chr5	137803344	137803347	P18146	0	+	137803344	137803347	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25999311
chr5	137803356	137803359	P18146	0	+	137803356	137803359	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25258363
chr5	137803374	137803377	P18146	0	+	137803374	137803377	102,0,51	1	3	0	.	Interaction	with	DNA.	Pubmed:25999311,	Pubmed:25258363
chr5	139715587	139715590	Q99075	0	-	139715587	139715590	102,0,51	1	3	0	.	Plays	a	critical	role	in	diphtheria	toxin	binding	and	toxin	sensitivity.
chr5	147207646	147207652	P00995	0	-	147207646	147207652	102,0,51	1	6	0	.	Necessary	for	sperm	binding.
chr5	147207652	147207658	P00995	0	-	147207652	147207658	102,0,51	1	6	0	.	Reactive	bond	for	trypsin.
chr5	147449939	147449945	Q9NQ38	0	+	147449939	147449945	102,0,51	1	6	0	.	Reactive	bond.
chr5	147553859	147553865	Q6IE38	0	+	147553859	147553865	102,0,51	1	6	0	.	Reactive	bond.
chr5	147593514	147593520	Q6UWN8	0	+	147593514	147593520	102,0,51	1	6	0	.	Reactive	bond.
chr5	147661720	147661726	Q1W4C9	0	+	147661720	147661726	102,0,51	1	6	0	.	Reactive	bond.
chr5	147693713	147693719	P58062	0	+	147693713	147693719	102,0,51	1	6	0	.	Reactive	bond.
chr5	147718094	147718100	Q5DT21	0	+	147718094	147718100	102,0,51	1	6	0	.	Reactive	bond.
chr5	149505137	149506085	P09619	0	-	149505137	149506085	102,0,51	1	948	0	.	Breakpoint	for	translocation	to	form	the	CEP85L-PDGFRB	fusion	protein.
chr5	149506172	149506178	P09619	0	-	149506172	149506178	102,0,51	1	6	0	.	Breakpoint	for	insertion	to	form	PDE4DIP-PDGFRB	fusion	protein.
chr5	149506172	149506178	P09619	0	-	149506172	149506178	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	TRIP11-PDGFRB.
chr5	149782873	149784246	P04233	0	-	149782873	149784246	102,0,51	1	1373	0	.	Breakpoint	for	translocation	to	form	a	CD74-ROS1	fusion	protein.
chr5	150175056	150175062	Q9BZL3	0	+	150175056	150175062	102,0,51	1	6	0	.	Cleavage.
chr5	151230995	151230998	P23415	0	-	151230995	151230998	102,0,51	1	3	0	.	Important	for	obstruction	of	the	ion	pore	in	the	closed	conformation.	Pubmed:25730860
chr5	154291401	154291404	Q8TEQ6	0	-	154291401	154291404	102,0,51	1	3	0	.	Interaction	with	U4	snRNA	and	with	the	7-methylguanosine	cap	of	RNA	molecules.	Pubmed:27834343,	Pubmed:27881600,	Pubmed:27881601
chr5	154292473	154292476	Q8TEQ6	0	-	154292473	154292476	102,0,51	1	3	0	.	Interaction	with	U4	snRNA	and	with	the	7-methylguanosine	cap	of	RNA	molecules.	Pubmed:27834343,	Pubmed:27881601
chr5	154292530	154292533	Q8TEQ6	0	-	154292530	154292533	102,0,51	1	3	0	.	Interaction	with	U4	snRNA	and	with	the	7-methylguanosine	cap	of	RNA	molecules.	Pubmed:27834343,	Pubmed:27881601
chr5	154296675	154296678	Q8TEQ6	0	-	154296675	154296678	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27881601
chr5	154297495	154297498	Q8TEQ6	0	-	154297495	154297498	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27881601
chr5	154300942	154300945	Q8TEQ6	0	-	154300942	154300945	102,0,51	1	3	0	.	Interaction	with	U4	snRNA	and	with	the	7-methylguanosine	cap	of	RNA	molecules.	Pubmed:27834343,	Pubmed:27881601
chr5	154300954	154300957	Q8TEQ6	0	-	154300954	154300957	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27881601
chr5	154305436	154305439	Q8TEQ6	0	-	154305436	154305439	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27881601
chr5	154305448	154305451	Q8TEQ6	0	-	154305448	154305451	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881601
chr5	154305571	154305574	Q8TEQ6	0	-	154305571	154305574	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881600,	Pubmed:27881601
chr5	154306947	154306950	Q8TEQ6	0	-	154306947	154306950	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881600,	Pubmed:27881601
chr5	154307019	154307022	Q8TEQ6	0	-	154307019	154307022	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881601
chr5	154308148	154308151	Q8TEQ6	0	-	154308148	154308151	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881601
chr5	154317594	154317597	Q8TEQ6	0	-	154317594	154317597	102,0,51	1	3	0	.	Interaction	with	U4	snRNA.	Pubmed:27834343,	Pubmed:27881600,	Pubmed:27881601
chr5	158500441	158500444	Q9UH73	0	-	158500441	158500444	102,0,51	1	3	0	.	Interaction	with	DNA.
chr5	158500468	158500471	Q9UH73	0	-	158500468	158500471	102,0,51	1	3	0	.	Interaction	with	DNA.
chr5	167517644	167517650	Q9NT68	0	+	167517644	167517650	102,0,51	1	6	0	.	Cleavage.
chr5	170818332	170818335	P06748	0	+	170818332	170818335	102,0,51	1	3	0	.	Interaction	between	pentamers.
chr5	170818407	170818410	P06748	0	+	170818407	170818410	102,0,51	1	3	0	.	Interaction	between	pentamers.
chr5	170819980	170827160	P06748	0	+	170819980	170827160	102,0,51	1	7180	0	.	Breakpoint	for	translocation	to	form	NPM1-MLF1.	Pubmed:8570204
chr5	173372103	173372106	Q17RY0	0	+	173372103	173372106	102,0,51	1	3	0	.	RNA-binding.
chr5	173378841	173378844	Q17RY0	0	+	173378841	173378844	102,0,51	1	3	0	.	Important	for	the	positionning	of	RRM1	relative	to	RRM2.	Pubmed:24990967
chr5	175110527	175110530	P25021	0	+	175110527	175110530	102,0,51	1	3	0	.	Essential	for	histamine	binding.
chr5	175110791	175110794	P25021	0	+	175110791	175110794	102,0,51	1	3	0	.	Essential	for	tiotidine	binding	and	implicated	in	H2	selectivity.
chr5	175110803	175110806	P25021	0	+	175110803	175110806	102,0,51	1	3	0	.	Implicated	in	histamine	binding.
chr5	176301099	176301105	Q6ZN44	0	+	176301099	176301105	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr5	179305308	179305311	Q66K14	0	-	179305308	179305311	102,0,51	1	3	0	.	Glutamine	finger.
chr5	179305425	179305428	Q66K14	0	-	179305425	179305428	102,0,51	1	3	0	.	Arginine	finger.
chr6	2833946	2833952	P30740	0	-	2833946	2833952	102,0,51	1	6	0	.	Reactive	bond	2.
chr6	2833949	2833955	P30740	0	-	2833949	2833955	102,0,51	1	6	0	.	Reactive	bond	1.
chr6	2890504	2890510	P50453	0	-	2890504	2890510	102,0,51	1	6	0	.	Reactive	bond.
chr6	2948636	2948642	P35237	0	-	2948636	2948642	102,0,51	1	6	0	.	Reactive	bond.
chr6	3104512	3104518	Q13546	0	+	3104512	3104518	102,0,51	1	6	0	.	Cleavage;	by	caspase-8.
chr6	3129317	3129320	Q86WA6	0	+	3129317	3129320	102,0,51	1	3	0	.	Binding	of	alpha-amino	group	of	substrate.
chr6	4119464	4119467	O75521	0	-	4119464	4119467	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr6	11104490	11104496	P60508	0	-	11104490	11104496	102,0,51	1	6	0	.	Cleavage.
chr6	12292725	12292731	P05305	0	+	12292725	12292731	102,0,51	1	6	0	.	Cleavage;	by	KEL.	Pubmed:10438732
chr6	24505099	24505102	P51649	0	+	24505099	24505102	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr6	26108153	26108156	P22492	0	-	26108153	26108156	102,0,51	1	3	0	.	Important	for	nucleosome	binding	properties.
chr6	28872429	28875005	P14373	0	-	28872429	28875005	102,0,51	1	2576	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr6	28872431	28875007	P14373	0	-	28872431	28875007	102,0,51	1	2576	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr6	28872440	28875016	P14373	0	-	28872440	28875016	102,0,51	1	2576	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr6	28873254	28875830	P14373	0	-	28873254	28875830	102,0,51	1	2576	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr6	28873307	28875883	P14373	0	-	28873307	28875883	102,0,51	1	2576	0	.	Breakpoint	for	translocation	to	form	the	TRIM27/RET	oncogene.
chr6	29523609	29523615	O15205	0	-	29523609	29523615	102,0,51	1	6	0	.	Activation	by	thioester	intermediate	formation	with	UBA6.
chr6	29523659	29523665	O15205	0	-	29523659	29523665	102,0,51	1	6	0	.	Activation	by	thioester	intermediate	formation	with	UBA6.
chr6	29637672	29637675	Q9NU63	0	-	29637672	29637675	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29640601	29640604	Q9NU63	0	-	29640601	29640604	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29640861	29640864	Q9NU63	0	-	29640861	29640864	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29640988	29640991	Q9NU63	0	-	29640988	29640991	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29641033	29641036	Q9NU63	0	-	29641033	29641036	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29641080	29641083	Q9NU63	0	-	29641080	29641083	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	29641577	29641580	Q9NU63	0	-	29641577	29641580	102,0,51	1	3	0	.	Crucial	for	5-methylcytosine	recognition.
chr6	30584910	30584913	Q5SQI0	0	+	30584910	30584913	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30585258	30585261	Q5SQI0	0	+	30585258	30585261	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30585652	30585655	Q5SQI0	0	+	30585652	30585655	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30587638	30587641	Q5SQI0	0	+	30587638	30587641	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30595415	30595418	Q5SQI0	0	+	30595415	30595418	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30640051	30640054	Q5SQI0	0	+	30640051	30640054	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30673870	30673873	Q5SQI0	0	+	30673870	30673873	102,0,51	1	3	0	.	Crucial	for	catalytic	activity.	Pubmed:23071318
chr6	30955455	30955779	Q5SSG8	0	+	30955455	30955779	102,0,51	1	324	0	.	Cleavage.
chr6	31525760	31525766	P01375	0	+	31525760	31525766	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31525772	31525778	P01375	0	+	31525772	31525778	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31525802	31525808	P01375	0	+	31525802	31525808	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31525808	31525814	P01375	0	+	31525808	31525814	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31526489	31526495	P01375	0	+	31526489	31526495	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31531026	31531032	P01375	0	+	31531026	31531032	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31531038	31531044	P01375	0	+	31531038	31531044	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31531068	31531074	P01375	0	+	31531068	31531074	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31531074	31531080	P01375	0	+	31531074	31531080	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31531755	31531761	P01375	0	+	31531755	31531761	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31533846	31533852	P01375	0	+	31533846	31533852	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31533858	31533864	P01375	0	+	31533858	31533864	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31533888	31533894	P01375	0	+	31533888	31533894	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31533894	31533900	P01375	0	+	31533894	31533900	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31534365	31534371	P01375	0	+	31534365	31534371	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31534377	31534383	P01375	0	+	31534377	31534383	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31534407	31534413	P01375	0	+	31534407	31534413	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31534413	31534419	P01375	0	+	31534413	31534419	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31534577	31534583	P01375	0	+	31534577	31534583	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31535094	31535100	P01375	0	+	31535094	31535100	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31543620	31543626	P01375	0	+	31543620	31543626	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31543632	31543638	P01375	0	+	31543632	31543638	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31543662	31543668	P01375	0	+	31543662	31543668	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31543668	31543674	P01375	0	+	31543668	31543674	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31544349	31544355	P01375	0	+	31544349	31544355	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31583068	31583074	P01375	0	+	31583068	31583074	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31583080	31583086	P01375	0	+	31583080	31583086	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31583110	31583116	P01375	0	+	31583110	31583116	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31583116	31583122	P01375	0	+	31583116	31583122	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31583797	31583803	P01375	0	+	31583797	31583803	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31595609	31595615	P46379	0	-	31595609	31595615	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr6	31598428	31598434	P46379	0	-	31598428	31598434	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr6	31598949	31598955	P46379	0	-	31598949	31598955	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr6	31608203	31608209	P46379	0	-	31608203	31608209	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr6	31619925	31619931	P01375	0	+	31619925	31619931	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31619937	31619943	P01375	0	+	31619937	31619943	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31619967	31619973	P01375	0	+	31619967	31619973	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31619973	31619979	P01375	0	+	31619973	31619979	102,0,51	1	6	0	.	Cleavage;	by	SPPL2A	or	SPPL2B.
chr6	31620654	31620660	P01375	0	+	31620654	31620660	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr6	31820782	31820785	Q53GD3	0	-	31820782	31820785	102,0,51	1	3	0	.	Breakpoint	for	translocation	with	NEU1.
chr6	31826145	31826148	Q53GD3	0	-	31826145	31826148	102,0,51	1	3	0	.	Breakpoint	for	translocation	with	NEU1.
chr6	31828978	31828981	Q53GD3	0	-	31828978	31828981	102,0,51	1	3	0	.	Breakpoint	for	translocation	with	NEU1.
chr6	31838601	31838604	Q53GD3	0	-	31838601	31838604	102,0,51	1	3	0	.	Breakpoint	for	translocation	with	NEU1.
chr6	31963873	31963876	P0C0L4	0	+	31963873	31963876	102,0,51	1	3	0	.	Responsible	for	effective	binding	to	form	amide	bonds	with	immune	aggregates	or	protein	antigens.
chr6	32034188	32034194	Q99941	0	-	32034188	32034194	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr6	32035008	32035011	Q99941	0	-	32035008	32035011	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32035017	32035020	Q99941	0	-	32035017	32035020	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32061509	32061515	Q99941	0	-	32061509	32061515	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr6	32062329	32062332	Q99941	0	-	32062329	32062332	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32062338	32062341	Q99941	0	-	32062338	32062341	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32085736	32085742	Q99941	0	-	32085736	32085742	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr6	32086556	32086559	Q99941	0	-	32086556	32086559	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32086565	32086568	Q99941	0	-	32086565	32086568	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32162163	32162169	Q99941	0	-	32162163	32162169	102,0,51	1	6	0	.	Cleavage;	by	PS1.
chr6	32162983	32162986	Q99941	0	-	32162983	32162986	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32162992	32162995	Q99941	0	-	32162992	32162995	102,0,51	1	3	0	.	Important	for	cleavage	by	PS2.
chr6	32733112	32733118	P28062	0	-	32733112	32733118	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32739489	32739495	P28062	0	-	32739489	32739495	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32744381	32746235	P28065	0	+	32744381	32746235	102,0,51	1	1854	0	.	Cleavage;	by	autolysis.
chr6	32750758	32752612	P28065	0	+	32750758	32752612	102,0,51	1	1854	0	.	Cleavage;	by	autolysis.
chr6	32800040	32801895	P28065	0	+	32800040	32801895	102,0,51	1	1855	0	.	Cleavage;	by	autolysis.
chr6	32810794	32810800	P28062	0	-	32810794	32810800	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32822063	32823917	P28065	0	+	32822063	32823917	102,0,51	1	1854	0	.	Cleavage;	by	autolysis.
chr6	32844270	32844276	P28062	0	-	32844270	32844276	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32850066	32850072	P28062	0	-	32850066	32850072	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32901511	32901517	P28062	0	-	32901511	32901517	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32964554	32964560	P28062	0	-	32964554	32964560	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	32975823	32977677	P28065	0	+	32975823	32977677	102,0,51	1	1854	0	.	Cleavage;	by	autolysis.
chr6	33193533	33193536	O15533	0	-	33193533	33193536	102,0,51	1	3	0	.	May	be	involved	in	interaction	with	TAP.
chr6	33200758	33200761	O15533	0	-	33200758	33200761	102,0,51	1	3	0	.	May	be	involved	in	interaction	with	TAP.
chr6	33249854	33249857	O15533	0	-	33249854	33249857	102,0,51	1	3	0	.	May	be	involved	in	interaction	with	TAP.
chr6	43109760	43109766	Q13308	0	+	43109760	43109766	102,0,51	1	6	0	.	Cleavage;	by	MMP14.
chr6	44387332	44387335	Q99459	0	+	44387332	44387335	102,0,51	1	3	0	.	Breakpoint	for	translocation.
chr6	46826666	46826672	Q8IZF2	0	-	46826666	46826672	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr6	46849324	46849330	Q8IZF2	0	-	46849324	46849330	102,0,51	1	6	0	.	Cleavage.
chr6	46867766	46867772	Q8IZF2	0	-	46867766	46867772	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr6	54173492	54173498	Q9UJW2	0	+	54173492	54173498	102,0,51	1	6	0	.	Cleavage;	by	furin.
chr6	55039514	55039517	O43614	0	+	55039514	55039517	102,0,51	1	3	0	.	Important	for	responses	to	orexin.	Pubmed:26950369
chr6	71571407	71571410	Q9NPZ5	0	-	71571407	71571410	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr6	71603912	71603915	Q9NPZ5	0	-	71603912	71603915	102,0,51	1	3	0	.	Interaction	with	galactose	moiety	of	substrate	glycoprotein.
chr6	78172055	78172058	P28222	0	-	78172055	78172058	102,0,51	1	3	0	.	Important	for	species-specific	agonist	sensitivity.
chr6	83963354	83963357	P48163	0	-	83963354	83963357	102,0,51	1	3	0	.	Important	for	activity.
chr6	86176789	86176792	P21589	0	+	86176789	86176792	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr6	86176798	86176801	P21589	0	+	86176798	86176801	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr6	109764000	109764003	O60906	0	+	109764000	109764003	102,0,51	1	3	0	.	Important	for	substrate	recognition.
chr6	111210060	111210066	P17707	0	+	111210060	111210066	102,0,51	1	6	0	.	Cleavage	(non-hydrolytic);	by	autolysis.	Pubmed:2687270,	Pubmed:2460457
chr6	117642555	117645498	P08922	0	-	117642555	117645498	102,0,51	1	2943	0	.	Breakpoint	for	translocation	to	form	GOPC-ROS1	fusion	protein.
chr6	117645576	117647390	P08922	0	-	117645576	117647390	102,0,51	1	1814	0	.	Breakpoint	for	translocation	to	form	SLC34A2-ROS1	and	CD74-ROS1	fusion	proteins.
chr6	117884545	117888020	Q9HD26	0	-	117884545	117888020	102,0,51	1	3475	0	.	Breakpoint	for	translocation	to	form	GOPC-ROS1	fusion	protein.
chr6	118790463	118791702	Q5SZL2	0	-	118790463	118791702	102,0,51	1	1239	0	.	Breakpoint	for	translocation	to	form	the	CEP85L-PDGFRB	fusion	protein.
chr6	123039005	123039008	Q5T0Z6	0	+	123039005	123039008	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	123039005	123039008	Q9C010	0	+	123039005	123039008	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	123039014	123039017	Q5T0Z6	0	+	123039014	123039017	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	123039014	123039017	Q9C010	0	+	123039014	123039017	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	123039017	123039020	Q5T0Z6	0	+	123039017	123039020	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	123039017	123039020	Q9C010	0	+	123039017	123039020	102,0,51	1	3	0	.	Important	for	inhibition.
chr6	124676490	124979334	Q5VXU1	0	+	124676490	124979334	102,0,51	1	302844	0	.	Breakpoint	for	interstitial	deletion	to	form	SUSP1-NKAIN2.
chr6	128388888	128388894	Q15262	0	-	128388888	128388894	102,0,51	1	6	0	.	Cleavage.
chr6	128393024	128393030	Q15262	0	-	128393024	128393030	102,0,51	1	6	0	.	Cleavage.
chr6	132168978	132168984	P22413	0	+	132168978	132168984	102,0,51	1	6	0	.	Cleavage.
chr6	132211615	132211618	P22413	0	+	132211615	132211618	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr6	135260530	135260533	Q9H2A2	0	-	135260530	135260533	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr6	137476096	137476099	Q969J5	0	-	137476096	137476099	102,0,51	1	3	0	.	Critical	for	IL22-binding.
chr6	137476252	137476255	Q969J5	0	-	137476252	137476255	102,0,51	1	3	0	.	Critical	for	IL22-binding.
chr6	138199896	138199902	P21580	0	+	138199896	138199902	102,0,51	1	6	0	.	Cleavage;	by	MALT1.
chr6	139095036	139097218	Q8IWP9	0	+	139095036	139097218	102,0,51	1	2182	0	.	Breakpoint	for	translocation	to	form	NUP98-CCDC28A.
chr6	142715069	142715075	Q86SQ4	0	+	142715069	142715075	102,0,51	1	6	0	.	Cleavage;	by	furin	like-convertase.	Pubmed:15189448
chr6	142732524	142732530	Q86SQ4	0	+	142732524	142732530	102,0,51	1	6	0	.	Cleavage.	Pubmed:15189448
chr6	143823572	143823575	Q9BTY2	0	-	143823572	143823575	102,0,51	1	3	0	.	May	be	important	for	catalysis.
chr6	145948560	145948563	O95278	0	-	145948560	145948563	102,0,51	1	3	0	.	Required	for	homodimerization.
chr6	160232791	160232794	Q8NA58	0	+	160232791	160232794	102,0,51	1	3	0	.	Interaction	with	poly(A).
chr6	160564643	160564646	O15245	0	+	160564643	160564646	102,0,51	1	3	0	.	Involved	in	affinity	and	selectivity	of	cations	as	well	as	in	translocation.
chr6	160663360	160663363	O15244	0	-	160663360	160663363	102,0,51	1	3	0	.	Involved	in	recognition	of	organic	cations	and	participates	in	structural	changes	that	occur	during	translocation	of	organic	cations.
chr6	161128777	161128783	P00747	0	+	161128777	161128783	102,0,51	1	6	0	.	Cleavage;	by	stromelysin-1.
chr6	161152221	161152227	P00747	0	+	161152221	161152227	102,0,51	1	6	0	.	Cleavage;	by	stromelysin-19.
chr6	161157974	161157980	P00747	0	+	161157974	161157980	102,0,51	1	6	0	.	Cleavage;	by	plasminogen	activator.
chr6	163899814	163899817	Q96PU8	0	+	163899814	163899817	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	163899883	163899886	Q96PU8	0	+	163899883	163899886	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	163899895	163899898	Q96PU8	0	+	163899895	163899898	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	163899913	163899916	Q96PU8	0	+	163899913	163899916	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	163983034	163983037	Q96PU8	0	+	163983034	163983037	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	163983043	163983046	Q96PU8	0	+	163983043	163983046	102,0,51	1	3	0	.	Involved	in	RNA	binding.	Pubmed:23630077
chr6	167424378	167426998	O95684	0	+	167424378	167426998	102,0,51	1	2620	0	.	Breakpoint	for	translocation	to	form	FGFR1OP-FGFR1	or	FGFR1-FGFR1OP	fusion	proteins.
chr6	168227887	168227890	P55196	0	+	168227887	168227890	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-AFDN.
chr7	2559750	2559756	Q8NES3	0	+	2559750	2559756	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr7	6094213	6094216	Q9BQI3	0	-	6094213	6094216	102,0,51	1	3	0	.	Heme-binding.
chr7	16348147	16348150	A4D126	0	-	16348147	16348150	102,0,51	1	3	0	.	Positions	substrate	for	the	nucleophilic	attack.
chr7	16415785	16415788	A4D126	0	-	16415785	16415788	102,0,51	1	3	0	.	Positions	substrate	for	the	nucleophilic	attack.
chr7	16460749	16460752	A4D126	0	-	16460749	16460752	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr7	16460770	16460773	A4D126	0	-	16460770	16460773	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr7	24324946	24324952	P01303	0	+	24324946	24324952	102,0,51	1	6	0	.	Cleavage;	by	FAP.	Pubmed:21314817
chr7	27204584	27204590	P31269	0	-	27204584	27204590	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	MSI2/HOXA9	fusion	protein.
chr7	27880481	27880487	Q86VZ6	0	-	27880481	27880487	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	JAZF1-SUZ12	oncogene.
chr7	30951689	30951692	P29972	0	+	30951689	30951692	102,0,51	1	3	0	.	Substrate	discrimination.
chr7	30961833	30961836	P29972	0	+	30961833	30961836	102,0,51	1	3	0	.	Substrate	discrimination.
chr7	30962193	30962196	P29972	0	+	30962193	30962196	102,0,51	1	3	0	.	Hg(2+)-sensitive	residue.
chr7	30962211	30962214	P29972	0	+	30962211	30962214	102,0,51	1	3	0	.	Substrate	discrimination.
chr7	44099679	44099685	Q9UJU6	0	+	44099679	44099685	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr7	44104467	44104470	P15259	0	-	44104467	44104470	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr7	44113396	44113399	Q9NP87	0	-	44113396	44113399	102,0,51	1	3	0	.	Responsible	for	the	low	discrimination	between	dNTP	and	rNTP.
chr7	50450290	50450293	Q13422	0	+	50450290	50450293	102,0,51	1	3	0	.	Required	for	both	pericentromeric	heterochromatin	localization	and	complete	DNA	binding.
chr7	50450299	50450302	Q13422	0	+	50450299	50450302	102,0,51	1	3	0	.	Required	for	both	pericentromeric	heterochromatin	localization	and	complete	DNA	binding.
chr7	50450377	50450380	Q13422	0	+	50450377	50450380	102,0,51	1	3	0	.	Required	for	both	pericentromeric	heterochromatin	localization	and	DNA	binding.
chr7	55268979	55268982	P00533	0	+	55268979	55268982	102,0,51	1	3	0	.	Important	for	interaction	with	PIK3C2B.
chr7	64451988	64451994	Q14264	0	-	64451988	64451994	102,0,51	1	6	0	.	Cleavage.
chr7	65338505	65338508	Q8N0U8	0	+	65338505	65338508	102,0,51	1	3	0	.	Important	for	the	reduction	of	the	redox-active	cysteines.
chr7	65338529	65338532	Q8N0U8	0	+	65338529	65338532	102,0,51	1	3	0	.	Important	for	the	reduction	of	the	redox-active	cysteines.
chr7	65705886	65705889	O60507	0	+	65705886	65705889	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr7	65751507	65751510	O60507	0	+	65751507	65751510	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr7	75959241	75959244	P61981	0	-	75959241	75959244	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr7	75959466	75959469	P61981	0	-	75959466	75959469	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr7	80303430	80303433	P16671	0	+	80303430	80303433	102,0,51	1	3	0	.	Critical	for	TLR4-TLR6	dimerization	and	signaling.	Pubmed:20037584
chr7	91503057	91503060	Q99551	0	-	91503057	91503060	102,0,51	1	3	0	.	Interaction	with	DNA.
chr7	91503243	91503246	Q99551	0	-	91503243	91503246	102,0,51	1	3	0	.	Interaction	with	DNA.
chr7	91503378	91503381	Q99551	0	-	91503378	91503381	102,0,51	1	3	0	.	Interaction	with	DNA.
chr7	91503501	91503504	Q99551	0	-	91503501	91503504	102,0,51	1	3	0	.	Interaction	with	DNA.
chr7	91503621	91503624	Q99551	0	-	91503621	91503624	102,0,51	1	3	0	.	Interaction	with	DNA.
chr7	92098741	92098747	Q9UQF0	0	-	92098741	92098747	102,0,51	1	6	0	.	Cleavage.
chr7	93516696	93516702	P48307	0	-	93516696	93516702	102,0,51	1	6	0	.	Reactive	bond.
chr7	93518482	93518488	P48307	0	-	93518482	93518488	102,0,51	1	6	0	.	Reactive	bond.
chr7	93519578	93519584	P48307	0	-	93519578	93519584	102,0,51	1	6	0	.	Reactive	bond.
chr7	95157402	95157405	Q9Y574	0	+	95157402	95157405	102,0,51	1	3	0	.	Essential	for	interaction	with	HIF1AN.
chr7	95215003	95215006	Q16654	0	-	95215003	95215006	102,0,51	1	3	0	.	Interaction	with	the	other	subunit	in	the	homodimer.
chr7	95222117	95222120	Q16654	0	-	95222117	95222120	102,0,51	1	3	0	.	Interaction	with	the	other	subunit	in	the	homodimer.
chr7	95222129	95222132	Q16654	0	-	95222129	95222132	102,0,51	1	3	0	.	Interaction	with	the	other	subunit	in	the	homodimer.
chr7	97363085	97363091	P20366	0	+	97363085	97363091	102,0,51	1	6	0	.	Cleavage;	by	FAP.	Pubmed:21314817
chr7	97484706	97484709	P08243	0	-	97484706	97484709	102,0,51	1	3	0	.	Important	for	beta-aspartyl-AMP	intermediate	formation.
chr7	100204171	100204177	Q15113	0	+	100204171	100204177	102,0,51	1	6	0	.	Cleavage.	Pubmed:10625689
chr7	100204174	100204180	Q15113	0	+	100204174	100204180	102,0,51	1	6	0	.	Cleavage.	Pubmed:10625689
chr7	100204189	100204195	Q15113	0	+	100204189	100204195	102,0,51	1	6	0	.	Cleavage.	Pubmed:10625689
chr7	100204207	100204213	Q15113	0	+	100204207	100204213	102,0,51	1	6	0	.	Cleavage.	Pubmed:10625689
chr7	100204219	100204225	Q15113	0	+	100204219	100204225	102,0,51	1	6	0	.	Cleavage.	Pubmed:10625689
chr7	100655580	100655586	Q9UKN1	0	+	100655580	100655586	102,0,51	1	6	0	.	Cleavage.
chr7	100693768	100693774	Q685J3	0	+	100693768	100693774	102,0,51	1	6	0	.	Cleavage.
chr7	100780298	100780304	P05121	0	+	100780298	100780304	102,0,51	1	6	0	.	Reactive	bond.
chr7	100880658	100880661	P56746	0	-	100880658	100880661	102,0,51	1	3	0	.	Important	for	the	formation	of	tight-junction	strand-like	structures.
chr7	100880670	100880673	P56746	0	-	100880670	100880673	102,0,51	1	3	0	.	Important	for	Na(+)-selective	paracellular	ion	transport.
chr7	100880697	100880700	P56746	0	-	100880697	100880700	102,0,51	1	3	0	.	Important	for	Na(+)-selective	paracellular	ion	transport.
chr7	104782752	104782758	P78362	0	-	104782752	104782758	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr7	104807884	104807890	P78362	0	-	104807884	104807890	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr7	107558473	107558476	P09622	0	+	107558473	107558476	102,0,51	1	3	0	.	Important	for	interaction	with	PDHX	and	activity	of	multienzyme	pyruvate	dehydrogenase	complex.	Pubmed:20385101
chr7	107559496	107559499	P09622	0	+	107559496	107559499	102,0,51	1	3	0	.	Important	for	interaction	with	PDHX	and	activity	of	multienzyme	pyruvate	dehydrogenase	complex.	Pubmed:20385101
chr7	116340056	116340062	P08581	0	+	116340056	116340062	102,0,51	1	6	0	.	Cleavage.
chr7	116412021	116412024	P08581	0	+	116412021	116412024	102,0,51	1	3	0	.	Required	for	ligand-induced	CBL-mediated	ubiquitination.	Pubmed:12244174
chr7	116412039	116414936	P08581	0	+	116412039	116414936	102,0,51	1	2897	0	.	Breakpoint	for	translocation	to	form	TPR-MET	oncogene.
chr7	121698991	121698994	P23471	0	+	121698991	121698994	102,0,51	1	3	0	.	Ancestral	active	site.
chr7	124493165	124493168	Q9NUX5	0	-	124493165	124493168	102,0,51	1	3	0	.	DNA	binding.
chr7	134136337	134136340	A0A024R7A8	0	-	134136337	134136340	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr7	134136337	134136340	E9PCX2	0	-	134136337	134136340	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr7	134136337	134136340	P15121	0	-	134136337	134136340	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr7	134215559	134215562	O60218	0	+	134215559	134215562	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr7	134346343	134346346	P07738	0	+	134346343	134346346	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134346394	134346397	P07738	0	+	134346394	134346397	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134346685	134346688	P07738	0	+	134346685	134346688	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134346799	134346802	P07738	0	+	134346799	134346802	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134346820	134346823	P07738	0	+	134346820	134346823	102,0,51	1	3	0	.	Transition	state	stabilizer.	Pubmed:17052986
chr7	134363738	134363741	P07738	0	+	134363738	134363741	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134363741	134363744	P07738	0	+	134363741	134363744	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134363759	134363762	P07738	0	+	134363759	134363762	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134363774	134363777	P07738	0	+	134363774	134363777	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	134363777	134363780	P07738	0	+	134363777	134363780	102,0,51	1	3	0	.	Not	glycated.	Pubmed:9832630
chr7	138239606	138239612	O15164	0	+	138239606	138239612	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	TRIM24-RET	oncogene.
chr7	138264170	138264173	O15164	0	+	138264170	138264173	102,0,51	1	3	0	.	Interaction	with	histone	H3	that	is	not	methylated	at	'Lys-4'	(H3K4me0).
chr7	138537012	138545887	Q9HCM3	0	-	138537012	138545887	102,0,51	1	8875	0	.	Breakpoint	for	translocation	to	form	KIAA1549-BRAF	fusion	protein.
chr7	138546199	138552723	Q9HCM3	0	-	138546199	138552723	102,0,51	1	6524	0	.	Breakpoint	for	translocation	to	form	KIAA1549-BRAF	fusion	protein.
chr7	139268572	139268578	Q9H2X6	0	-	139268572	139268578	102,0,51	1	6	0	.	Cleavage;	by	CASP6.
chr7	139268755	139268761	Q9H2X6	0	-	139268755	139268761	102,0,51	1	6	0	.	Cleavage;	by	CASP6.
chr7	140481490	140482823	P15056	0	-	140481490	140482823	102,0,51	1	1333	0	.	Breakpoint	for	translocation	to	form	KIAA1549-BRAF	fusion	protein.
chr7	140487381	140494110	P15056	0	-	140487381	140494110	102,0,51	1	6729	0	.	Breakpoint	for	translocation	to	form	KIAA1549-BRAF	fusion	protein.
chr7	142460406	142460409	P07477	0	+	142460406	142460409	102,0,51	1	3	0	.	Required	for	specificity.
chr7	142532902	142532905	P07478	0	+	142532902	142532905	102,0,51	1	3	0	.	Required	for	specificity.
chr7	150217368	150217371	Q8NHV1	0	+	150217368	150217371	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr7	150746047	150746050	Q9UHC3	0	+	150746047	150746050	102,0,51	1	3	0	.	Potassium	ion	selectivity	and	permeability.
chr7	155596172	155596175	Q15465	0	-	155596172	155596175	102,0,51	1	3	0	.	Essential	for	auto-cleavage.
chr7	155596181	155596184	Q15465	0	-	155596181	155596184	102,0,51	1	3	0	.	Involved	in	auto-cleavage.
chr7	155596253	155596256	Q15465	0	-	155596253	155596256	102,0,51	1	3	0	.	Involved	in	cholesterol	transfer.
chr7	155596388	155596394	Q15465	0	-	155596388	155596394	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr7	157926640	157926646	Q92932	0	-	157926640	157926646	102,0,51	1	6	0	.	Cleavage.
chr8	8654996	8655002	Q9Y4C4	0	-	8654996	8655002	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	chimeric	MASL1.
chr8	21883181	21883184	Q86SE8	0	+	21883181	21883184	102,0,51	1	3	0	.	Interaction	between	pentamers.
chr8	21883262	21883265	Q86SE8	0	+	21883262	21883265	102,0,51	1	3	0	.	Interaction	between	pentamers.
chr8	25280768	25280771	P01148	0	-	25280768	25280771	102,0,51	1	3	0	.	Appears	to	be	essential	for	biological	activity.
chr8	25890638	25890641	Q9HAK2	0	-	25890638	25890641	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	25890665	25890668	Q9HAK2	0	-	25890665	25890668	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	30332306	30332309	Q93062	0	+	30332306	30332309	102,0,51	1	3	0	.	Interaction	with	RNA.	Pubmed:26347403
chr8	30335350	30335353	Q93062	0	+	30335350	30335353	102,0,51	1	3	0	.	Interaction	with	RNA.	Pubmed:26347403
chr8	30922507	30922510	Q14191	0	+	30922507	30922510	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	30999086	30999089	Q14191	0	+	30999086	30999089	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	32453344	32453347	Q02297	0	+	32453344	32453347	102,0,51	1	3	0	.	Breakpoint	for	translocation	to	form	gamma-heregulin.
chr8	35579855	35579861	Q6UXZ4	0	+	35579855	35579861	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr8	37690534	37690540	Q96PE1	0	+	37690534	37690540	102,0,51	1	6	0	.	Cleavage;	by	thrombin.	Pubmed:22013897
chr8	37690621	37690627	Q96PE1	0	+	37690621	37690627	102,0,51	1	6	0	.	Cleavage;	by	thrombin.	Pubmed:22013897
chr8	38271316	38271319	P11362	0	-	38271316	38271319	102,0,51	1	3	0	.	Mediates	interaction	with	PLCG1	and	SHB.
chr8	38275888	38277053	P11362	0	-	38275888	38277053	102,0,51	1	1165	0	.	Breakpoint	for	translocation	to	form	CNTRL-FGFR1	OR	FGFR1-CNTRL	fusion	proteins.	Pubmed:10688839
chr8	38275888	38277053	P11362	0	-	38275888	38277053	102,0,51	1	1165	0	.	Breakpoint	for	translocation	to	form	FGFR1OP2-FGFR1.	Pubmed:15034873,	Pubmed:16946300,	Pubmed:17389761
chr8	38275888	38277053	P11362	0	-	38275888	38277053	102,0,51	1	1165	0	.	Breakpoint	for	translocation	to	form	FGFR1OP-FGFR1	or	FGFR1-FGFR1OP	fusion	proteins.	Pubmed:9949182
chr8	38865472	38865478	Q13443	0	+	38865472	38865478	102,0,51	1	6	0	.	Cleavage.
chr8	38876377	38876383	Q13443	0	+	38876377	38876383	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr8	41791096	41791102	Q92794	0	-	41791096	41791102	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6A-CREBBP.
chr8	41792383	41794777	Q92794	0	-	41792383	41794777	102,0,51	1	2394	0	.	Breakpoint	for	translocation	to	form	KAT6A-EP300	and	KAT6A-NCOA2.
chr8	41798956	41798962	Q92794	0	-	41798956	41798962	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6A-ASXL2.
chr8	42033663	42033666	P00750	0	-	42033663	42033666	102,0,51	1	3	0	.	Important	for	single-chain	activity.
chr8	42036552	42036555	P00750	0	-	42036552	42036555	102,0,51	1	3	0	.	Important	for	single-chain	activity.
chr8	42040280	42040283	P00750	0	-	42040280	42040283	102,0,51	1	3	0	.	Not	glycosylated.
chr8	42045481	42045484	P00750	0	-	42045481	42045484	102,0,51	1	3	0	.	Important	for	binding	to	LRP1.
chr8	48772315	48772321	P78527	0	-	48772315	48772321	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr8	52321303	52321306	A1KZ92	0	-	52321303	52321306	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr8	61178552	61178555	P35219	0	-	61178552	61178555	102,0,51	1	3	0	.	Ancestral	zinc	ligand.
chr8	71057078	71057084	Q15596	0	-	71057078	71057084	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	KAT6A-NCOA2.	Pubmed:15657427,	Pubmed:9558366,	Pubmed:12676584
chr8	79510664	79510667	A0A024R7Y9	0	+	79510664	79510667	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	79510664	79510667	P61925	0	+	79510664	79510667	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	79510673	79510676	A0A024R7Y9	0	+	79510673	79510676	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	79510673	79510676	P61925	0	+	79510673	79510676	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	79510676	79510679	A0A024R7Y9	0	+	79510676	79510679	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	79510676	79510679	P61925	0	+	79510676	79510679	102,0,51	1	3	0	.	Important	for	inhibition.
chr8	87474073	87474076	Q9H0M0	0	+	87474073	87474076	102,0,51	1	3	0	.	Required	for	ubiquitin-thioester	formation.
chr8	93029586	93029592	Q06455	0	-	93029586	93029592	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	AML1-MTG8	in	AML-M2.	Pubmed:8334990
chr8	97620679	97620685	P34741	0	+	97620679	97620685	102,0,51	1	6	0	.	Cleavage	of	ectodomain.
chr8	99560368	99560374	Q13188	0	-	99560368	99560374	102,0,51	1	6	0	.	Cleavage;	by	caspase-3.
chr8	101937180	101937183	P63104	0	-	101937180	101937183	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr8	101960949	101960952	P63104	0	-	101960949	101960952	102,0,51	1	3	0	.	Interaction	with	phosphoserine	on	interacting	protein.
chr8	103851946	103851949	O14977	0	-	103851946	103851949	102,0,51	1	3	0	.	Not	modified.
chr8	117864303	117864309	O60216	0	-	117864303	117864309	102,0,51	1	6	0	.	Cleavage;	by	ESPL1.
chr8	117868501	117868507	O60216	0	-	117868501	117868507	102,0,51	1	6	0	.	Cleavage;	by	caspase-3	or	caspase-7.
chr8	117869674	117869680	O60216	0	-	117869674	117869680	102,0,51	1	6	0	.	Cleavage;	by	ESPL1.
chr8	119936618	119936621	O00300	0	-	119936618	119936621	102,0,51	1	3	0	.	Involved	in	dimerization.
chr8	120569793	120569796	Q13822	0	-	120569793	120569796	102,0,51	1	3	0	.	Essential	for	catalytic	activity.
chr8	133883645	133883648	P01266	0	+	133883645	133883648	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:8615697
chr8	133899102	133899105	P01266	0	+	133899102	133899105	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:8615697
chr8	133978860	133978863	P01266	0	+	133978860	133978863	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:8615697
chr8	134024246	134024249	P01266	0	+	134024246	134024249	102,0,51	1	3	0	.	Not	glycosylated.	Pubmed:8615697
chr8	144398168	144398171	Q969P6	0	-	144398168	144398171	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144398222	144398225	Q969P6	0	-	144398222	144398225	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144399992	144399995	Q969P6	0	-	144399992	144399995	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144403412	144403415	Q969P6	0	-	144403412	144403415	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144403505	144403508	Q969P6	0	-	144403505	144403508	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144406291	144406294	Q969P6	0	-	144406291	144406294	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144406726	144406729	Q969P6	0	-	144406726	144406729	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144407586	144407589	Q969P6	0	-	144407586	144407589	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144408418	144408421	Q969P6	0	-	144408418	144408421	102,0,51	1	3	0	.	Interaction	with	DNA.
chr8	144644127	144644133	P57764	0	+	144644127	144644133	102,0,51	1	6	0	.	Cleavage;	by	inflammatory	caspases	CASP1	and	CASP4.	Pubmed:26375003
chr8	144696816	144696819	Q13630	0	-	144696816	144696819	102,0,51	1	3	0	.	Lowers	pKa	of	active	site	Tyr.
chr8	144696998	144697001	Q13630	0	-	144696998	144697001	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr8	144697004	144697007	Q13630	0	-	144697004	144697007	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chr9	5055785	5064885	O60674	0	+	5055785	5064885	102,0,51	1	9100	0	.	Breakpoint	for	translocation	to	form	PCM1-JAK2	fusion	protein.
chr9	5066786	5069024	O60674	0	+	5066786	5069024	102,0,51	1	2238	0	.	Breakpoint	for	translocation	to	form	PCM1-JAK2	fusion	protein.
chr9	5069042	5069048	O60674	0	+	5069042	5069048	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	PCM1-JAK2	fusion	protein.
chr9	5069204	5069926	O60674	0	+	5069204	5069926	102,0,51	1	722	0	.	Breakpoint	for	translocation	to	form	PCM1-JAK2	fusion	protein.
chr9	5078440	5080230	O60674	0	+	5078440	5080230	102,0,51	1	1790	0	.	Breakpoint	for	translocation	to	form	PCM1-JAK2	fusion	protein.
chr9	5812179	5812182	Q7Z2K6	0	-	5812179	5812182	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr9	6251201	6251207	O95760	0	+	6251201	6251207	102,0,51	1	6	0	.	Cleavage;	by	CTSG.
chr9	6251213	6251219	O95760	0	+	6251213	6251219	102,0,51	1	6	0	.	Cleavage;	by	ELANE.
chr9	6251243	6251249	O95760	0	+	6251243	6251249	102,0,51	1	6	0	.	Cleavage;	by	CTSG.
chr9	8465633	8465639	P23468	0	-	8465633	8465639	102,0,51	1	6	0	.	Cleavage.
chr9	18504868	18504871	Q8N6G6	0	+	18504868	18504871	102,0,51	1	3	0	.	Not	glycosylated.
chr9	20354865	20354868	P42568	0	-	20354865	20354868	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient	F1).
chr9	20413718	20413721	P42568	0	-	20413718	20413721	102,0,51	1	3	0	.	KMT2A/MLL1	fusion	point	(in	acute	myeloid	leukemia	patient	CO).
chr9	21854710	21854713	B4DUC8	0	+	21854710	21854713	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	21854710	21854713	J3QSB7	0	+	21854710	21854713	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	21854710	21854713	Q13126	0	+	21854710	21854713	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	21854857	21854860	J3QSB7	0	+	21854857	21854860	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	21859307	21859310	B4DUC8	0	+	21859307	21859310	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	21859307	21859310	Q13126	0	+	21859307	21859310	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chr9	33166933	33166939	P15291	0	-	33166933	33166939	102,0,51	1	6	0	.	Cleavage;	to	produce	soluble	form.
chr9	33246652	33246658	O60575	0	+	33246652	33246658	102,0,51	1	6	0	.	Reactive	bond.
chr9	33798608	33798611	P35030	0	+	33798608	33798611	102,0,51	1	3	0	.	Required	for	specificity.
chr9	34635784	34635787	Q99720	0	-	34635784	34635787	102,0,51	1	3	0	.	Important	for	ligand	binding.	Pubmed:11476895
chr9	34637060	34637063	Q99720	0	-	34637060	34637063	102,0,51	1	3	0	.	Important	for	ligand	binding.	Pubmed:11476895
chr9	36882100	36923355	Q02548	0	-	36882100	36923355	102,0,51	1	41255	0	.	Breakpoint	for	translocation	to	form	PAX5-ZNF521.
chr9	36923478	36966548	Q02548	0	-	36923478	36966548	102,0,51	1	43070	0	.	Breakpoint	for	translocation	to	form	PAX5-FOXP1.
chr9	37002771	37006473	Q02548	0	-	37002771	37006473	102,0,51	1	3702	0	.	Breakpoint	for	translocation	to	form	PAX5-ETV6.
chr9	37432089	37432092	Q9UBQ7	0	+	37432089	37432092	102,0,51	1	3	0	.	Raises	pKa	of	active	site	His.	Pubmed:16756993
chr9	75540522	75540525	P00352	0	-	75540522	75540525	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr9	78601089	78601095	Q92824	0	+	78601089	78601095	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chr9	87482306	87482309	Q16620	0	+	87482306	87482309	102,0,51	1	3	0	.	Interaction	with	SHC1.
chr9	87570423	87570426	Q16620	0	+	87570423	87570426	102,0,51	1	3	0	.	Interaction	with	SH2D1A.
chr9	87636331	87636334	Q16620	0	+	87636331	87636334	102,0,51	1	3	0	.	Interaction	with	PLCG1.
chr9	97355909	97355912	O00757	0	-	97355909	97355912	102,0,51	1	3	0	.	Important	for	the	conversion	from	active	R-state	to	inactive	T-state	in	the	presence	of	AMP.
chr9	97717552	97717555	Q8N6M6	0	+	97717552	97717555	102,0,51	1	3	0	.	Transition	state	stabilizer.
chr9	104184093	104184096	P05062	0	-	104184093	104184096	102,0,51	1	3	0	.	Necessary	for	preference	for	fructose	1,6-bisphosphate	over	fructose	1-phosphate.
chr9	113013664	113013667	P10599	0	-	113013664	113013667	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr9	113013667	113013670	P10599	0	-	113013667	113013670	102,0,51	1	3	0	.	Contributes	to	redox	potential	value.
chr9	113013688	113013691	P10599	0	-	113013688	113013691	102,0,51	1	3	0	.	Deprotonates	C-terminal	active	site	Cys.
chr9	114691797	114691800	Q16739	0	+	114691797	114691800	102,0,51	1	3	0	.	May	play	an	important	role	in	binding	to	the	inhibitors	DEPC	and	PDMP.
chr9	116823337	116823343	P02760	0	-	116823337	116823343	102,0,51	1	6	0	.	Inhibitory	(P1)	(trypsin).
chr9	116823830	116823836	P02760	0	-	116823830	116823836	102,0,51	1	6	0	.	Inhibitory	(P1)	(chymotrypsin,	elastase).
chr9	117552917	117552920	O95150	0	-	117552917	117552920	102,0,51	1	3	0	.	Important	for	binding	TNFRSF6B.
chr9	117552926	117552929	O95150	0	-	117552926	117552929	102,0,51	1	3	0	.	Important	for	binding	TNFRSF6B.
chr9	117555842	117555848	O95150	0	-	117555842	117555848	102,0,51	1	6	0	.	Cleavage.
chr9	123675818	123675824	Q13077	0	-	123675818	123675824	102,0,51	1	6	0	.	Cleavage;	by	CASP8.
chr9	123933823	123935523	Q7Z7A1	0	+	123933823	123935523	102,0,51	1	1700	0	.	Breakpoint	for	translocation	to	form	CEP110-FGFR1.
chr9	124519442	124521179	Q5VWQ8	0	+	124519442	124521179	102,0,51	1	1737	0	.	Breakpoint	for	translocation	to	form	KMT2A/MLL1-DAB2IP.
chr9	125154607	125154610	P23219	0	+	125154607	125154610	102,0,51	1	3	0	.	Aspirin-acetylated	serine.
chr9	125827653	125827656	Q9Y3P9	0	+	125827653	125827656	102,0,51	1	3	0	.	Arginine	finger.
chr9	125832664	125832667	Q9Y3P9	0	+	125832664	125832667	102,0,51	1	3	0	.	Glutamine	finger.
chr9	127083764	127083767	Q9HC98	0	+	127083764	127083767	102,0,51	1	3	0	.	Autoinhibitory.
chr9	127563902	127563908	Q68BL7	0	+	127563902	127563908	102,0,51	1	6	0	.	Cleavage.
chr9	130889732	130889738	Q9H7Z7	0	-	130889732	130889738	102,0,51	1	6	0	.	Cleavage.
chr9	131361247	131361253	Q13813	0	+	131361247	131361253	102,0,51	1	6	0	.	Cleavage;	by	mu-calpain.
chr9	131456318	131456922	Q01105	0	+	131456318	131456922	102,0,51	1	604	0	.	Breakpoint	for	translocation	to	form	SET-CAN	oncogene.
chr9	132719653	132719656	Q96RU3	0	-	132719653	132719656	102,0,51	1	3	0	.	Mediates	end-to-end	attachment	of	dimers.
chr9	133710908	133729452	P00519	0	+	133710908	133729452	102,0,51	1	18544	0	.	Breakpoint	for	translocation	to	form	BCR-ABL	oncogene.
chr9	133779540	133779543	Q8N539	0	-	133779540	133779543	102,0,51	1	3	0	.	Implicated	in	ligand	binding.
chr9	133779543	133779546	Q8N539	0	-	133779543	133779546	102,0,51	1	3	0	.	Implicated	in	ligand	binding.
chr9	133779591	133779594	Q8N539	0	-	133779591	133779594	102,0,51	1	3	0	.	Implicated	in	ligand	binding.
chr9	133779621	133779624	Q8N539	0	-	133779621	133779624	102,0,51	1	3	0	.	Implicated	in	ligand	binding.
chr9	134027278	134034772	P35658	0	+	134027278	134034772	102,0,51	1	7494	0	.	Breakpoint.
chr9	136501607	136501613	P09172	0	+	136501607	136501613	102,0,51	1	6	0	.	Cleavage.
chr9	136899943	136899949	Q15059	0	-	136899943	136899949	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	BDR3-NUT	fusion	protein.
chr9	137007124	137007127	P61964	0	+	137007124	137007127	102,0,51	1	3	0	.	Important	for	interaction	with	histone	H3.
chr9	137007496	137007499	P61964	0	+	137007496	137007499	102,0,51	1	3	0	.	Important	for	interaction	with	histone	H3.
chr9	137020859	137020862	P61964	0	+	137020859	137020862	102,0,51	1	3	0	.	Important	for	interaction	with	histone	H3.
chr9	137023073	137023076	P61964	0	+	137023073	137023076	102,0,51	1	3	0	.	Important	for	interaction	with	histone	H3.
chr9	137801688	137801691	O00602	0	-	137801688	137801691	102,0,51	1	3	0	.	Mediates	specificity	for	sialic	acids.	Pubmed:17897951
chr9	137801724	137801727	O00602	0	-	137801724	137801727	102,0,51	1	3	0	.	Mediates	specificity	for	sialic	acids.	Pubmed:20032467,	Pubmed:17897951
chr9	139397637	139397643	P46531	0	-	139397637	139397643	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr9	139397667	139397673	P46531	0	-	139397667	139397673	102,0,51	1	6	0	.	Cleavage;	by	ADAM17.
chr9	139399147	139399153	P46531	0	-	139399147	139399153	102,0,51	1	6	0	.	Cleavage;	by	furin-like	protease.
chr9	139412237	139412240	P46531	0	-	139412237	139412240	102,0,51	1	3	0	.	Interaction	with	DLL4.
chr9	140811856	140811859	Q00975	0	+	140811856	140811859	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr9	140901230	140901233	Q00975	0	+	140901230	140901233	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr9	140952307	140952310	Q00975	0	+	140952307	140952310	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chr9	140972578	140972581	Q00975	0	+	140972578	140972581	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chrX	7223124	7223127	P08842	0	+	7223124	7223127	102,0,51	1	3	0	.	Not	glycosylated.
chrX	7252144	7252147	P08842	0	+	7252144	7252147	102,0,51	1	3	0	.	Not	glycosylated.
chrX	10174511	10174514	P51793	0	+	10174511	10174514	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	outer	aqueous	phase	to	the	interior	of	the	protein;	involved	in	linking	H(+)	and	Cl(-)	transport.
chrX	10174813	10174816	P51793	0	+	10174813	10174816	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	protein	to	the	inner	aqueous	phase.
chrX	14627279	14627282	P23416	0	+	14627279	14627282	102,0,51	1	3	0	.	Important	for	obstruction	of	the	ion	pore	in	the	closed	conformation.
chrX	15270487	15270490	Q96DX5	0	-	15270487	15270490	102,0,51	1	3	0	.	Essential	for	binding	to	CKB.
chrX	15270499	15270502	Q96DX5	0	-	15270499	15270502	102,0,51	1	3	0	.	Essential	for	binding	to	CKB.
chrX	24732711	24732717	P09884	0	+	24732711	24732717	102,0,51	1	6	0	.	Cleavage.
chrX	43591992	43591995	P21397	0	+	43591992	43591995	102,0,51	1	3	0	.	Important	for	substrate	specificity.
chrX	43599940	43599943	P21397	0	+	43599940	43599943	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	43634510	43634513	P27338	0	-	43634510	43634513	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	43637970	43637973	P27338	0	-	43637970	43637973	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	43661426	43661429	P27338	0	-	43661426	43661429	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	48117969	48117975	Q16384	0	+	48117969	48117975	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX1	fusion	protein	(rare).	Pubmed:7539744
chrX	48121247	48123219	Q16384	0	+	48121247	48123219	102,0,51	1	1972	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX1	fusion	protein.	Pubmed:7539744
chrX	48895636	48895724	P19532	0	-	48895636	48895724	102,0,51	1	88	0	.	Breakpoint	for	translocation	to	form	ASPSCR1-TFE3	oncogene.
chrX	48895964	48896634	P19532	0	-	48895964	48896634	102,0,51	1	670	0	.	Breakpoint	for	translocation	to	form	PRCC-TFE3	oncogene.
chrX	49067925	49067928	O60840	0	-	49067925	49067928	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chrX	49072852	49072855	O60840	0	-	49072852	49072855	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chrX	49079282	49079285	O60840	0	-	49079282	49079285	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chrX	49084736	49084739	O60840	0	-	49084736	49084739	102,0,51	1	3	0	.	Calcium	ion	selectivity	and	permeability.
chrX	49107836	49107842	Q9BZS1	0	-	49107836	49107842	102,0,51	1	6	0	.	Cleavage;	by	PCSK1	or	PCSK2.	Pubmed:19117830
chrX	49114806	49114812	Q9BZS1	0	-	49114806	49114812	102,0,51	1	6	0	.	Cleavage.	Pubmed:19117830
chrX	49846411	49846414	P51795	0	+	49846411	49846414	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	outer	aqueous	phase	to	the	interior	of	the	protein;	involved	in	linking	H(+)	and	Cl(-)	transport.
chrX	49850714	49850717	P51795	0	+	49850714	49850717	102,0,51	1	3	0	.	Mediates	proton	transfer	from	the	protein	to	the	inner	aqueous	phase.
chrX	51487367	51487370	Q8IYD1	0	+	51487367	51487370	102,0,51	1	3	0	.	Interacts	with	GTP/GDP.
chrX	51487769	51487772	Q8IYD1	0	+	51487769	51487772	102,0,51	1	3	0	.	Interacts	with	GTP/GDP.
chrX	52729625	52731633	Q16385	0	-	52729625	52731633	102,0,51	1	2008	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX2	fusion	protein.
chrX	52733619	52733625	Q16385	0	-	52733619	52733625	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX2	fusion	protein	(rare).
chrX	52782931	52782937	Q16385	0	+	52782931	52782937	102,0,51	1	6	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX2	fusion	protein	(rare).
chrX	52784923	52786933	Q16385	0	+	52784923	52786933	102,0,51	1	2010	0	.	Breakpoint	for	translocation	to	form	the	SSXT-SSX2	fusion	protein.
chrX	54964076	54964079	P16118	0	-	54964076	54964079	102,0,51	1	3	0	.	Transition	state	stabilizer.
chrX	55030256	55030259	Q9UBZ4	0	+	55030256	55030259	102,0,51	1	3	0	.	Transition	state	stabilizer.
chrX	55033139	55033142	Q9UBZ4	0	+	55033139	55033142	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	55033220	55033223	Q9UBZ4	0	+	55033220	55033223	102,0,51	1	3	0	.	Interaction	with	DNA	substrate.
chrX	56755873	56755876	A0A0U1RRE5	0	+	56755873	56755876	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	56755885	56755888	A0A0U1RRE5	0	+	56755885	56755888	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	56843934	56843937	A0A0U1RRE5	0	+	56843934	56843937	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	56843946	56843949	A0A0U1RRE5	0	+	56843946	56843949	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	56843952	56843955	A0A0U1RRE5	0	+	56843952	56843955	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	56843964	56843967	A0A0U1RRE5	0	+	56843964	56843967	102,0,51	1	3	0	.	Required	for	interaction	with	EDC4.	Pubmed:27918561
chrX	66931518	66931521	P10275	0	+	66931518	66931521	102,0,51	1	3	0	.	Interaction	with	coactivator	LXXL	motif.
chrX	66943611	66943614	P10275	0	+	66943611	66943614	102,0,51	1	3	0	.	Interaction	with	coactivator	FXXLF	motif.
chrX	69176954	69176960	Q92838	0	+	69176954	69176960	102,0,51	1	6	0	.	Cleavage;	by	furin.	Pubmed:11416205
chrX	69370063	69370069	P78318	0	+	69370063	69370069	102,0,51	1	6	0	.	Cleavage;	by	calpain.
chrX	70517785	70518321	Q15233	0	+	70517785	70518321	102,0,51	1	536	0	.	Breakpoint	for	translocation	to	form	NONO-TFE3.
chrX	77224577	77224580	Q8N0Y7	0	-	77224577	77224580	102,0,51	1	3	0	.	Transition	state	stabilizer.
chrX	102974029	102974032	Q5JXX5	0	-	102974029	102974032	102,0,51	1	3	0	.	Important	for	obstruction	of	the	ion	pore	in	the	closed	conformation.
chrX	106083994	106083997	Q0IIM8	0	+	106083994	106083997	102,0,51	1	3	0	.	Arginine	finger.
chrX	106084111	106084114	Q0IIM8	0	+	106084111	106084114	102,0,51	1	3	0	.	Glutamine	finger.
chrX	123514775	123514781	Q9UKZ4	0	-	123514775	123514781	102,0,51	1	6	0	.	Cleavage.
chrX	132351867	132351870	Q5H9I0	0	-	132351867	132351870	102,0,51	1	3	0	.	Critical	for	repression	of	E2F	activity.
chrX	132351894	132351897	Q5H9I0	0	-	132351894	132351897	102,0,51	1	3	0	.	Critical	for	repression	of	E2F	activity.
chrX	132351897	132351900	Q5H9I0	0	-	132351897	132351900	102,0,51	1	3	0	.	Critical	for	repression	of	E2F	activity.
chrX	132351924	132351927	Q5H9I0	0	-	132351924	132351927	102,0,51	1	3	0	.	Critical	for	repression	of	E2F	activity.
chrX	135736576	135736582	P29965	0	+	135736576	135736582	102,0,51	1	6	0	.	Cleavage.
chrX	138633270	138633276	P00740	0	+	138633270	138633276	102,0,51	1	6	0	.	Cleavage;	by	factor	XIa.
chrX	138633375	138633381	P00740	0	+	138633375	138633381	102,0,51	1	6	0	.	Cleavage;	by	factor	XIa.
chrX	152966415	152966421	P51572	0	-	152966415	152966421	102,0,51	1	6	0	.	Cleavage;	by	caspase-8.
chrX	152968495	152968501	P51572	0	-	152968495	152968501	102,0,51	1	6	0	.	Cleavage;	by	caspase-8.
chrX	153052929	153052932	P51553	0	-	153052929	153052932	102,0,51	1	3	0	.	Critical	for	catalysis.
chrX	153053295	153053298	P51553	0	-	153053295	153053298	102,0,51	1	3	0	.	Critical	for	catalysis.
chrX	153219577	153219583	P51610	0	-	153219577	153219583	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153219877	153219883	P51610	0	-	153219877	153219883	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153219961	153219967	P51610	0	-	153219961	153219967	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153220516	153220522	P51610	0	-	153220516	153220522	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153220603	153220609	P51610	0	-	153220603	153220609	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153220789	153220795	P51610	0	-	153220789	153220795	102,0,51	1	6	0	.	Cleavage;	by	autolysis.
chrX	153533656	153533659	P51854	0	+	153533656	153533659	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	153540953	153540956	P51854	0	+	153540953	153540956	102,0,51	1	3	0	.	Important	for	catalytic	activity.
chrX	153583010	153583016	P21333	0	-	153583010	153583016	102,0,51	1	6	0	.	Cleavage;	by	calpain.
chrX	154156937	154156943	P00451	0	-	154156937	154156943	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chrX	154157060	154157066	P00451	0	-	154157060	154157066	102,0,51	1	6	0	.	Cleavage	(activation).
chrX	154158065	154158071	P00451	0	-	154158065	154158071	102,0,51	1	6	0	.	Cleavage	(activation).
chrX	154159784	154159790	P00451	0	-	154159784	154159790	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
chrX	154194795	154194801	P00451	0	-	154194795	154194801	102,0,51	1	6	0	.	Cleavage;	by	thrombin.
